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1.2 Abstract(Immunotherapeutic! approaches! to! treat! cancers! have! been! pursued! for! many!years! with! very! little! success.! However! recent! success! in! the! treatment! of!melanoma,!have!confirmed!the!potential!utility!of!the!approach.!!Oncolytic! viruses! are! emerging! therapies! that! work! in! part! by! directly! killing!cells! they! infect,! but! also! by! stimulating! antiItumour! immune! responses.!Radiotherapy! is! generally! considered! an! immuneIsuppressive! treatment! but!recent!preclinical!evidence!suggests!that!it!can!render!cancer!cells!susceptible!to!immuneImediated! attack! and! generate! antiItumour! immunity! when! combined!with!additional!therapies.!!!In! the! work! described! measles! virus,! a! potential! oncolytic! virus,! kills! human!melanoma!cells,!both!immortalised!cell!lines!and!freshly!resected!primary!cells,!and! generates! an! inflammatory! pattern! of! cytokines,! chemokines! and! danger!signals! as! it! does! so.! The! virus,! and! virusItreated! cancer! cells! enhance! innate!effector!cells!and!mature!dendritic!cells.!Virally!treated!melanoma!cells!stimulate!adaptive!TIcell!antiImelanoma!responses.!!External! beam! radiotherapy! in! the! palliative! dose! range! was! combined! with!combinations!of!adoptive!cell!therapy!and!vesicular!stomatitis!virus!and!did!not!enhance!therapy.!SealedIsource!brachytherapy!was!also!combined!with!adoptive!cell!therapy!and!virotherapy,!but!without!synergy.!!In! order! to! study! the! effects! of! existing! and! proposed! immunotherapeutic!approaches! against! melanoma! that! has! metastasised! to! the! brain,! a! model! of!intracranial! melanoma! was! established! and! in! initial! therapy! experiments!survival! was! improved! following! treatment! with! intravenous! oncolytic!virotherapy.!!Immunotherapeutic! approaches! hold! promise! for! the! treatment! of! melanoma.!Clinical!testing!of!measles!virus!in!trials!with!patients!suffering!from!metastatic!melanoma!should!be!considered.!! !
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1.3 Plain(language(summary(For!a!long!time!the!immune!system!has!been!considered!irrelevant!in!the!treatment!of!cancer.!Most!patients!who!develop!cancer!have!perfectly!normal!immune!systems!during!the!period!that!the!cancer!developed.!Thus!the!argument!goes!if!the!immune!system!could!play!a!role!it!would!have!done!so!already.!Moreover!conventional!therapies,!namely!chemotherapy!and!radiotherapy,!famously!suppress!the!immune!system;!people!having!chemotherapy!are!at!much!higher!risk!of!catching!infections,!for!example.!These!are!the!views!held!by!most!doctors,!including!the!specialists!who!treat!cancer.!Increasingly!all!of!these!views!can!be!challenged.!Cancers!do!develop!despite!apparently!normal!immune!systems,!but!it’s!not!a!smooth!ride!for!them.!Many!cancer!therapies!do!have!side!effects!that!dampen!the!immune!system,!but!they!can!also!have!some!positive!effects.!Cancers!have!to!evade!the!immune!system!during!their!development!and!emerge!from!the!process!having!acquired!several!tricks!that!make!them!invisible!to!the!body’s!defences.!This!raises!the!prospect!of!subverting!that!subversion;!by!developing!therapies!that!can!overcome!the!immune!evasion!that!most!cancers!set!up,!it!will!be!possible!to!recruit!a!person’s!own!immune!system!to!attack!their!cancer.!Some!viruses!are!better!at!infecting!cancer!cells!than!normal!human!cells.!These!oncolytic!viruses!are!being!developed!across!the!world!in!labs!and!also!in!clinical!trials.!A!strain!of!measles,!commonly!used!in!vaccinations,!is!one!such!oncolytic!virus!that!I!have!used!in!laboratory!models!of!melanoma!to!show!two!things.!Firstly!the!measles!virus!kills!melanoma!cells.!Secondly!the!measles!virus!is!able!to!trigger!an!immune!response!against!the!melanoma.!Based!on!these!data!I’m!developing!a!trial!that!will!test!the!measles!virus!for!patients!with!melanoma.!Amongst!its!many!effects,!medical!students!are!taught!that!radiotherapy!is!immunosuppressive.!In!many!senses!this!is!true!but!it!is!a!complicated!picture.!Giving!radiotherapy!to!the!whole!body!will!eliminate!many!of!the!cells!required!to!produce!an!immune!response,!but!we!don’t!often!give!radiotherapy!to!the!whole!body.!Modern!radiotherapy!tends!to!focus!on!ever!more!precisely!directed!areas!for!treatment;!the!tumour!and!as!small!an!area!around!it!as!possible.!Immune!cells!in!that!area!are!likely!to!be!damaged!by!the!radiation,!but!other!
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cells!outside!the!treatment!region!may!even!benefit!from!the!therapy.!Tumour!cells!treated!by!radiotherapy!seem!to!become!more!visible!to!the!immune!system!and!release!signals!that!are!capable!of!activating!immune!cells.!Several!groups!worldwide!have!found!ways!to!make!radiotherapy!combine!with!the!immune!system!in!mouse!models!of!cancer.!However!in!my!models!I!found!that!there!was!little!positive!effect;!this!contradicts!the!results!of!other!scientists,!but!suggests!that!if!radiotherapy!can!be!used!in!concert!with!the!immune!system!then!doses!and!timing!will!need!to!be!carefully!worked!out!before!we!can!get!the!best!results!for!patients.!One!of!the!areas!that!melanoma!will!commonly!spread!to!is!the!brain,!in!fact!melanoma!spreads!to!the!brain!more!commonly!than!almost!any!other!cancer.!This!is!horribly!debilitating!for!patients!and!always!carries!a!bleak!prognosis!when!it!happens.!One!of!the!challenges!for!any!cancer!therapy!is!to!reach!the!brain,!as!it!is!carefully!protected!behind!a!unique!obstacle!called!the!bloodIbrain!barrier.!This!bloodIbrain!barrier!keeps!the!brain!safe!from!infections!but!actually!obstructs!many!therapies!reaching!their!targets.!In!order!to!find!ways!to!allow!immunotherapies!to!reach!the!brain!I!established!a!model!in!mice!that!will!be!used!to!test!how!well!existing!and!new!therapies!reach!cancers!hiding!behind!the!bloodIbrain!barrier.!!! !
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1.6 Abbreviations(!AACR! American!Association!of!Cancer!Research!ACT! Adoptive!cell!therapy!APC! Antigen!presenting!cells!ARRIVE! Animal!research:!reporting!in!vivo!experiments!guidelines!ATCC! American!type!culture!collection!BBB! BloodIbrain!barrier!BHK! Baby!hamster!kidney!CART! Chimeric!antigen!receptor!TIcells!!CCL21! Chemokine!(CIC!motif)!ligand!21!CD! Cluster!of!differentiation!CEA! Carcinoembryonic!antigen!CLL! Chronic!lymphocytic!leukaemia!CNS! Central!nervous!system!CPE! Cytopathic!effects!CPM! Counts!per!minute!CRUK! Cancer!Research!UK!CT! Computed!tomography!CTL! Cytotoxic!T!lymphocytes!CTLA4! Cytotoxic!T!lymphocyteIassociated!antigen!4!DC! Dendritic!cell!DICOM! Digital!imaging!and!communications!in!medicine!DMEM! Dulbecco’s!modified!Eagle’s!media!DMSO! Dimethylsulfoxide!DNA! Deoxyribonucleic!acid!EBRT! External!beam!radiotherapy!EGFR! Epidermal!growth!factor!receptor!ELISA! Enzyme!linked!immunosorbent!assay!ESMO! European!society!of!medical!oncology!ESO! European!society!of!oncology!F! MV!fusion!protein!FACS! Fluorescence!activated!cell!sorting!
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FCS! Foetal!calf!serum!FITC! Fluorescein!isothiocyanate!FoxP3! Forkhead!box!P3!GFP! Green!fluorescent!protein!GMICSF! Granulocyte!macrophage!colonyIstimulating!factor!gp100! Glycoprotein!100!H! MV!haemagglutinin!protein!H&E! Haematoxylin!and!eosin!HBSS! Hank’s!balanced!saline!solution!HLA! Human!leukocyte!antigen!HMGB1! High!mobility!group!box!1!HPV! Human!papilloma!virus!HSV! Herpes!simplex!virus!i.c.! Intracranial!ICA! IntraIcarotid!arterial!injection!ICP34.5! Infected!cell!protein!34.5!IDO! Indoleamine!2,3!dioxygenase!IFN! Interferon!IHC! Immunohistochemistry!IL! Interleukin!IMDM! Iscove’s!modified!Dulbecco’s!medium!ip! Intraperitoneal!iv! Intravenous!L! MV!large!protein!LPS! Lipopolysaccharide!M! MV!matrix!protein!MACS! Magnetic!activated!cell!sorting!MART1! Melanoma!antigen!recognised!by!TIcells!MDSC! Myeloid!derived!suppressor!cells!MFI! Median!fluorescence!intensity!MHC! Major!histocompatibility!complex!MOI! Multiplicity!of!infection!MRI! Magnetic!resonance!imaging!
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MTT! Methylthiazolyldiphenyl!tetrazolium!bromide!MV! Measles!virus!(Edmonston!strain)!MW! Molecular!weight!N! MV!nucleocapsid!protein!NAP! Neutrophil!activating!protein!NARA! Neutralising!antiIreovirus!antibodies!NCI! National!cancer!institute!NIS! SodiumIIodide!symporter!NK! Natural!Killer!NMR! Nuclear!magnetic!resonance!OV! Oncolytic!viruses!Ova! Ovalbumin!P! MV!phosphoprotein!PBMC! Peripheral!blood!mononuclear!cells!PBS! Phosphate!buffered!saline!PCR! Polymerase!chain!reaction!PD1! Programmed!cell!death!1!PDL1! Programmed!cell!death!1!ligand!1!PE! Phycoerythrin!PET! Positron!emission!tomography!PFA! Paraformaldehyde!RAG! Recombination!activating!gene!RANTES! Regulated!and!normal!TIcell!expressed!and!secreted!RECIST! Radiological!!RNA! Ribonucleic!acid!RNP! Ribonucleoprotein!RPMI! Roswell!Park!Memorial!Institute!medium!RT! Radiotherapy!s.c.! Subcutaneous!SBRT! Stereotactic!body!radiotherapy!scFv! SingleIchain!variable!region!antibody!fragments!SCID! Severe!combined!immunodeficiency!SEM! Standard!error!of!the!mean!
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SLAM! Signalling!lymphocyteIactivation!molecule!SMO! Smoothened!SPECT! Single!photon!emission!computed!tomography!TIcell! Thymic!derived!lymphocyte!TIregs! Regulatory!TIcells!TAA! Tumour!associated!antigen!TBI! Total!body!irradiation!TCID50! Tissue!culture!infectious!dose!50%!TCM! TumourIconditioned!media!TCR! TIcell!receptor!TDLN! TumourIdraining!lymph!nodes!Th1! TIhelper!1!TIL! TumourIinfiltrating!lymphocytes!TLR! TollIlike!receptor!TNF! Tumour!necrosis!factor!TW! Transwells!UV! Ultraviolet!VRS! VirchowIRobin!space!VSV! Vesicular!stomatitis!virus!wtMV! Wildtype!measles!virus!(Pathogenic!strain)!!!!!!
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2 Introduction(
!
Efforts!to!generate!antiItumour!immune!responses!in!cancer!patients!have!been!studied!for!over!a!hundred!years,!but!many!scientists!and!clinicians!were!(or!are)!profoundly!sceptical!that!such!efforts!could!ever!be!fruitful.!Janeway!and!preIJaneway!models!of!the!immune!system!suggested!that!the!immune!system!would!not!and!could!not!act!against!tumours!derived!from!host!cells.!The!broadly!equal!incidence!of!tumours!amongst!immunosuppressed!versus!immuneIcompetent!patients!supported!such!pessimism.!Several!developments!have!challenged!that!view,!but!most!compellingly!the!recent!emergence!of!Ipilimumab!as!an!effective!melanoma!treatment!has!confirmed!that!the!immune!system!can!be!compelled!to!act!against!tumours!and!produce!real!benefits!for!patients!with!cancer.!
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Figure!1.!Melanoma!cases!(1975I2010).!A.!Cases!of!melanoma!in!men!have!caught!up!with!those!occurring!in!women.!B.!AgeIstandardised!rates!show!consistent! increases,! in!both!men!and!women,!over!at! least!35!years.! Data! obtained! from! CRUK! CancerStats! website,! originally! derived! from! the! Office! of! National!statistics,! the! Welsh! Cancer! Intelligence! and! Surveillance! Unit! and! the! Information! Services! Division!Scotland.!! !
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2.1 Melanoma(Melanoma!is!a!malignancy!derived!from!melanocytic!cells.!Though!melanomas!most!commonly!develop!in!the!skin,!melanocytes!have!their!embryological!origin!in!the!neural!crest,!and!therefore!nonIcutaneous!melanomas!may!also!arise!in!the!eye,!alimentary!tract!and!meninges.!Unlike!the!other!skin!cancers,!melanoma!has!a!strong!proclivity!toward!metastasis,!even!from!small!primary!tumours.!Macroscopically,!cutaneous!melanomas!tend!to!be!heavily!pigmented,!though!amelanotic!lesions!are!not!uncommon.!Melanomas!are!recognised!clinically!as!asymmetric!lesions!with!irregular!borders!and!variegated!pigmentation,!as!well!as!the!size!and!evolution!over!time!of!the!lesion,!and!to!no!small!degree,!a!clinician’s!experience.!There!are!numerous!subtypes!of!melanoma,!associated!with!differing!behaviours!and!prognoses,!which!are!based!on!specialist!histological!examination!(Garbe!et!al.,!2012).!An!important!element!of!the!histological!assessment!is!to!measure!the!depth!of!invasion,!which!is!critical!in!determining!the!stage!(Balch!et!al.,!2009).!!!!12,818!people!were!diagnosed!with!melanoma!in!the!UK!in!2010!(CRUK!website,!accessed!2012I09I23).!The!ageIstandardised!rate!has!risen!over!the!last!35!years,!with!a!dramatic!rise!in!the!last!decade!(Figure!1).!Historically!melanoma!more!commonly!affected!women!than!men,!but!the!gender!imbalance!has!recently!resolved!and!melanoma!is!now!the!6th!most!common!cancer!diagnosis!for!each,!and!the!fifth!overall.!The!incidence!has!increased!more!rapidly!than!any!of!the!other!common!cancers,!particularly!during!the!last!decade,!and!not!simply!due!to!increasing!public!awareness!or!early!presentation!(Lee!and!Weinstock,!2009;!Linos!et!al.,!2009).!!As!with!most!cancers!the!ageIspecific!rate!of!melanoma!increases!decadeIbyIdecade!(Figure!2).!However!the!increase!begins!earlier!in!life!than!the!other!common!cancers;!as!a!fraction!of!the!ageIspecific!rate!for!all!cancers,!melanoma!peaks!in!the!third!decade!for!women!and!the!fourth!to!fifth!decades!for!men!(Figure!2B).!Because!of!this!early!emergence,!melanoma!is!the!second!commonest!cancer!of!women!between!15!and!49!years,!after!breast!cancer,!and!
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second!only!to!testicular!amongst!men!of!the!same!ages!(CRUK!website).!Of!course!in!absolute!numbers!most!cases!still!occur!in!older!people!(Figure!2C).!! !
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Figure!2.!Preponderance!of!melanoma!in!younger!people.!A.!Melanoma!rates!increase!with!age,!in!common!with! other! cancers,! however! there! is! a! relative! preponderance! of! the! cancer! in! younger! age! groups,! in!contrast! to! other! cancers! (note! the!differing! scales! of! each! axis).! B.! The! ageIspecific! rate! of!melanoma! is!expressed! as! a! fraction! of! the! ageIspecific! rate! of! all! cancers! and! illustrates! the! early! emergence! of!melanoma! compared! to! other! cancers.! C.! The! absolute! number! of!melanoma! cases! per! year! in! each! age!group.! Data! obtained! from! the! CRUK! CancerStats! website,! originally! derived! from! the! Office! of! National!statistics,! the! Welsh! Cancer! Intelligence! and! Surveillance! Unit! and! the! Information! Services! Division!Scotland.!!! !
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The!aetiology!of!melanoma!is!multifactorial!though!exposure!to!UV!radiation!is!a!likely!(Menzies,!2008),!albeit!controversial!(Shuster,!2008),!risk!factor.!SunbedIuse!is!widely!implicated!as!potentially!causative!(Boniol!et!al.,!2012),!despite!some!evidence!to!the!contrary!(Elliott!et!al.,!2012).!Certainly!melanoma!is!more!common!wherever!there!is!confluence!of!fairIskinned!Caucasians!with!highIlevels!of!sunlight!(Garbe!et!al.,!2012).!!A!family!history!of!melanoma!increases!an!individual’s!risk,!but!such!cases!may!only!contribute!to!less!than!10%!of!the!burden!of!disease!(Olsen!et!al.,!2010).!Familial!atypical!multiple!moleImelanoma!syndrome!is!the!most!common!familial!syndrome,!though!others!such!as!xeroderma!pigmentosum!and!albinism!also!lead!to!melanomas!(Bonadies!and!Bale,!2011).!!Although!earlyIstage!melanomas!are!commonly!cured!by!surgical!excision,!locally!advanced!or!metastatic!melanoma!has!a!dismal!prognosis.!The!survival!of!patients!with!melanoma!varies!from!97%!at!five!years!for!patients!with!small,!easily!resected!tumours,!through!to!33%!at!one!year!for!patients!with!the!most!advanced!metastatic!disease!(Balch!et!al.,!2009).!One!UK!cancer!registry!has!reported!that!20%!of!patients!aged!65!or!over!were!found!to!be!stage!III!or!IV!at!the!time!of!diagnosis,!though!the!rate!was!7%!amongst!younger!patients!(Eastern!Cancer!Registration!and!Information!service,!cited!on!the!CRUK!website).!!Surgery!or!radiotherapy!are!commonly!used!to!control!limited!volumes!of!metastatic!disease!in!order!to!allay!symptoms,!and!in!some!situations!to!improve!survival,!but!systemic!treatments!are!the!mainstay!of!treatment!for!metastatic!melanoma!(Garbe!et!al.,!2012).!!!Chemotherapy!for!melanoma!continues!to!be!used,!commonly!dacarbazine!or!temozolomide,!despite!a!limited!response!rate!(13I20%)!and!no!improvement!in!survival!(Eggermont!and!Kirkwood,!2004).!Treatments!with!immunomodulatory!agents!such!as!recombinant!interferon!alpha!2b!(IFNα2b)!or!interleukinI2!(IL2)!have!been!attempted.!Both!are!associated!with!significant!toxicity!and!minimal!survival!benefits!in!the!adjuvant!setting!(Tsao!et!al.,!2004).!Metastatic!melanoma!
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has!been!treated!with!intravenous!IL2,!with!one!trial!achieving!a!response!rate!of!16%;!moreover!some!patients!benefited!from!enduring!complete!responses!(Atkins!et!al.,!1999).!Unfortunately!treatment!with!IL2!is!profoundly!toxic!and!given!the!low!rates!of!significant!clinical!benefit,!and!cost,!its!use!has!not!become!routine.!!!Ipilimumab!is!a!human!monoclonal!antibody!directed!against!CTLAI4!(cytotoxic!T!lymphocyteIassociated!antigenI4).!In!the!process!of!CD8+!TIcell!stimulation,!dendritic!cells!(DC)!present!antigen!to!the!TIcell!receptor!in!the!context!of!MHC!class!I,!along!with!coIstimulatory!signals!(including!B7.1/CD80!and!B7.2/CD86).!The!coIstimulatory,!or!‘second’,!signals!are!recognised!by!CD28!on!the!TIcell,!triggering!activation!as!shown!in!Figure!3A.!The!activated!TIcell!will!then!begin!to!upregulate!surface!expression!of!an!inhibitory!molecule!–!CTLAI4.!CTLAI4!competes!with!CD28!for!the!B7!markers!and!in!so!doing!terminates!TIcell!activation,!acting!to!regulate!cytotoxic!TIcell!responses.!Inhibition!of!CTLAI4!by!Ipilimumab!maintains!TIcell!activation!and!resulted!in!objective!responses!in!around!15%!of!patients!with!metastatic!melanoma,!and!prolonged!survival!by!two!to!three!months!(Figure!3B)!(Hodi!et!al.,!2010;!O’Day!et!al.,!2010;!Ribas,!2012).!The!action!of!Ipilimumab!is!not!specific!to!antiImelanoma!lymphocytes!and!therefore!its!major!limitation!is!the!generation!of!significant!autoimmune!toxicities,!which!can!be!lifeIthreatening!(Attia!et!al.,!2005;!Berthod!et!al.,!2012).!Several!autoimmune!manifestations!are!already!well!recognised!and!include!hepatitis,!vitiligo!and!dermatitis,!and!enterocolitis.!Melanoma!frequently!metastasises!to!the!brain;!isolated!metastases!may!be!resected,!and!limited!numbers!of!small!metastases!may!be!treated!by!stereotactic!radiosurgery!(personal!communication,!Dr!P.!Hatfield,!2012).!Melanoma!brain!metastases!are!associated!with!very!poor!outcomes,!and!as!such!are!often!an!exclusion!criteria!in!clinical!trials,!however!there!has!been!a!report!of!a!small!study!showing!some!efficacy!of!ipilimumab!in!this!setting!(Margolin!et!al.,!2012).!Further!work!to!identify!therapies!that!continue!to!be!effective!for!intracranial!disease!is!clearly!needed.!For!several!decades!researchers!and!clinicians!have!trialled!several!immunotherapeutic!approaches!in!the!treatment!of!melanoma,!but!without!ever!
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reliably!improving!on!the!existing!standard!of!care.!Ipilimumab!was!the!first!therapy!shown!in!randomised!clinical!trials!to!prolong!survival!in!patients!with!metastatic!melanoma.!It!is!a!toxic!therapy!for!many!patients,!and!the!response!rate!is!relatively!low,!but!its!efficacy!further!asserts!that!the!immune!system!can!be!coerced!into!yielding!significant!benefits!for!patients!with!melanoma.!!!!The!first!ever!report!of!an!effective!therapy!in!the!treatment!of!metastatic!melanoma!was!followed!within!months!by!another!(Donnelly!et!al.,!2012b).!Vemurafenib!is!an!inhibitor!of!mutated!forms!of!BRAF,!present!in!around!half!of!metastatic!melanomas.!Half!the!patients!treated!with!vemurafenib!benefited!from!objective!responses,!and!early!analysis!suggests!a!3Imonth!improvement!in!progressionIfree!survival!(Chapman!et!al.,!2011).!! !
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!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Figure!3.! Inhibition!of! the! immunological!synapses.!A.!Schematic! illustrating! the!synapse!between!DC!and!lymphocytes,! and! lymphocytes! with! their! targets.! Both! CTLAI4! and! PD1/PDL1! serve! to! regulate! TIcell!responses;! accordingly! inhibitory! antibodies! can! enhance! antiItumour! immune! responses.! B.! Phase! III!clinical! testing! of! Ipilimumab,! an! antiICTLA4! monoclonal! antibody,! improved! survival! in! patients! with!metastatic!melanoma.!!!Figures!reproduced!with!permission!from;![Ribas,!Antoni.!“Tumor!Immunotherapy!Directed!at!PDI1.”!New$
England$Journal$of$Medicine!366,!no.!26!(June!28,!2012):!2517–2519.]!and!![Hodi,!F.!et!al.!“Improved!Survival!with!Ipilimumab!in!Patients!with!Metastatic!Melanoma.”!N$Engl$J$Med!363,!no.8!(June!14,!2010)!711I723.],!both!copyright!Massachusetts!Medical!Society.!
A(
B(
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2.2 Immunology(of(Cancer(Most!cancers!arise!in!patients!possessed!of!perfectly!normal!immune!systems,!and!most!cancers!arise!from!previously!normal,!autologous!cells.!Unsurprisingly!then,!the!existence!or!absence!of!a!role!for!the!immune!system!in!cancer!development!and!elimination!was!controversial!for!a!long!time!(Dunn!et!al.,!2002).!However!the!theories!of!immunoediting!and!immunosurveillance!are!increasingly!accepted,!and!the!recent!reIdrafting!by!Hanahan!and!Weinberg!of!their!seminal!hallmarks!of!cancer!seems!to!have!cemented!the!importance!of!the!immune!system(Hanahan!and!Weinberg,!2011;!Finn,!2012).!Emerging!autochthonous!cancers!are!recognised!by!innate!immune!effector!cells.!Innate!cells!such!as!NKIcells!will!destroy!cancers!cells,!releasing!cellular!debris!for!processing!by!antigen!presenting!cells,!which!in!turn!can!activate!an!adaptive!immune!response,!specific!for!tumourIassociated!antigens!(Kim!et!al.,!2007;!Finn,!2012).!The!immune!system!has!the!upper!hand!against!these!small!emerging!tumours!and!may!successfully!eliminate!the!tumour!at!this!point;!if!so!then!it!is!intriguing!to!speculate!on!the!number!of!initiated!cancers!that!never!successfully!emerge!as!detectable!tumours!(Dunn!et!al.,!2002).!However!if!the!immune!system!fails!to!eliminate!the!cancer!then!tumours!and!the!immune!system!likely!exist!in!a!state!of!equilibrium;!the!immune!system!unable!to!eradicate!the!tumour!completely!and!the!tumour!unable!to!outgrow!without!reIactivating!innate!and!adaptive!responses!(Dunn!et!al.,!2002).!In!the!process!all!outgrowing!tumour!clones!that!are!sufficiently!immunogenic!are!eliminated,!and!only!immunologicallyImuted!outgrowths!will!succeed;!thus!tumours!that!do!eventually!escape!control!in!immuneIcompetent!hosts!have!effectively!evolved!to!evade!immune!responses,!soIcalled!immune!editing!(Prestwich!et!al.,!2008a).!The!preclinical!model!which!most!elegantly!supports!this!theory!used!immune!competent!and!immune!incompetent!mice!(Shankaran!et!al.,!2001).!Tumours!were!elicited!in!mice!following!subcutaneous!injection!of!the!mutagen!methylcholanthrene,!and!arose!more!commonly!and!more!quickly!in!mice!deficient!for!lymphocytes!or!interferon!pathways,!or!both,!when!compared!to!wild!type!mice!of!the!same!strain.!Tumours!arising!in!the!knockout!mice!without!fully!functioning!immune!systems,!when!transplanted!to!syngeneic!mice!with!normal!immune!systems,!failed!to!grow!(Figure!4).!! !
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!!!!!!!!!!!!!!Figure! 4.! Immune! editing! of! tumours.! A.! Shankaran! et! al.! injected!mice!with! subcutaneous!mutagen! and!monitored!the!animals!for!the!development!of!sarcomatous!tumours.!Tumours!developed!in!wildtype!mice,!but!they!were!slower!to!emerge,!and!less!frequent,!than!in!syngeneic!mice!lacking!functional!lymphocytes!(RAGI/I!knockout!mice).!When!the!tumours!were!harvested!and!reinjected!into!naïve!mice,!of!each!strain,!wildtype!mice!were! found!to!be!resistant! to! tumours! from!RAGI/I!mice.!These!data!suggest! that! tumours!developing!in!immunodeficient!mice!retain!their!immunogenicity,!whereas!those!that!are!able!to!emerge!in!an! immunocompetent! host! have! been! ‘edited’! by! the! immune! system! resulting! in! immunologically! silent!tumours.! B.! Figure! taken! from! the! original! paper! described! above,! showing! the! kinetics! of! the! emerging!tumours.!Solid!lines!indicate!tumours!that!completely!regressed.!Figure!4B!reprinted!by!permission!from!MacMillan!Publishers!Ltd.!Shankaran,!et!al.!“IFNγ!and!Lymphocytes!Prevent!Primary!Tumour!Development!and!Shape!Tumour! Immunogenicity.”!Nature! 410,!no.!6832! (April!26,!2001):!1107–1111.! !
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Tumours!that!do!successfully!evade!competent!immune!systems!do!so!in!a!number!of!ways.!Tumours!commonly!obscure!their!antigens!from!immune!examination!by!downregulating!MHC!class!I!expression!and!interrupting!antigen!processing!and!MHC!loading!pathways!(Meissner!et!al.,!2005;!Zitvogel!et!al.,!2006;!Campoli!and!Ferrone,!2008).!Low!expression!of!class!I!molecules!can!leave!cells!vulnerable!to!innate!attack,!but!tumour!cells!can!resist!at!least!one!of!the!established!cell!killing!mechanisms!that!lymphocytes!employ!by!expressing!inhibitors!of!granzyme!B,!and!are!also!able!to!release!the!ligands!that!Natural!Killer!cells!(NK)!principally!use!to!recognise!their!targets!(Bladergroen!et!al.,!2002;!Groh!et!al.,!2002).!Furthermore!the!function!of!incoming!lymphocytes!is!attacked!by!tumour!cells,!which!express!Fas!ligand!(CD95L)!on!their!surface,!and!simultaneously!downregulate!their!own!expression!of!the!Fas!receptor!(Real!et!al.,!2001;!Whiteside,!2002).!Moreover!by!reducing!expression!of!adhesion!molecules!present!on!the!intimal!surface!of!tumour!vasculature!the!ability!of!immune!cells!to!enter!tumours!is!diminished!(Castermans!and!Griffioen,!2007;!Wu,!2007;!Schmidt!et!al.,!2012).!!Tumours!also!release!cytokines!and!other!soluble!mediators!that!either!deter!immune!cells,!or!impede!their!function,!including!indoleamine!2,3!dioxygenase!(IDO)!(Uyttenhove!et!al.,!2003).!IDO!is!an!enzyme!that!degrades!tryptophan,!leading!to!local!depletion!of!the!essential!amino!acid!which!in!turn!inhibits!TIcell!proliferation!(Curti!et!al.,!2009).!It!is!worth!noting!that!examining!the!role!of!these!factors!in!isolation!can!lead!to!mixed!results,!and!cytokines!may!have!starkly!contrasting!effects!systemically!or!locally!(Teng!et!al.,!2011).!A!study!in!2002!found!colorectal!tumour!cells!transfected!to!overexpress!interleukinI10!(IL10)!inhibited!systemic!immunity!(Kawamura!et!al.,!2002).!!Contrastingly!a!more!recent!study!found!that!IL10!contributes!to!successful!immunosurveillance!of!tumours!by!upregulating!MHC!class!I,!and!pegylated!IL10!caused!regression!of!established!tumours!in!vivo,!recruiting!CD8+!TIcells!to!the!tumours!(Mumm!et!al.,!2011).!!Architectural!or!organisational!changes!can!also!modify!the!effects!of!a!competent!immune!system.!CCL21Iexpressing!melanoma!tumours!in!mice,!despite!recruiting!more!leukocytes!and!APC!grew!to!be!much!larger!than!the!same!tumour!cell!line!expressing!lower!levels!of!CCL21!(Shields!et!al.,!2010).!The!
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authors!found!that!CCL21!drove!tumours!to!adopt!a!phenotype!that!mimics!the!stroma!of!lymph!nodes,!recruiting!suppressive!immune!cells,!which!in!turn!promoted!tolerogenic!responses.!!!The!role!of!host!immune!cells!subverted!to!suppress!other!immune!cells!is!well!recognised.!The!CD25+!subset!of!CD4+!TIcells!makes!up!around!10%!of!circulating!CD4+!cells!and!plays!a!key!role!in!diminishing!antiItumour!immunity.!Mice!deficient!for!CD4+CD25+!cells!develop!a!broad!spectrum!of!autoimmune!disorders!indicating!that!these!regulatory!TIcells!(TIregs),!manage!the!homeostasis!of!immune!responses!(Dranoff,!2005).!Levels!of!circulating!CD4+CD25+!TIregs!were!considerably!higher!in!patients!with!metastatic!melanoma!when!compared!to!healthy!volunteers,!or!patients!with!early!stage!melanomas,!though!the!relative!importance!of!circulating!and!tumoural!TIregs!remains!unclear!(McCarter!et!al.,!2007).!A!further!marker,!FoxP3!is!clearly!important!in!identifying!these!suppressive!lymphocytes,!and!has!been!associated!with!a!poorer!prognosis!in!patients!with!ovarian!cancer,!though!FoxP3!is!a!less!clear!cut!marker!of!suppressive!cells!in!humans!than!it!is!in!mice!(Curiel!et!al.,!2004;!Vries!et!al.,!2011).!The!mechanisms!by!which!TIregs!exert!their!effects!are!varied,!but!include!secretion!of!inhibitory!cytokines!and!direct!effects!on!DC,!such!as!inducing!their!expression!of!IDO!and!inhibiting!expression!of!the!costimulatory!receptors!(Sakaguchi!et!al.,!2009).!A!further!species!of!cell!that!tumours!recruit!to!protect!themselves!from!immune!responses!are!the!myeloidIderived!suppressor!cells!(MDSC)!(Gabrilovich!and!Nagaraj,!2009).!MDSC!suppress!by!a!range!of!actions,!predominantly!contactIdependent,!and!including!stimulating!the!generation!of!TIregs!(Lechner!et!al.,!2010).!MyeloidIderived!cells!have!also!been!shown!to!contribute!to!tumour!recovery!in!mice,!after!therapeutic!radiotherapy!(Kozin!et!al.,!2010).!!Although!MDSC!have!certainly!been!demonstrated!to!be!present!in!increased!numbers!in!cancer!patients,!some!evidence!suggests!that!their!importance!in!humans!in!vivo!is!somewhat!less!than!that!observed!in!mice;!given!the!challenges!of!identifying!the!various!subsets!of!MDSC,!across!both!species,!further!correlative!studies!will!be!needed!to!confirm!that!assertion!(Gros!et!al.,!2012).!
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2.2.1 TumourCassociated(antigens(The!notion!that!the!immune!system!serves!only!to!distinguish!between!native!antigen!(self)!and!alien!antigen!(nonIself),!was!rebuffed!by!Matzinger’s!refinement!of!the!immunological!model,!which!sought!to!explain!the!prevalence!of!autoimmune!diseases!(Matzinger,!1994).!Matzinger’s!danger!hypothesis!asserted!that!the!immune!system!processes!antigen,!in!part!at!least,!according!to!the!environment!in!which!it!is!encountered!(Matzinger,!2002).!Accordingly,!although!all!nonIvirally!initiated!cancers!would!be!expected!to!express!only!native!antigens,!those!antigens!can!yield!immune!responses!if!they!are!processed!in!an!immunologically!‘dangerous’!context!(Offringa,!2009).!!TumourIassociated!antigens!(TAA)!have!been!categorised!as!follows!(Buonaguro!et!al.,!2011;!Restifo!et!al.,!2012):!
• Unique(TAA!(formerly!tumourIspecific!antigens)!are!the!product!of!gene!mutations!confined!to!transformed!cells!and!therefore!expressed!only!by!cancer!cells!(Rommelfanger!et!al.,!2012).!Several!antigens!once!thought!to!be!tumourIspecific!have!subsequently!been!identified!from!other,!nonItransformed!sources,!hence!the!altered!nomenclature.!!
• Differentiation(antigens!are!persisting!markers!of!the!cancer’s!tissue!of!origin.!In!melanoma!these!antigens!are!often!considered!acceptable!targets,!however!for!most!other!tumour!sites!targeting!these!antigens!could!result!in!unacceptable!toxicity.!! !
• CancerYtestis(antigens!are!expressed!on!normal!cells!during!embryological!development!but!are!subsequently!lost!until!cancer!mutations!revive!their!expression.!They!may!continue!to!be!expressed!in!germ!cells!but!immunological!privilege!(absent!expression!of!MHC)!allows!for!targeting!of!these!antigens!with!minimal!risk!of!toxicity!(Restifo!et!al.,!2012).!!
• WidelyYoccurring(overexpressed(antigens!are!expressed!on!several!normal!cell!types!but!are!aberrantly!overexpressed!on!cancer!cells,!allowing!some!distinction!of!tumour!from!healthy!tissues.!p53,!Her2!and!Survivin!are!examples!(Buonaguro!et!al.,!2011).!
• Viral(antigens!may!be!expressed!in!tumours!resulting!from!oncogenic!viruses!such!as!EpsteinIBarr!or!HPV.!
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!It!must!be!remembered!that!successfully!generating!a!response!against!any!of!these!antigens!carries!the!risk!of!causing!coincident!autoimmune!toxicities,!if!the!antigen!is!expressed!elsewhere!in!the!host.!
2.2.2 Immunology(of(melanoma(Melanoma!is!widely!considered!to!be!a!particularly!immunogenic!tumour,!even!though!some!suggest!that!perception!was!borne!more!of!necessity!than!rigorous!analysis!(Houghton!et!al.,!2001).!Nevertheless!human!and!murine!melanomas!are!commonly!used!in!preclinical!models,!both!in!vitro!and!in!vivo,!of!tumour!immunology!and!immunotherapies,!probably!for!practical!reasons!as!much!as!immunological.!The!relative!accessibility!of!many!metastatic!melanoma!lesions,!and!the!paucity!of!treatment!options!hitherto!available!mean!that!human!tissue!has!often!been!widely!available!for!study,!and!topical!mutagens!allowed!the!development!of!murine!melanoma!cell!lines.!Accordingly!numerous!reagents!have!been!developed!and!are!commercially!available!for!the!study!of!melanoma!immunology,!perhaps!more!so!than!most!other!tumour!sites.!Moreover!the!lack!of!effective!therapies!and!the!significant!numbers!of!young!patients!probably!enhance!recruitment!to!trials!for!metastatic!melanoma!relative!to!some!other!tumour!sites!(Houghton!et!al.,!2001;!Maio,!2012).!!Practical!considerations!aside!there!is!certainly!evidence!that!melanoma!is!a!paragon!tumour!with!which!to!study!potential!immunotherapies:!!!
• Spontaneous!and!complete!tumour!regressions!have!been!reported!in!melanoma!primaries,!and!some!degree!of!regression!is!quite!commonly!evident!on!histological!examination!of!resected!melanoma!primary!lesions!(Menzies!and!McCarthy,!1997;!Martires!KJ,!2012).!!
• Despite!cost,!low!response!rates!and!toxicity!precluding!widespread!use,!clinicians!making!use!of!interleukinI2!(IL2),!interferonIα!(IFNα)!and!adoptive!cell!therapy!(ACT)!have!convincingly!adduced!that!immune!manipulations!can!impact!on!established!metastatic!melanoma!(Atkins!et!al.,!1999;!Dudley!and!Rosenberg,!2003;!Mocellin!et!al.,!2010;!Maio,!2012).!!
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• TumourIinfiltrating!lymphocytes!(TIL)!in!melanoma!lesions!are!associated!with!a!better!prognosis!(Clemente!et!al.,!1996;!Mihm!Jr!et!al.,!1996).!
• Numerous!TAA!have!been,!and!continue!to!be,!identified!in!melanoma!(Houghton!et!al.,!2001).!
2.3 Adoptive(cell(therapy(Despite!the!numerous!impediments!to!their!function,!lymphocytes!capable!of!recognising!a!wide!range!of!TAA!are!commonly!present!in!tumours!–!TIL.!Adoptive!cell!therapy!(ACT)!involves!surgically!excising!a!metastatic!lesion!(predominantly!melanoma)!then!extracting!the!TIL!and!expanding!them!in!culture!with!IL2!(Dudley!and!Rosenberg,!2003).!The!lymphocytes!that!are!successfully!expanded!are!examined!for!evidence!of!reactivity!to!TAA,!prior!to!reinfusion!into!patients!(Dudley!et!al.,!2003).!Current!iterations!of!the!approach!include!preconditioning!patients!before!the!lymphocyte!infusion!with!combinations!of!chemotherapy!and!total!body!irradiation!(up!to!12!Gy)!to!deplete!circulating!lymphocytes!that!would!otherwise!compete!for!cytokines!(Restifo!et!al.,!2012).!Lymphodepletion!also!allows!homeostatic!expansion!of!the!infused!lymphocytes.!!Predominantly!used!for!patients!with!metastatic!melanoma,!the!therapy!has!impressive!results.!Over!the!course!of!three!trials,!enrolling!93!patients,!Rosenberg!reports!complete!responses!in!20!patients,!19!of!whom!remained!apparently!free!of!disease!at!least!57!months!later!(Rosenberg!et!al.,!2011;!Restifo!et!al.,!2012).!Results!outside!the!context!of!a!randomised!clinical!trial!must!always!be!interpreted!with!caution,!and!by!the!authors’!own!admission!these!are!carefully!selected!patients,!but!a!20%!complete!response!rate!in!the!context!of!heavily!pretreated!melanoma!remains!an!astounding!result.!There!are!significant!limitations!to!the!approach:!!
• Patients!must!have!surgically!accessible!disease,!and!be!fit!enough!to!tolerate!the!surgical!procedure!required!to!obtain!enough!tissue.!
• Ex!vivo!preparation!of!TIL!is!technically!challenging,!and!around!50%!of!patients!never!receive!treatment!because!the!culture!fails!to!yield!enough!lymphocytes!for!reIinfusion!(Dudley!et!al.,!2003;!Johnson!et!al.,!2009).!
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• The!conditioning!regimens!are!extremely!toxic,!limiting!the!number!of!patients!who!are!suitable!for!treatment.!Rosenberg!reports!at!least!1!treatment!related!death!amongst!93!treated!patients!(Rosenberg!et!al.,!2011).!!Most!concerning!is!the!fact!that!despite!longstanding!experience!at!the!National!Cancer!Institute!in!Bethesda,!no!other!centre!routinely!performs!ACT,!suggesting!that!despite!apparent!efficacy!for!a!subset!of!patients!the!therapy!in!its!current!form!is!simply!impracticable!for!widespread!use.!!Rosenberg!and!others!have!attempted!to!refine!ACT!by!developing!TIcells!engineered!to!express!a!defined!TIcell!receptor!(TCR).!The!group!cloned!a!TCR!to!the!MART1!antigen!(melanoma!antigen!recognised!by!TIcells,!also!known!as!MelanIA!(Coulie!et!al.,!1994;!Kawakami!et!al.,!1994)),!from!a!patient!who!had!experienced!a!good!response!after!reinfusion!of!expanded!TIL!(Dudley!et!al.,!2002;!Hughes!et!al.,!2005).!Peripheral!CD8+!lymphocytes!collected!from!31!patients!were!transfected!with!a!retroviral!vector!expressing!the!antiIMART1!TCR!(Morgan!et!al.,!2006).!Responses!were!seen!in!only!4!of!the!treated!patients.!A!subsequent!trial,!using!TCR!with!higher!affinity!for!either!MART1!or!gp100,!achieved!responses!in!9!of!36!treated!patients,!but!at!the!cost!of!offItarget!toxicities!(Johnson!et!al.,!2009).!!Despite!the!apparently!reduced!efficacy!of!this!approach!compared!to!TILIbased!ACT!(patients!receiving!engineered!lymphocytes!did!not!have!the!complete!lymphodepleting!regimen!which!improves!the!effectiveness!of!TILIACT),!there!are!considerable!potential!advantages.!Preparation!of!lymphocytes!collected!from!peripheral!blood!is!technically!easier,!and!considerably!more!tolerable!for!patients!than!a!surgical!procedure!to!access!tissue.!The!process!is!also!quicker,!as!more!lymphocytes!can!be!collected,!and!less!time!is!needed!for!ex!vivo!expansion.!The!therapy!is!based!around!the!retroviral!vector,!which!makes!it!considerably!easier!to!implement!in!other!centres,!when!compared!to!the!particular!expertise!needed!in!the!generation!of!activated!tumourIantigenIspecific!TIL.!A!limitation!of!the!approach!is!that!the!vector!used,!and!therefore!the!lymphocytes!produced,!are!HLAIrestricted,!so!either!a!panel!of!vectors!must!be!
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produced,!or!a!significant!proportion!of!patients!will!not!be!suitable!for!the!therapy.!!In!order!to!circumvent!that!critical!limitation!other!groups!have!developed!the!use!of!chimeric!antigen!receptors.!These!are!receptors!expressed!on!the!surface!of!TIcells!that!recognise!antigen!using!a!single!chain!antibody!fragment!rather!than!TCR,!in!an!HLAIindependent!manner.!The!first!generation!of!chimeric!antigen!receptor!T!cells!(CART)!had!the!extracellular!antibody!fragment!tethered!to!an!intracellular!CD3Iζ!domain!in!order!to!stimulate!TIcell!functions!(Brenner!and!Heslop,!2010).!These!first!generation!CART!cells!were!limited!by!a!lack!of!proliferation!and!survival!in!vivo,!so!subsequent!vectors!have!encoded!additional!costimulatory!signalling!domains!(Figure!5).!In!a!recent!report!that!has!garnered!much!attention!third!generation!CART!cells,!targeted!against!CD19,!were!given!to!patients!with!refractory!CLL,!resulting!in!improved!blood!counts!and,!in!one!patient,!apparent!tumour!lysis!syndrome!(Kalos!et!al.,!2011;!Porter!et!al.,!2011).! !!! !
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Figure!5.!The!evolution!of!TIcell!receptors!in!adoptive!cell!therapy.!Antigen!recognition,!whether!presented!by!MHC!molecules!to!the!αβ!chains!of!a!native!TCR,!or!recognised!by!the!variable!region!of!a!singleIchain!antibody!fragment!doesn’t!stimulate!TIcell!proliferation!unless!accompanied!by!additional!signals.!Chimeric!antigen!receptors!have!developed!to!include!additional!intracellular!signalling!domains.!!Reproduced!with!permission!from!Urba,!WJ,!and!Longo,!DL.!“Redirecting!T!Cells.”!The$New$England$Journal$
of$Medicine!365,!no.!8!(August!25,!2011):!754–757.!copyright!Massachusetts!Medical!Society.!!
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2.4 The(immune(effects(of(conventional(therapies(The!concept!of!immunogenic!cell!death!is!emerging!as!an!important!mode!of!action!for!several!existing!cancer!treatments!(Golden!et!al.,!2012).!Cell!death!that!releases!tumourIassociated!antigens!along!with!damageIassociated!molecular!patterns!or!danger!signals!may!mature!DC!or!other!APC!to!recruit!antiItumour!immune!responses.!A!significant!amount!of!preclinical!evidence!now!suggests!that!conventional!therapies!such!as!chemotherapy!and!radiotherapy,!in!addition!to!their!canonical!mechanisms,!can!cause!inflammatory!cell!death!that!recruits!immune!responses!(Zitvogel!et!al.,!2008).!Indeed!in!a!number!of!models!the!efficacy!of!chemotherapy!and!radiotherapy!are!diminished!in!mice!lacking!elements!of!the!immune!response!(Ma!et!al.,!2010).!!!Much!of!the!work!in!this!areas!has!come!from!the!groups!of!Guido!Kroemer!and!Laurence!Zitvogel,!beginning!with!their!finding,!published!in!2005,!that!chemotherapyIinduced!cell!death!could!yield!antiItumour!immune!responses!(Casares!et!al.,!2005).!The!seminal!publication!from!the!group!demonstrated!that!several!chemotherapy!agents,!and!local!radiotherapy,!killed!cancer!cells!and!in!so!doing!stimulated!the!dying!cells!to!release!High!Mobility!Group!Box!1!(HMGB1)!(Apetoh!et!al.,!2007b).!HMGB1!is!a!potent!danger!signal!that!is!recognised!by!the!TollIlike!receptor!4!(TLR4)!within!DC.!DC!are!in!turn!activated!to!process!and!crossIpresent!released!TAA!to!TIcells.!The!paper!went!on!to!demonstrate!that!the!generation!of!antitumour!immunity!as!a!result!of!immunogenic!cell!death!was!in!fact!a!requisite!of!therapy,!rather!than!just!an!incidental!effect!–!mice!deficient!for!TLR4!obtained!considerably!less!benefit!from!chemotherapy!or!radiotherapy!than!the!wildtype!mice.!!A!previous!paper!from!the!same!group!found!that!a!critical!determinant!of!whether!cell!killing!was!immunogenic!or!not!was!the!exposure,!or!not,!of!calreticulin!on!the!surface!of!dying!tumour!cells!(Obeid!et!al.,!2007b).!Exposed!calreticulin!on!the!external!surface!of!cells!acts!as!an!‘eatIme’!signal!to!phagocytic!cells.!Insult!to!the!endoplasmic!reticulum!appeared!to!be!the!critical!effect!of!therapies!that!yield!immunogenic!cell!death!and!was!independent!of!the!efficiency!of!cell!killing!(Panaretakis!et!al.,!2009).!!!
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One!criticism!of!these!findings!has!been!that!a!relatively!small!number!of!groups!have!been!able!to!demonstrate!these!effects.!Ciampricotti!et!al.!recently!published!a!direct!retort!to!the!work!of!Zitvogel!and!Kroemer.!Ciampricotti!et!al.!reported!that!the!effect!of!the!immune!system!did!not!contribute!to!the!efficacy!of!platinumIbased!chemotherapy!in!models!of!spontaneouslyIdeveloping!mammary!tumours!(Ciampricotti!et!al.,!2012).!No!difference!in!the!response!to!chemotherapy!was!seen!in!RAG!knockout!mice!compared!to!RAG!heterozygotes.!The!authors!contend!that!their!model!is!a!far!better!mimic!of!the!way!that!human!tumours!emerge,!i.e.!in!the!presence!of!a!functioning!immune!system,!and!that!the!findings!of!Zitvogel!and!Kroemer!are!in!part!due!to!the!artifice!of!using!mutagens!or!implanting!large!numbers!of!immortalised!tumour!cells.!Zitvogel!and!Kroemer!were!afforded!an!immediate!rightItoIreply,!and!in!the!same!journal!issue!argued!that!the!effects!they!had!previously!reported!are!likely!to!be!extremely!dependent!on!the!therapy!used,!the!tumour!treated!and!hostIrelated!factors!(Zitvogel!and!Kroemer,!2012).!It!is!also!worth!noting!that!their!2006!paper!included!a!retrospective!analysis!of!280!breast!cancer!patients,!stratified!according!to!TLR4!polymorphisms,!which!found!worse!progressionIfree!survival!after!anthracyclineIbased!chemotherapy!for!women!with!an!aberrant!TLR!allele!(Apetoh!et!al.,!2007b).!A!separate!group!reported!that!even!Imatinib,!the!doyen!of!rationally!designed!molecular!therapies,!generates!and!relies!upon!immune!responses;!treatment!with!imatinib!reduced!tumour!cell!production!of!IDO!in!mice!with!gastrointestinal!stroma!tumours,!and!successful!therapy!was!diminished!when!CD8+!TIcells!were!depleted!(Balachandran!et!al.,!2011).!!!Taken!together!these!data!suggest!that!careful!selection!of!anticancer!therapy!could!be!combined!with!other!strategies!to!yield!more!robust!antiItumour!immunity!than!either!alone.!Moreover!combining!novel!immuneIbased!approaches!with!proven!therapies!is!likely!to!be!a!more!appealing!strategy!to!patients!and!clinicians!than!simply!testing!new!immunotherapies!alone.!!Some!of!the!established!methods!by!which!a!cancer!will!endeavour!to!evade!and!overcome!host!immune!responses!are!described!above,!though!of!course!more!are!known,!and!yet!more!are!not!–!some!of!the!mechanisms!specifically!
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identified!in!murine!melanoma,!as!opposed!to!other!tumour!types,!are!listed!in!Overwijk’s!review!(Overwijk,!2005).!What!seems!clear!is!that!simply!generating!an!adaptive!response!against!a!tumour!antigen!is!unlikely!to!be!sufficient;!successful!immunotherapy!will!presumably!need!to!overcome!tumourImediated!immune!suppression,!sometimes!referred!to!as!‘breaking!tolerance’!(Mapara!and!Sykes,!2004).!Most!of!the!mechanisms!employed!by!a!tumour!are!corruptions!of!normal!systems!in!place!to!protect!against!inadvertent!and!inappropriate!autoimmune!responses,!and!therefore!overcoming!them!has!remained!challenging.!Notably!the!immunotherapies!that!have!demonstrated!efficacy,!discussed!above,!have!only!produced!benefits!for!a!small!proportion!of!the!patients!treated,!but!often!profound!benefits!for!that!minority!–!most!of!the!patients!who!completely!respond!to!ACT!for!metastatic!melanoma!have!remained!free!of!disease!throughout!their!followIup!(Rosenberg,!2012).!It!is!possible,!though!speculative,!that!the!cancers!of!that!minority!mount!only!minimal!barriers!to!immunotherapy,!which!can!be!overcome!simply!by!force!of!numbers!when!bombarded!by!ACT!(Overwijk,!2005).!Approaches!which!are!able!to!reverse!the!immunosuppressive!environment!created!by!tumours!may!therefore!improve!the!response!rates!of!existing!immunotherapeutic!approaches.! !! !
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2.5 Oncolytic(viruses(Oncolytic!viruses!(OV)!are!naturally!occurring!or!genetically!engineered!viruses,!which!specifically!replicate!in!and!kill!malignant!cells,!whilst!sparing!nonItransformed!cells!(Kirn!et!al.,!2001).!Their!study!and!development!emerged!as!a!result!of!the!long!history!of!sporadic!cancer!remissions!associated!with!viral!illnesses!(Kelly!and!Russell,!2007).!Although!efforts!to!use!viruses!have!been!pursued!since!the!1940s!and!50s,!in!the!last!two!decades!advances!in!virology!and!molecular!biology!have!accelerated!progress!in!the!field.!At!present!around!20!such!OV!are!being!studied!for!oncolytic!potential!preclinically,!and!half!a!dozen!have!been!administered!in!clinical!trials!(Donnelly!et!al.,!2012a).!The!unmodified!OV!in!use!are!suitably!benign!in!most!humans:!Newcastle!disease!virus!is!a!pathogen!for!poultry!but!not!associated!with!illness!in!people!(Donnelly!et!al.,!2012a).!Vesicular!stomatitis!virus!(VSV)!doesn’t!cause!serious!or!widespread!illness!in!humans!but!is!of!particular!concern!in!cattle!as!its!clinical!pattern!mimics!foot!and!mouth!disease!(Pringle,!2001).!Its!use,!preclinical!or!therapeutic,!is!currently!prohibited!in!the!UK!(personal!communication!Prof!A.!Melcher!2012)!but!is!used!in!several!laboratories!in!North!America,!and!a!clinical!trial!is!underway!in!the!USA!(personal!communication!Prof!R.!Vile!2012).!Reovirus!is!thought!to!cause!one!of!the!legion!of!unnamed!and!trivial!viral!illnesses!of!childhood,!but!not!serious!illness!in!adulthood!(Forsyth!et!al.,!2008).!Measles!virus!(MV),!as!discussed!further!below,!is!a!serious!pathogen!but!the!strains!in!use!as!OV!are!based!on!attenuated!vaccine!products!(Donnelly!et!al.,!2013).!Other!viruses,!with!genuine!pathogenic!potential,!are!also!in!use,!but!have!been!attenuated!by!genetic!modification.!Adenovirus!generally!has!the!E1!gene!deleted,!herpes!simplex!virus!(HSV)!commonly!has!its!neurovirulence!gene!(ICP34.5)!deleted,!and!thymidine!kinase!is!removed!from!vaccinia!strains!before!use!(Kelly!and!Russell,!2007;!Merrick!et!al.,!2009;!Donnelly!et!al.,!2012a).!!The!selectivity!of!OV!can!be!mediated!by!viral!tropism!for!receptors!overexpressed,!or!uniquely!expressed,!on!cancer!cells!relative!to!normal!cells!(Anderson!et!al.,!2004).!Alternatively,!or!additionally,!aberrant!cellular!pathways!within!cancer!cells,!such!as!deficient!IFN!responsiveness,!make!them!more!conducive!hosts!for!OV,!compared!to!normal!cells!(Stojdl!et!al.,!2000;!CritchleyI
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Thorne!et!al.,!2009).!Engineered!viruses!can!also!be!rendered!dependent!on!tissueIspecific!promoters!for!successful!viral!replication,!or!in!the!case!of!vaccinia!lacking!thymidine!kinase,!cycling!cells!for!the!production!of!nucleotides!(Merrick!et!al.,!2009;!Donnelly!et!al.,!2012a).!The!clinical!experience!with!OV!has!predominantly!focussed!on!addressing!concerns!about!safety,!both!to!patient!and!their!attendants.!Thus!far!there!have!been!no!significant!safety!concerns!and!for!most!viruses!the!doses!reached!in!phase!I!trials!have!been!limited!by!manufacturing!issues,!rather!than!dose!limiting!toxicities!(Donnelly!et!al.,!2012a;!Russell!et!al.,!2012).!Clear!evidence!of!efficacy!is!somewhat!lacking!so!far.!H101,!a!modified!adenovirus!was!tested!in!a!randomised!phase!III!trial,!performed!in!China,!in!which!patients!with!head!and!neck!cancers!received!intratumoural!injections!of!the!virus!in!combination!with!systemic!chemotherapy.!The!results!were!analysed!in!a!per!protocol!fashion,!and!an!improvement!in!response!rate!from!40%!to!79%!was!reported!(Xia!et!al.,!2004).!Survival!data!were!incompletely!gathered,!apparently!due!to!the!challenges!associated!with!follow!up!in!rural!areas!of!the!world’s!most!populous!country.!More!recently!a!phase!III!trial!of!OncoVex,!a!type!I!HSV!engineered!to!express!GMICSF!(granulocyte!macrophage!colonyIstimulating!factor),!and!with!deletions!of!the!genes!encoding!ICP34.5!and!ICP47,!has!completed!accrual!and!data!are!expected!in!early!2013.!In!the!preceding!phase!II!trial!50!patients!with!metastatic!melanoma,!were!treated!with!intratumoural!injections!of!the!virus!into!accessible!lesions.!10!patients!had!complete!responses,!and!there!were!objective!responses!in!some!uninjected!visceral!metastases!(Senzer!et!al.,!2009).!The!clinical!experience!of!OV!so!far!has!asserted!their!safety!but!more!needs!to!be!done!to!demonstrate!or!enhance!efficacy!(Bell,!2010).!!The!concept!of!OV!was!originally!based!on!the!premise!that!a!successful!therapy!would!be!mediated!by!the!direct!oncolytic!activity!of!a!virus,!however!there!is!burgeoning!recognition!amongst!the!field!that!a!significant!element!of!therapy!is!in!fact!the!development!of!antitumour!immune!responses!as!a!result!of!treatment!with!OV!(Russell!et!al.,!2012).!There!is!abundant!evidence!from!preIclinical!studies!that!therapy!with!OV!can!stimulate!both!innate!and!adaptive!antiItumour!immune!responses!(Errington!et!al.,!2008a,!2008b;!Prestwich!et!al.,!
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2008b,!2008c,!2009a;!Worschech!et!al.,!2009).!The!Melcher!group!has!published!extensively!on!the!immune!consequences!of!treatment!with!OV,!principally!reovirus.!Having!demonstrated!the!oncolytic!activity!of!reovirus!in!several!human!melanoma!cell!lines!in!vitro!they!also!identified!an!inflammatory!pattern!of!cytokines!released!in!the!course!of!oncolysis!that!contrasted!with!killing!by!conventional!modalities!(Errington!et!al.,!2008b).!This!cytokine!release!activated!dendritic!cells,!as!did!direct!treatment!with!reovirus,!which!in!turn!were!able!to!enhance!innate!tumour!cell!killing!(Errington!et!al.,!2008a).!Subsequent!work!demonstrated!that!DC!cultured!with!reovirusItreated!melanoma!cells!were!able!to!crossIpresent!melanoma!antigens!and!prime!melanomaIspecific!TIcell!responses!from!autologous!lymphocytes,!in!both!in!vitro!and!in!vivo!models!(Prestwich!et!al.,!2008b).!Similar!results!have!also!been!reported!in!models!of!mesothelioma!and!ovarian!cancer!using!measles!and!reovirus!respectively!(Gauvrit!et!al.,!2008!and!personal!communication!Dr!V!Jennings!2011).!An!in!vivo!study!of!mice!bearing!either!colorectal!or!melanoma!tumours,!treated!intratumourally!with!HSV!found!increases!in!tumour!antigenIspecific!TIcells!(Toda!et!al.,!1999).!!Moreover!there!is!evidence!from!preIclinical!models!that,!in!some!tumourIOV!dyads!at!least,!therapy!is!in!fact!dependant!on!the!immune!enhancing!effects!of!OV,!rather!than!direct!oncolysis!per!se!(Diaz!et!al.,!2007;!Wongthida!et!al.,!2010;!Prestwich!et!al.,!2009b).!Diaz!et!al!demonstrated!that!therapy!with!VSV!reduced!the!metastatic!burden!in!melanomaIbearing!immuneIcompetent!C57BL/6!mice,!but!not!in!lymphocyte!depleted!mice!(Diaz!et!al.,!2007).!Prestwich!et!al!reported!similar!discrepancies!between!C57BL/6!and!SCID!mice!(Prestwich!et!al.,!2009b).!Additionally,!tumour!cell!lines!that!are!resistant!to!OV!in!vitro,!have!responded!in!vivo,!suggesting!the!need!for!elements!of!the!immune!system!to!mediate!therapy!(Apostolidis!et!al.,!2007;!Prestwich!et!al.,!2009b).!Several!clinical!trials!of!OV!have!taken!the!opportunity!to!explore!translational!endpoints,!including!the!immunological!effects!of!therapy,!albeit!within!early!phase,!nonIrandomised!trials.!As!mentioned!above,!trials!of!OncoVEX!in!melanoma!patients!have!demonstrated!tumour!responses,!including!uninjected!lesions!(Senzer!et!al.,!2009).!A!companion!report!identified!evidence!of!MART1!specific!antiItumour!immune!responses,!when!tissue!samples!from!trial!patients!
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were!compared!with!untreated!nonItrial!melanoma!patients,!with!decreased!numbers!of!suppressive!Tregs!and!MDSC!observed!within!treated!tumours!(Kaufman!et!al.,!2010).!In!one!of!his!innumerable!and!exemplary!expostulations!of!the!traditional!view!of!OV!efficacy,!Prestwich!details!the!proposed!mechanisms!by!which!OV!are!thought!to!overcome!tumourIgenerated!immunosuppression!and!raise!adaptive!immune!responses!(Prestwich!et!al.,!2008c!and!Figure!6).!! !
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!
!Figure!6.!OVItreatment!of!tumours! leads!to!adaptive!antiItumour!immune!responses.! In!addition!to!direct!oncolysis,!OV!will!stimulate!infected!tumour!cells!to!release!numerous!inflammatory!cytokines!and!danger!signals! that! recruit!and!activate!DC.!These!DC! in! turn!will! take!up!and!present!TAA,!priming!antiItumour!immune!responses.!!Reproduced! from!Prestwich! et! al.! “Oncolytic!Viruses:! a!Novel! Form!of! Immunotherapy.”!Expert$Review$of$
Anticancer$Therapy!8,!no.!10!(October!2008):!1581–1588!with!permission!of!Expert!Reviews!Ltd.!! !
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The!best!route!of!delivery!for!OV!remains!contentious!(Donnelly!et!al.,!2012c).!!A!concern!about!the!practicability!of!OV!was!that!systemic!delivery!would!result!in!significant!antiIviral!immune!responses,!which!could!clear!the!virus,!and!abrogate!therapy!(Donnelly!et!al.,!2012c).!Systemically!administered!viruses!will!adhere!to!erythrocytes!and!other!blood!cells,!be!bound!up!within!the!spleen!and!liver,!and!face!neutralisation!by!neutralising!antibodies!and!complement.!Circulating!antibodies!will!be!present!for!commonly!encountered!viruses,!and!will!be!produced!whenever!repeated!doses!of!OV!are!used!(Iankov!et!al.,!2007;!White!et!al.,!2008).!Clinical!testing!of!OncoVEX!was!performed!with!intraItumoural!injections!in!an!effort!to!circumvent!such!concerns!(Senzer!et!al.,!2009).!!Two!recently!reported!studies!have!shown!that!OV!can!reach!tumours,!even!in!the!face!of!neutralising!antibodies,!though!the!mechanisms!involved!are!the!subject!of!ongoing!investigations!(Breitbach!et!al.,!2011;!Adair!et!al.,!2012).!Breitbach!et!al.!administered!intravenous!JX594!to!patients!with!a!variety!of!tumours!(Breitbach!et!al.,!2011).!JX594!is!a!vaccinia!virus!derived!from!the!Wyeth!strain,!modified!to!remove!viral!thymidine!kinase,!armed!with!GMICSF!and!labelled!with!βIgalactosidase!(Merrick!et!al.,!2009).!Patients!with!a!number!of!different!tumour!types!receiving!the!higher!doses!of!virus!had!evidence!(immunohistochemistry!for!viral!proteins!or!βIgalactosidase,!or!polymerase!chain!reaction!for!viral!sequences)!of!viral!gene!or!protein!expression,!including!one!patient!who!had!preIexisting!antiIvaccinia!antibodies.!Another!study!involved!delivery!of!intravenous!reovirus!daily!for!up!to!five!days!1I4!weeks!before!surgical!resection!of!hepatic!metastases!(Adair!et!al.,!2012).!In!contrast!to!the!Breitbach!study,!all!ten!patients!had!existing!neutralising!antiIreovirus!antibodies!(NARA),!which!increased!over!the!course!of!repeated!doses!of!reovirus.!Reovirus!was!identified!in!resected!tumours!by!IHC,!but!crucially!replicating!virus!was!recovered!by!plaque!assay.!This!finding!provides!compelling!evidence!that!intravenously!delivered!virus!can!reach!tumour.!A!further!notable!result!from!this!study!was!the!identification!of!replicating!virus,!by!plaque!assay,!in!the!peripheral!blood!mononuclear!cells!(PBMC),!granulocytes!and!platelets.!Reovirus!was!detected!in!plasma!by!PCR,!but!not!plaque!assay,!suggesting!that!the!virus!was!functionally!neutralised!by!NARA,!but!carried!
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safely!by!elements!of!the!cell!fraction.!It!has!previously!been!reported!that!oncolytic!viruses!can!be!loaded!onto!or!into!several!cell!species!ex!vivo,!then!readministered!to!enhance!delivery!to!tumours,!in!a!mechanism!commonly!referred!to!as!hitchhiking!(Ilett!et!al.,!2009,!2011;!Peng!et!al.,!2009).!The!results!of!Adair’s!clinical!study!suggest!that!hitchhiking!is!a!phenomenon!that!can!occur!entirely!in!vivo,!without!the!need!for!an!ex!vivo!loading!step;!if!so!this!newly!identified!process!could!be!augmented!in!order!to!enhance!the!efficacy!of!OV!therapy.!!
2.5.1 Measles(virus(Measles!virus!(MV)!was!one!of!the!first!viruses!tested!as!a!potential!oncolytic!virus!(OV).!Indeed!some!of!the!earliest!reports!of!cancer!regressions!associated!with!viral!infections,!which!in!turn!prompted!the!genesis!of!the!field,!were!following!the!measles!illness!(Bluming!and!Ziegler,!1971;!Kelly!and!Russell,!2007).!!The!pathogenic!or!wild!type!strain!of!MV!(hereafter!wtMV)!remains!a!significant!cause!of!morbidity!and!mortality!worldwide;!the!WHO!website!estimates!that!there!continue!to!be!139,000!deaths!per!year!as!a!result!of!wtMV!infections.!This!is!despite!the!existence!of!an!efficacious!and!safe!vaccine!strain!for!over!half!a!century.!Enders!and!Peeble!were!the!first!to!isolate!MV!from!throat!swabs!taken!from!a!young!boy!called!David!Edmonston!in!1954!(Katz,!2009).!After!repeated!passages!in!several!cell!lines!the!resulting!strain,!known!as!the!Edmonston!strain,!has!fathered!the!generation!of!most!MV!vaccines!ever!since.!After!a!long!history!of!application!as!a!replication!competent!but!attenuated!vaccine!the!Edmonston!strain!of!MV!(hereafter!simply!MV)!has!been!demonstrated!to!be!safe!and!well!tolerated!(Blechacz!and!Russell,!2008).!!!Measles!is!a!singleIstranded!negativeIsense!RNA!enveloped!morbillivirus!of!the!paramyxoviridae!family.!The!viral!genome!is!16!kb!in!length!and!encodes!8!proteins!within!6!genes!(Griffin!and!Oldstone,!2009)!(Figure!7).!!MV!binds!its!cell!surface!receptors!using!the!fusion!(F)!and!haemagglutinin!(H)!viral!envelope!glycoproteins.!A!trimer!is!formed!between!one!FIprotein!and!a!dimer!of!HIproteins!that!forms!a!spike!exposed!on!the!surface!of!the!viral!
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membrane.!When!the!HIprotein!binds!its!receptor!conformational!changes!are!induced!in!the!FIprotein,!triggering!the!fusion!process!(Navaratnarajah!et!al.,!2009).!CD46!has!been!demonstrated!to!be!the!preferred!receptor!for!the!Edmonston!strain!(Dörig!et!al.,!1993).!CD46,!also!known!as!the!membrane!cofactor!receptor,!is!expressed!on!all!nucleated!human!cells.!It!binds!the!complement!components!C3b!and!C4b!and!serves!as!a!cofactor!for!their!proteolytic!inactivation,!protecting!host!cells!from!complementImediated!lysis!by!the!membrane!attack!complex!(Kemper!and!Atkinson,!2009).!CD46!is!internalized!on!cells!infected!with!EdMV,!which!could!perhaps!render!the!cell!more!vulnerable!to!complementImediated!lysis!(Gerlier!et!al.,!1995).!wtMV!strains!require!an!alternative!receptor,!CD150,!also!known!as!signalling!lymphocyteIactivation!molecule!(SLAM);!the!Edmonston!strain!is!also!able!to!use!this!receptor!(Tatsuo!et!al.,!2000).!!SLAM!is!expressed!predominantly!on!immune!cells!and!the!dependence!of!wtMV!on!this!cellIsurface!protein!probably!explains!the!predilection!of!wtMV!for!lymphoid!cells!and!immunosuppressive!clinical!manifestations!(Dhiman!et!al.,!2004).!Two!groups!have!recently!reported!that!Nectin4,!a!protein!overexpressed!on!several!tumour!types,!is!an!additional!receptor!for!both!the!wtMv!and!Edmonston!strains!(Mühlebach!et!al.,!2011;!Noyce!et!al.,!2011).!Once! a! virion! has! fused! with! a! target! cell! and! successfully! transcribed! viral!mRNAs,! viral! spread! can! be! propagated! by! two! mechanisms;! in! addition! to!generating! and! shedding! new! viral! particles,! cells! may! directly! fuse! with!uninfected!neighbours!by!virtue!of!viral!F!and!H!expression.!This! leads,! in!vivo!and! in! vitro,! to! the! characteristic! cytopathic! effect! (CPE)! of! giant!multinuclear!cells!or!syncytia,!large!fused!cells!that!may!contain!hundreds!of!nuclei.!Warthin!and!Finkeldey!independently!recognised!such!appearances!in!the!lymph!nodes!of!children!suffering!measles!infection!(Paik!et!al.,!2002).!The!nucleocapsid!(N)!protein,!phosphoprotein!(P)!and!large!(L)!protein,!together!with! the! 16k! negativeIsense! single! strand! RNA,! form! the! ribonucleoprotein!(RNP),!with!P!and!L!also! forming!the!RNAIdependent!RNA!polymerase!(RdRp).!!Matrix!protein!(M)!underlies!the!viral!membrane!and!is!thought!to!interact!with!the!transmembrane!domains!of!F!and!H.! !Regions!within!the!P!gene!encode!the!remaining! proteins,! C! and! V;! whilst! neither! is! involved! in! viral! structure,! nor!
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requisite! for!viral!replication,! they!may!play!roles!within!host!cells!moderating!IFN!signalling!pathways!(Fields!et!al.,!2007).!
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!
!Figure!7.!The!measles!virion!A.!Schematic!representation!of!the!MV!genome!and!depiction!of!the!relative!transcription!levels!of!!each!gene!(N!nucleocapsid;!P!phosphoprotein,!M!matrix,!F!fusion,!H!haemagluttinin,!L!polymerase.!C!and!V!proteins!are!encoded!within!the!P!gene.).!This!figure!illustrates!a!MV!expressing!GFP.!Most!published!MV!variants!express!inserted!genes!at!the!3'!end.!B.!Coloured!transmission!electron!microscopy!of!a!measles!virion.!!Figure!7A!adapted!from!!Duprex,and!Rima.!“Using!Green!Fluorescent!Protein!to!Monitor!Measles!Virus!CellItoICell!Spread!by!TimeILapse!Confocal!Microscopy.”!In!Green$Fluorescent$Protein,!297–307,!2002.!Figure!7B!courtesy!of!C.!Goldsmith!and!W.!Bellini,!via!the!Public!Health!Image!Library!of!the!Center!for!Disease!Control!and!Prevention,!freely!available!at!phil.cdc.gov.!!!!!
3'# #5'GFP N P M F H L
B(
A(
!! Introduction! !
52!
Study!of!MV!as!a!potential!OV!has!been!performed!by!several!groups!internationally,!but!most!importantly!by!teams!at!the!Mayo!clinic,!USA.!They!have!demonstrated!the!virus’!efficacy!against!a!number!of!human!tumours,!based!on!in!vitro!techniques!and!xenograft!models!and!performed!preclinical!toxicity!assessments!(Grote!et!al.,!2001;!Peng!et!al.,!2003b;!Fielding,!2005;!Hasegawa!et!al.,!2006;!Myers!et!al.,!2007,!2008;!Blechacz!and!Russell,!2008).!Other!groups!have!also!explored!the!virus,!most!notably!a!small!study!of!intratumoural!injections!of!MV!for!5!patients!with!cutaneous!TWcell!lymphoma!was!performed!in!Switzerland!(Heinzerling!et!al.,!2005;!Kunzi!et!al.,!2006).!The!Swiss!group!found,!in!addition!to!tumour!regressions,!some!evidence!of!increased!TWcell!recruitment!to!tumours,!although!patients!were!also!treated!with!systemic!IFNα!prior!to!virotherapy.!!The!preclinical!data!have!in!turn!led!to!earlyWphase!clinical!trials!in!patients!with!ovarian!cancer,!glioblastoma!multiforme,!multiple!myeloma!and!mesothelioma,!with!the!virus!proving!to!be!well!tolerated!when!delivered!systemically,!intraperitoneally!or!intracranially!(Msaouel!et!al.,!2009).!No!maximum!tolerated!dose!has!yet!been!reported,!instead!manufacturing!limits!currently!cap!the!dose!at!around!1010!TCID50!(personal!communication!Dr!Mark!Federspiel!2012).!!!Most!of!the!efforts!of!the!Mayo!group!have!focussed!on!the!direct!oncolytic!potential!of!MV,!rather!than!the!immunological!consequences!of!such!therapy.!Several!variants!of!MV!have!been!developed!by!appending!recombinant!proteins!or!singleWchain!variable!region!antibody!fragments!(scFv)!on!the!MV!H!protein,!which!then!target!tumours!more!specifically.!Latterly!several!groups!have!sought!to!improve!the!efficacy!of!MV!by!‘arming‘!the!virus!in!a!number!of!ways!(Table!1).!The!development!of!MV!has!closely!mirrored!that!of!the!whole!OV!field,!in!that!initial!concerns!about!safety!rightly!necessitated!some!diminution!of!viral!efficacy;!as!toxicity!has!proved!to!be!a!rare!problem!with!OV,!so!many!groups!are!now!seeking!to!restore,!or!increase,!viral!potency.!
!
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54!A!key!publication!by!Gauvrit!et!al.!showed!that!the!Schwarz!strain!of!MV,!has!oncolytic!activity!against!human!mesothelioma,!causing!apoptosis!and!syncytia!formation!(Gauvrit!et!al.,!2008).!Moreover!the!group!observed!phagocytosis!of!MVHinfected!mesothelioma!cells!by!dendritic!cells,!which!in!turn!were!matured,!and!able!to!cause!the!proliferation!of!THcells!specific!for!mesotheliomaHassociated!antigen.!Measles!is!commonly!perceived!to!be!an!immunosuppressive!virus!because!of!the!potent!immunosuppression!associated!with!the!wildtype!virus.!Gauvrit!demonstrated!that!by!contrast!a!vaccine!strain!of!MV,!as!might!be!expected!given!its!longstanding!use!in!prophylaxis,!is!not!immunosuppressive!in!an!in!vitro!model.!Specifically!DC,!which!are!thought!to!be!particularly!vulnerable!to!the!effects!of!wtMV!were!not!found!to!be!susceptible!to!the!Schwarz!MV.!Though!little!of!the!work!with!MV!undertaken!by!the!Russell!group!has!explored!the!immunogenicity!of!therapy!with!MV,!and!was!predominantly!done!in!immunodeficient!mice!bearing!xenografts,!the!group!has!previously!reported!the!role!of!neutrophils!in!MVHtherapy.!Comparing!MV!modified!to!express!GMHCSF,!with!unmodified!MV,!Grote!et!al.!identified!neutrophils!as!enhancing!virotherapy!(Grote!et!al.,!2003).!!A!recent!followHup!by!one!of!the!original!authors!suggests!that!this!stimulation!of!neutrophils!is!achieved!only!by!MV,!and!not!wtMV,!and!argues!that!this!differential!effect!on!neutrophils!is!key!to!the!success!of!MV!as!an!oncolytic!agent!(Zhang!et!al.,!2012).!The!Mayo!group!have!recently!sought!to!exploit!this!phenomenon!by!generating!MV!which!expresses!a!neutrophil!activating!protein!(NAP)!(Iankov!et!al.,!2012).!The!NAP!used!is!derived!from!H.pylori!and!significantly!enhanced!therapeutic!efficacy!in!a!number!of!tumour!models.!As!discussed!above!several!groups!have!sought!to!evade!neutralising!host!antiHviral!immunity,!which!might!deplete!systemically!administered!virus.!The!groups!based!at!the!Mayo!clinic!have!described!the!use!of!THcells!and!mesenchymal!stem!cells!for!viral!hitchhiking!(Ong!et!al.,!2006a;!Mader!et!al.,!2009).!!Notably,!prior!to!the!research!outlined!in!this!thesis!there!were!no!published!reports!describing!the!use!of!MV!in!melanoma,!either!as!a!directly!oncolytic!agent,!or!as!an!activator!of!the!innate!or!adaptive!immune!systems!(Donnelly!et!al.,!2013).!
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2.6 Radiotherapy/Radiotherapy!(RT)!was!used!to!treat!cancers!almost!as!soon!as!the!existence!of!XHrays!was!identified.!In!external!beam!RT!highHenergy!photons!generated!by!a!linear!accelerator!are!directed!toward!the!tumour!and!a!minimal!margin!of!surrounding!tissue.!Brachytherapy!is!the!use!of!internal!radiation!sources,!generally!sealed!sources!such!as!the!titanium!coated!pellets!of!IodineH125!that!are!used!in!prostate!brachytherapy!and!plaqueHbased!brachytherapy!for!ocular!melanoma.!In!either!format!of!RT,!high!energy!photons!interact!with!the!tissue!they!traverse,!depositing!energy!and!triggering!ionising!events.!These!events!in!turn!lead!to!the!generation!of!reactive!oxygen!species!that!can!damage!components!of!the!cell,!critically!DNA.!When!DNA!in!the!cell!is!damaged!beyond!the!ability!of!the!cell!to!repair!it,!that!cell!becomes!replicationHincompetent!and!will!either!undergo!apoptosis!or!mitotic!catastrophe!when!it!does!try!to!replicate.!Classical!radiobiological!experiments,!including!the!use!of!microbeam!irradiators!to!selectively!target!organelles,!isolated!the!nucleus!as!the!critical!organelle!of!the!cell!that!mediates!vulnerability!to!radiation;!most!other!forms!of!damage!are!generally!thought!to!be!repaired!or!ignored!(Joiner!and!Van!der!Kogel,!2009;!Hall!and!Giaccia,!2011).!!The!therapeutic!index!of!RT!is!based!on!the!deficient!damage!sensing!and!repair!pathways!of!most!cancer!cells,!relative!to!adjacent!normal!tissue.!In!practice!the!dose!delivered!to!tumour!is!generally!limited!by!the!dose!that!adjacent!normal!structures!can!safely!tolerate.!The!sensitivity!of!different!tumours!to!the!effects!of!radiotherapy!varies!according!to!histology,!and!generally!melanoma!has!been!considered!to!be!one!of!the!most!radioresistant!tumours.!Though!RT!is!certainly!used!in!the!palliative!setting!for!melanoma,!there!has!been!little!enthusiasm!to!expand!its!use!otherwise!(Stevens!and!McKay,!2006).!Despite!this,!a!recent!clinical!trial!has!demonstrated!a!small!advantage!in!local!control!when!RT!is!used!as!an!adjuvant!treatment!after!highHrisk!lymph!node!dissections!(Burmeister!et!al.,!2012).!Irradiating!lymph!node!basins!is!invariably!associated!with!morbidity,!and!the!treatment!did!not!result!in!an!overall!survival!benefit.!These!results!are!unlikely!to!yield!major!changes!in!clinical!practice,!however!they!do!confirm!that!RT!can!have!activity!against!melanoma.!!The!potential!immune!enhancing!effect!of!radiotherapy!has!been!much!neglected,!partly!because!early!researchers!chose!to!focus!on!human!tumour!and!cell!lines,!reasoning!that!the!resulting!estimates!of!radiosensitivity!and!fractionation!
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56!sensitivity!would!be!more!clinically!applicable.!Of!course!this!meant!that!much!of!the!early!radiobiology!was!studied!in!immune!deficient!mouse!models,!or!human!in!vitro!cell!cultures,!such!that!the!immune!element!of!therapy!would!inevitably!be!overlooked.!!!RT!is!known!to!have!numerous!effects!on!tumour!cells!that!could!enhance!their!immunogenicity!(Figure!8).!Proteins!damaged!by!ionising!events!are!marked!for!degradation,!increasing!the!pool!of!peptides!within!the!cytoplasm!and!in!turn!enhancing!MHC!class!I!expression!on!the!cell!surface;!a!key!paper!by!Reits!et!al.!found!irradiated!cells!express!novel!antigens!and!were!more!vulnerable!to!the!effects!of!ACT!in!mouse!models!(Reits!et!al.,!2006).!Whereas!tumour!cells!often!depress!expression!of!Fas!receptor!in!order!to!evade!cytotoxic!T!cells,!irradiated!cancer!cells!upregulate!the!Fas!receptor!(Chakraborty!et!al.,!2004).!Obeid!et!al.!demonstrated!that!RT!results!in!exposure!of!calreticulin!on!the!surface!of!cells!irradiated!in!vivo,!an!established!eatHme!signal!as!discussed!above!(Obeid!et!al.,!2007a,!2007b).!A!further!group!found!evidence!that!blocking!the!translocation!of!calreticulin!to!the!surface!of!cells!impeded!their!phagocytosis!by!DC!(Perez!et!al.,!2009).!A!study!of!the!effects!of!ultraviolet!radiation,!and!some!chemotherapy!agents,!found!that!the!exposure!of!calreticulin!is!not!dependent!on!damage!to!DNA!but!instead!mediated!by!effects!upon!the!endoplasmic!reticulum!(Panaretakis!et!al.,!2009).!Irradiated!cancer!cells!release!danger!signals,!including!HMGB1!and!adenosine!triphosphate!and!in!mouse!models,!wherein!RT!successfully!controls!established!tumours,!depletion!of!the!TLR4!pathway!that!responds!to!HMGB1!led!to!diminished!therapy!(Apetoh!et!al.,!2007b;!Ohshima!et!al.,!2010).!Further!work!has!supported!the!concept!that!the!efficacy!of!RT!in!immune!competent!mouse!models!is!at!least!in!part!mediated!by,!and!therefore!partly!dependent!upon,!elements!of!the!immune!system.!The!growth!of!B16!melanoma!tumours!established!on!C57BL/6!mice!was!slowed!by!25!Gy!external!beam!RT,!but!when!the!mice!were!pretreated!with!a!CD8Hdepleting!antibody!any!benefit!from!RT!was!lost!(Lee!et!al.,!2009).!!Although!the!role!of!the!immune!system!in!radiotherapy!is!far!from!recognised!or!accepted!in!the!clinical!environment!several!groups!have!explored!combination!therapies!in!the!preclinical!setting!that!seek!to!harness!this!relatively!newly!posited!effect.!The!growth!factor!FltH3,!expands!numbers!of!DC.!Chakravarty!et!al.!
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57!established!Lewis!lung!tumours!on!the!footpads!of!mice,!which!rapidly!metastasise!to!the!lung!(Chakravarty!et!al.,!1999).!The!combination!of!local!RT,!limited!to!the!footpad!tumours,!with!a!systemic!agent!that!expands!numbers!of!DC,!FltH3,!resulted!in!cures!in!50%!of!treated!mice.!
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! !Figure!8.!Immunologically!relevant!extraHnuclear!effects!of!radiotherapy.!Irradiated!tumour!cells!release!inflammatory!cytokines!and!chemokines!and!danger!signals!including!HMGB1!and!ATP.!RT!has!also!been!shown!to!cause!upregulation!of!antigen!presentation,!including!novel!RTHinduced!antigens,!and!increased!expression!of!MHC!class!I.!RT!upregulates!receptors!and!ligands!on!tumour!cells!that!enable!the!actions!of!cytotoxic!THcells!and!innate!effector!cells,!such!as!the!Fas!receptor!and!NK!ligands.!Figure!prepared!with!David!Factor,!Mayo!Clinic!Illustrations!Department,!for!a!manuscript!pending!submission.!
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59!Demaria!et!al.!confirmed!this!effect!in!a!bilateral!flank!tumour!model!of!breast!cancer,!in!which!unilateral!RT!combined!with!FltH3!yielded!responses!in!the!unirradiated!tumour,!in!a!tumourHspecific!fashion!(Demaria!et!al.,!2004);!the!effect!could!not!be!repeated!in!nude!mice,!by!either!group.!Responses!in!tumours!outside!the!treatment!field!have!been!noted!sporadically!over!many!years!of!radiation!oncology,!and!R.H.!Mole!coined!the!expression!‘abscopal’!(ab!–!away!from,!scopal!H!target)!in!his!presentation!in!1952!(Mole,!1953).!The!mechanism!by!which!abscopal!responses!occur!remains!uncertain,!though!the!groups!of!Demaria!and!Formenti!who!are!at!the!forefront!of!this!field!assert!that!their!preclinical!data!strongly!suggest!that!it!is!an!immune!phenomenon.!Further!supporting!that!notion,!combination!of!CTLAH4!blockade!with!local!radiotherapy!in!mice!resulted!in!abscopal!tumour!responses!(Demaria!et!al.,!2005).!Demonstrating!some!of!the!challenges!that!remain!to!this!potential!synergy,!it!was!observed!that!successful!combination!of!local!RT!with!systemic!antiHCTLAH4!was!very!dependant!on!the!RT!fraction!sizes!used!(Dewan!et!al.,!2009).!!Several!observational!studies!have!found!supporting!evidence!that!the!immune!effects!of!RT!are!relevant!in!clinical!treatments,!and!not!just!in!mice;!at!least!three!papers!have!described!the!effects!of!pelvic!RT!on!enhancing!numbers!of!effector!THcells,!both!circulating!and!within!subsequently!resected!lymph!nodes!(Schaue!et!al.,!2008;!Battaglia!et!al.,!2010;!Tabi!et!al.,!2010).!Some!small!scale!studies!have!combined!RT!and!immune!manipulations!in!patients!with!modest!success!(Gulley!et!al.,!2005;!Formenti!and!Demaria,!2009;!Hasumi!et!al.,!2011).!RT!for!melanoma!is!being!reHexplored,!not!least!given!the!emergence!of!modern!hypofractionated!radiotherapy!techniques!that!better!fit!the!established!radiobiology!of!melanoma!(Stevens!and!McKay,!2006;!Jahanshahi!et!al.,!2012).!Therefore!one!of!the!most!appealing!combinations,!given!the!recent!success!of!ipilimumab,!would!be!to!combine!the!blockade!of!CTLAH4!with!stereotactic!body!radiotherapy!(SBRT).!Such!trials!are!reportedly!underway!(clinicaltrials.gov!and!personal!communication!Dr!BarHAd!2012)!and!a!case!has!recently!been!reported!of!abscopal!responses!in!a!solitary!patient!treated!with!ipilimumab!and!SBRT!(Postow!et!al.,!2012).!! !
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2.7 Summary/Therapy!for!melanoma!has!changed!considerably!over!the!course!of!the!period!of!postHgraduate!study!described!within!this!thesis.!The!emergence!of!ipilimumab,!and!vemurafenib,!have!finally!begun!to!change!the!outlook!for!patients!with!metastatic!melanoma.!Despite!this!progress!the!numbers!of!patients!experiencing!significantly!improved!survival!with!therapy!is!low.!Longer!established!immune!approaches!such!as!ACT!have!yet!to!demonstrate!that!they!can!be!widely!applied,!though!developments!in!CARHT!cells!hold!promise.!Given!the!evidence!that!immuneHmediated!therapies!can!result!in!clinical!benefits!it!is!therefore!appropriate!to!explore!additional!therapies!that!can!generate!immune!responses,!or!enhance!immunotherapies.!!OV!are!emerging!as!viable!clinical!therapies!that!can!stimulate!antiHtumour!immune!responses.!MV!has!not!previously!been!tested!in!melanoma,!despite!reaching!clinical!testing!in!a!number!of!other!tumour!sites.!RT!is!a!longstanding!and!readily!clinically!deliverable!therapy!that!is!being!reconsidered!in!melanoma,!just!as!its!immune!effects!are!being!identified.!!Therefore!the!aims!of!the!studies!described!within!the!following!chapters!were!as!follows;!1. Determine!the!oncolytic!activity!of!measles!virus!in!human!melanoma!cells.!2. Determine!the!effects!of!measles,!and!measlesHinduced!melanoma!cell!death!upon!cells!of!the!innate!and!adaptive!immune!systems.!3. Explore!combinations!of!external!beam!radiotherapy!with!adoptive!cell!therapy!and!virotherapy.!!4. Explore!combinations!of!brachytherapy!with!adoptive!cell!therapy!and!virotherapy.!5. Develop!an!intracranial!model!of!melanoma,!with!which!to!test!therapeutic!strategies!in!the!context!of!a!commonly!encountered!pattern!of!melanoma!metastasis.!
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3 Materials/and/methods/For!the!sake!of!clarity!and!brevity!reagents,!media,!buffers!and!cell!lines!are!initially!listed,!along!with!details!of!sources!and!suppliers.!Further!details,!where!appropriate,!follow!in!the!subsequent!text!describing!the!techniques!used.!!Human!and!mouse!experiments!were!performed!on!different!sites,!therefore!important!distinctions!in!the!reagents!used!are!provided.!When!identical!products!were!used!on!both!sites,!but!from!different!intermediary!suppliers,!only!the!UK!supplier!or!UK!branch!is!detailed.!
3.1 Reagents/and/media/
Reagent' Supplier' Location'
Amphotericin' Sigma! Poole,!UK!
BSA'(Bovine'serum'albumin'as'lyophilised'powder)' Sigma! Poole,!UK!
Chromium>51' Perkin!Elmer! Risley,!UK!
DMEM'–'Human'use'
(Dulbecco’s'modified'Eagles'media)'
Gibco,!Invitrogen! Paisley,!UK!
DMEM'–'Murine'use'
(Dulbecco’s'modified'Eagles'media)'
HyClone,!Thermo!Scientific!
Barrington,!IL,!USA!
DMSO'
(Dimethylsulfoxide)'
Sigma! Poole,!UK!
EDTA' Sigma! Poole,!UK!
FCS'>'Human'use'
(foetal'calf'serum)'
heat'inactivated'at'56°C'for'30'minutes'prior'to'storage'
BioSera! East!Sussex,!UK!
FCS'>'Murine'use'
supplied'heat'inactivated'by'the'manufacturer'
Gibco,!Invitrogen! Paisley,!UK!
Gentamicin' Sigma! Poole,!UK!
HBSS'
(Hank’s'balanced'saline'solution)'
Sigma! Poole,!UK!
HEPES'buffer' Sigma! Poole,!UK!
IMDM'(Iscove’s'modified'Dulbecco’s'medium)' Gibco,!Invitrogen! Paisley,!UK!
Insulin,'transferrin,'selenium' Gibco,! Paisley,!UK!
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Reagent' Supplier' Location'Invitrogen!
Interleukin'2'(IL>2)' R&D!systems! Abingdon,!UK!
Interleukin'4'(IL>4)' R&D!systems! Abingdon,!UK!
Interleukin'7'(IL>7)' R&D!systems! Abingdon,!UK!
Ketamine' Mayo!pharmacy!supplies!
L>glutamine' Gibco,!Invitrogen! Paisley,!UK!
Live/Dead'®'assay' Invitrogen! Paisley,!UK!
MTT''
(Thiazolyl'Blue'Tetrazolium'Bromide)'
Sigma! Poole,!UK!
Neomycin'
(G418'sulfate)'
CellGro! Manassas,!Va!
Non>essential'amino'acids' Sigma! Poole,!UK!
Opti>MEM' Invitrogen! Paisley,!UK!
PBS'–'Human'use'
(Dulbecco’s'phosphate'buffered'saline)'
Oxoid!! Basingstoke,!UK!
PBS'–'Murine'use' Thermo!Scientific! Barrington,!IL,!USA!
Penicillin' Sigma! Poole,!UK!
PenStrep'
(Penicillin/streptomycin)'
CellGro! Manassas,!Va!
Recombinant'human'gp100' Mayo!Peptide!synthesis!facility!
RPMI'
(Roswell'Park'Memorial'Institute'medium)'
Gibco,!Invitrogen! Paisley,!UK!
Saponin' Sigma! Poole,!UK!
SIINFEKL'
Octomeric'amino'acid'sequence'from'ovalbumin'
Mayo!Peptide!synthesis!facility!
Sodium'Azide' Sigma! Poole,!UK!
Streptomycin' Sigma! Poole,!UK!
Triton'X>100' Sigma! Poole,!UK!
Trp2' Mayo!Peptide!synthesis!facility!
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Reagent' Supplier' Location'
Trypan'Blue' CellGro! Manassas,!Va!
Trypsin>EDTA' Sigma! Poole,!UK!
VSV'surface'antigen' Mayo!Peptide!synthesis!facility!
Xylazine' Mayo!pharmacy!supplies!! !
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3.2 Prepared/media/
Prepared'media' Constituents'
Complete'medium'–'human'in'vitro'use' DMEM!10%!v/v!FCS!!1%!v/v!LHglutamine!
Complete'medium'–'murine'in'vitro'use' DMEM!10%!v/v!FCS!!4mM!LHglutamine!(added!by!manufacturer)!
Complete'medium'(Vero'cells)' DMEM!5%!v/v!FCS!!1%!v/v!LHglutamine!
Complete'medium'(B16>Ova'cells)' DMEM!10%!v/v!FCS!!1%!v/v!LHglutamine!5!mg/mL!neomycin!Sterile!filtered!after!preparation!
Complete'tissue'media'(Human'
melanoma'explants)'
RPMI!10%!v/v!FCS!1%!v/v!LHglutamine!!25!mg/L!gentamicin!1!U/L!penicillin!!1!µg/L!streptomycin!0.1!mg/L!amphotericin!1%!v/v!nonHessential!amino!acids!1%!v/v!insulin,!transferrin!and!selenium!25!mM!HEPES!buffer!
Cytotoxic'T>lymphocyte'media'(CTL'
media)'
RPMI!7.5%!v/v!human!serum!2!mM!LHglutamine!1%!v/v!0.45!mM!sodium!pyruvate!1%!v/v!25!mM!HEPES!1%!v/v!nonHessential!amino!acids!20!μM#2β&mercaptoethanol!
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Prepared'media' Constituents'
Monocyte'media'(for'preparation'of'
dendritic'cells)'
RPMI!10%!v/v!FCS!2!mM!LHglutamine!5000!U/mL!ILH4!!800!U/mL!GMHCSF!
OT1'T>cell'media' IMDM!5%!v/v!FCS!1%!penicillin/streptomycin!0.1%!v/v!2β&mercaptoethanol#
50#U/mL#IL&2#
1#μg/mL#SIINFEKL!
All'prepared'media'were'stored'at'4°'C'and'warmed'to'37°'C'prior'to'use,'unless'
otherwise'indicated'! !
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3.3 Buffers/
Compound'reagent' Constituents'
FACS'(fluorescence>activated'cell'
sorting)'buffer'(mouse)'
PBS!0.1%!w/v!BSA!0.1%!w/v!sodium!azide!
FACS'buffer'(human)' PBS!1%!v/v!FCS!0.1%!w/v!sodium!azide!
MACS'buffer'(mouse)' PBS!0.5%!w/v!BSA!2mM!EDTA!
MACS'buffer'(human)' PBS!1%!v/v!FCS!2mM!EDTA!
Red'cell'lysis'buffer'(mouse)' Distilled!water!0.15!M!Ammonium!chloride!(Sigma)!10!mM!Potassium!bicarbonate!(Sigma)!0.1!mM!EDTA!pH!adjusted!to!7.2H7.4!then!sterile!filtered!
Laemmli'buffer'' Distilled!water!0.0625M!Tris!buffer!10%!v/v!glycerol!!2%!v/v!SDS!5%!v/v!βHmercaptoethanol,!!0.025%!v/v!bromophenolblue!! !
!! Materials!and!Methods! !
67!
3.4 Cell/lines/
Origin' Cell'line' Medium' Supplier/source'
Human'' Mel888! Complete!medium! CRUK!(Cancer!research!UK)!
!Mel624!MeWO!SkMel28!
African'green'
monkey'
Vero!!(green!monkey!kidney)!
Complete!medium!(5%!FCS!v/v!)! ATCC!(American!type!culture!collection)! Virginia!USA!
Hamster' BHK!!(baby!hamster!kidney)! Complete!medium!
Murine'
(C3H/An)'
L929! Complete!medium!
Murine'
(C57BL/6)'
B16HOva;!stably!transfected!to!express!Ovalbumin!and!a!neomycin!resistance!gene!
Complete!medium!+!neomycin! Longstanding!kind!gift!from!Edith!Lord!
Department!of!microbiology!and!immunology,!University!of!Rochester!medical!center,!Rochester,!NY,!USA!
Low'passage,'master'bank'cell'line'stocks'were'stored'in'liquid'nitrogen'between'
uses.'Cell'lines'were'routinely'tested'for'mycoplasma'contamination'and'found'to'
be'free'of'infection.'! !
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3.5 Tissue/culture/All!cell!handling!was!performed!in!a!dedicated!tissue!culture!facility!using!Nuaire!Class!II!biological!safety!cabinets!(human!cell!work)!or!Sterigard!class!II!safety!hoods!(mouse!cell!work),!and!standard!aseptic!precautions.!A!dedicated!Class!II!biological!safety!cabinet!was!available!for!all!work!using!MV!or!MVHGFP.!All!cells!were!grown!in!dedicated!Sanyo!MCOH20A1C!CO2!incubators!(human!cell!work,!supplied!by!Sanyo,!Loughborough,!UK)!or!Forma!series!Scientific!waterHjacketed!CO2!incubators!(mouse!work,!supplied!by!Thermo!Scientific)!at!37°C,!humidified!and!supplemented!with!5%!CO2!unless!otherwise!stated.!Cells!were!routinely!grown!in!vented!plastic!tissue!culture!flasks!with!adherent!surface!areas!of!25,!75,!150!or!175!cm2!and!passaged!before!reaching!confluency.!Plasticware!for!human!in!vitro!experiments!were!supplied!by!Corning!Costar,!High!Wycombe,!UK.!Flasks!and!other!plasticware!for!mouse!work!were!supplied!by!BD!Falcon!San!Jose,!Ca,!USA.!For!passage!and!harvest!of!cells!media!was!aspirated!and!discarded,!then!trypsinHEDTA!added!(0.2!mL!for!T25!cm2!flasks,!0.5!mL!for!T75!cm2!flasks!and!1.5!mL!to!T150!cm2!or!T175!cm2!flasks).!After!harvest,!cells!were!washed!with!media!in!order!to!neutralise!residual!trypsinHEDTA.!All!cell!washing!was!performed!by!centrifugation!at!1500!rpm!for!5!minutes!at!room!temperature!with!an!Eppendorf!5810R!centrifuge!(Fisher!scientific,!Loughborough,!UK)!unless!otherwise!stated!and!using!BD!Falcon!tubes,!either!15mL!or!50mL.!!Cells!for!freezing!were!resuspended!in!freezing!media!comprising!10%!DMSO!in!FCS!and!cooled!to!H80°C!(at!H1°C!per!minute)!then!kept!at!H80°C!if!used!within!1H2!weeks,!or!in!liquid!nitrogen!if!stored!for!longer!periods.!Cells!were!recovered!from!frozen!by!brisk!thawing!in!a!37°C!water!bath!then!washed!in!media!to!remove!residual!DMSO.!!Routine!microscopy!was!performed!using!a!CKX41!indirect!microscope!(Olympus,!SouthendHonHsea,!UK).!Photographs!were!taken!using!a!CH7070!camera!mounted!on!a!CKX41!indirect!microscope!(all!Olympus).!Routine!cell!counts!were!performed!with!0.2%!trypan!blue!exclusion!using!a!haemocytometer!(Fisher!Scientific).!Fresh!melanoma!explants!were!collected!under!the!auspices!of!a!preHexisting!ethical!approval,!and!anonymised!and!logged!upon!receipt,!in!accordance!with!guidance!from!the!Human!Tissue!Authority.!After!rinsing!with!HBSS,!tumours!were!coarsely!dissected!by!scalpel,!passed!through!a!cell!strainer!(Sigma)!and!treated!
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69!with!either!collagenase!I!or!III!or!both!(Worthington,!Lakewood,!USA)!at!37°C!in!complete!tissue!media!for!1!hour.!Resulting!cell!suspensions!were!placed!in!flasks!in!complete!tissue!media!to!allow!adherence!of!melanoma!cells.!
3.6 Viral/bulking/and/titration/
3.6.1 Measles/virus/Two!strains!of!MV!were!kindly!supplied!by!S.!Russell,!Mayo!Clinic,!Minnesota,!USA,!at!second!passage.!The!Edmonston!MV!strain!was!derived!from!a!cDNA!as!described!previously!(Radecke!et!al.,!1995).!A!GFPHexpressing!MV,!based!on!the!same!clone!but!with!GFP!encoded!upstream!of!the!viral!N!protein!was!also!kindly!furnished!(Peng!et!al.,!2002).!Both!viruses!were!titrated!against!VERO!cells!to!estimate!the!TCID50!(Tissue!culture!50%!infectious!dose)!using!a!96!well!plate!format!and!the!ReedHMuench!method!of!calculation!(Reed!and!Muench,!1938;!Fields!et!al.,!2007).!Briefly!VERO!cells!were!seeded!at!7000!cells!in!50!µL!media!per!well!into!96!well!plates.!Viral!preparations!were!then!added!in!serial!10Hfold!dilutions!to!each!column.!The!viral!titre!was!calculated,!based!on!the!number!of!wells!with!evidence!of!the!characteristic!MV!cytopathic!effect!(CPE)!6!days!later,!thus;! log!" !"#$!"!" = ! + ! ! − 0.5 + log!" !!! !!ℎ!"!!! = !"#$%&'"! log!" !"#$%#&%!!"#$%"&'! ℎ!"!!!""! "#!"!!"#$%$&' !! = log!" !"#$%"&'!!"#$%&!!!"#$%"&'!!"#$%& = !"#!#"$%#&!!"!!"#$%$&'! "##$!!"!!"#!!"#$%&!! = !!"#$%"&'!!"#$%&!!!,!ℎ!"!!!!"#$%"&'!!"#$%& ≠ 1!! = !"#$%&!!"!!"#$%&%'!!MV!stocks!were!bulked!as!required!from!P2!or!P3!virus!as!follows!(personal!communication!from!Elizabeth!Hadac,!2009):!T75!flasks!were!each!seeded!with!1.5x106!subconfluent!VERO!cells!and!allowed!to!adhere!overnight.!The!following!day!supernatant!media!was!discarded!and!P2!or!P3!virus!was!added!at!a!multiplicity!of!infection!(MOI)!of!0.02!(i.e.!3x104!TCID50)!in!2mL!of!OptiHMEM!reduced!serum!media!(Invitrogen)!per!flask.!Cells!were!replaced!in!an!incubator!and!gently!agitated!every!30minutes!to!ensure!widespread!and!evenly!distributed!infection.!After!2!hours!10mL!of!complete!DMEM!was!added!to!each!flask.!Between!24!and!48!hours!later,!when!microscopy!revealed!50%!syncytial!coverage,!flasks!
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70!were!moved!to!32°C!for!8H12!hours!(generally!overnight)!and!then!restored!to!37°C.!When!cells!reached!80%!syncytial!coverage!supernatant!was!discarded!and!cells!harvested!with!a!cell!scraper!using!minimal!volumes!of!OptiHMEM.!Cells!were!then!subjected!to!3!freeze/thaw!cycles!by!immersion!in!a!methanol!and!dry!ice!mixture!to!release!cellHassociated!virions.!Virus!was!aliquoted!and!stored!at!H80°C.!
3.6.2 Vesicular/Stomatitis/Virus/VSVHOva!amplification!was!performed!by!infecting!subconfluent!BHK!in!15!cm!diameter!culture!dishes!with!stock!VSVHOva!at!an!MOI!of!0.01!in!serum!free!media.!After!1!hour!the!media!was!aspirated!and!replaced!with!complete!media.!After!24H36!hours!the!completion!of!cytopathic!effect!was!confirmed!and!the!supernatant!first!clarified!by!centrifugation!at!1500rpm!for!ten!minutes,!then!filtered!using!0.45!μm!pore!size!vacuum!driven!Nunc!Nalgene!filtration!units!(Thermo!scientific).!The!resulting!filtrates!were!further!purified!by!cushion!centrifugation!through!10%!w/v!sucrose!in!PBS!at!27000!rpm!for!1!hour!at!4°C!using!an!Optima!LH90k!Ultracentrifuge!with!SW32!swinging!bucket!rotor!(Beckman!Coulter,!Pasadena!Ca,!USA).!The!resulting!pellets!were!resuspended!in!PBS!and!further!centrifuged!through!10%!sucrose!prior!to!final!resuspension!in!1mL!PBS!and!division!into!aliquots.!VSVHOva!from!amplification!was!titrated!using!plaque!assay.!Cultures!of!L929!were!prepared!in!6!well!plates,!seeding!7.5x105!cells!per!well!overnight.!The!following!day!viral!dilutions!were!prepared!by!serial!tenHfold!dilutions!with!serumHfree!DMEM.!Media!was!aspirated!from!each!well,!the!cells!washed!with!PBS!and!then!1mL!of!each!viral!dilution!applied!to!each!well.!After!one!hour!the!viral!media!was!discarded!and!cells!overlaid!with!2mL!of!an!equal!mixture!of!1%!noble!agar!and!double!strength!DMEM!with!20%!v/v!FCS,!both!having!been!equilibrated!to!42°C!prior!to!use.!Plaques!were!visible!and!counted!within!48!hours.!VSVHGFP!and!VSVHgp100!were!kind!gifts!from!Mr!Tim!Kottke,!Mayo!Clinic.!!
3.7 Flow/cytometry//Cells!were!washed!and!stained!in!FACS!buffer!after!addition!to!FACS!tubes!(BD!biosciences,!Cowley,!UK)!unless!otherwise!indicated.!After!washing,!cells!were!stained!with!the!appropriate!volume!of!antibody!for!20!minutes!at!4°C.!Cells!were!subsequently!washed!again!and!fixed!in!200H300!µL!1%!paraformaldehyde!(PFA)!and!stored!at!4°C,!shielded!from!light,!prior!to!acquisition.!
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71!Intracellular!staining!was!performed!after!fixation!by!washing!cells!with!2mL!FACS!buffer,!resuspending!the!pellet!in!0.5mL!0.3%!w/v!saponin!(Sigma)!in!FACS!buffer!for!15!minutes!at!room!temperature.!Cells!were!then!centrifuged!at!4°C!and!resuspended!in!0.1%!w/v!saponin!in!FACS!buffer!with!antibody!to!the!relevant!intracellular!antigen!and!incubated!at!4°C!for!30!minutes.!Where!secondary!antibodies!were!required!the!cells!were!washed!with!0.1%!w/v!saponin!prior!to!incubation!with!an!appropriately!conjugated!secondary!antibody.!Cells!were!then!washed!with!0.1%!w/v!saponin!and!resuspended!in!200H300!µL!FACS!buffer!prior!to!immediate!acquisition.!!Flow!cytometry!of!human!cells!was!performed!using!a!2Hlaser,!4Hcolour!BD!Biosciences!FACSCalibur!and!arising!data!analysed!using!the!manufacturer’s!CellQuest!Pro!software.!Cytometry!of!murine!cells!was!performed!by!the!Mayo!clinic!flow!cytometry!core!facility.!The!resulting!data!was!analysed!by!the!candidate!using!FlowJo!software.!
3.8 Flow/cytometry/antibodies/
Target'molecule' Fluorochrome' Volume'
added(to≈5x104cells)'
Manufacturer'
CD107a/b' FITC! 1!µL! BD!Pharmingen!
CD150' PE! 2!µL! BD!Pharmingen!
CD40' PE! 2!µL! Invitrogen!
CD46' FITC! 2!µL! BD!Pharmingen!
CD56' PE! 2!µL! Serotec!
CD8' FITC! 1!µL! ProImmune!
CD80' PE! 2!µL! BD!Pharmingen!
CD86' PE! 2!µL! BD!Pharmingen!
Goat'anti>mouse'Ig' FITC! 2!µL! BD!Pharmingen!
gp100'(clone'
HMB45)'
N/A! 5!µL! NeoMarkers!
HLA>A*201' N/A! 5!µL! CRUK!services!
IFNγ' FITC! 2!μL! BD!Pharmingen!
Isotype'control' Triple!(MultiMix)! 2!µL! Dako!
Melan>A' N/A! 5!µL! Santa!Cruz!
3.9 Enzyme/linked/Immunosorbent/assays/(ELISA)/!NUNC!96!well!MAXISORP!flatHbottomed!plates!(Thermo!Scientific)!were!used!unless!otherwise!stated.!100µL!capture!antibody!was!added!to!each!well,!diluted!
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72!as!detailed!in!section!3.10,!in!0.1M!NaHCO3,!and!the!plate!left!overnight!at!4°C.!Plates!were!then!washed!three!times!with!0.05%!v/v!Tween!(Sigma)!diluted!in!PBS!(PBS/Tween),!using!a!Skan!Washer!300B!(Molecular!devices,!Sunnyvale,!USA).!NonHspecific!antibody!binding!was!blocked!by!adding!200µL!of!10%!v/v!FCS!in!PBS!to!each!well!for!at!least!2!hours!at!room!temperature.!After!a!further!three!washes,!as!above,!known!concentrations!of!recombinant!proteins!were!added!in!triplicate!to!standard!wells.!‘Blank’!wells!were!prepared!by!adding!appropriate!media!alone.!Samples!were!added!in!triplicate!with!or!without!dilution!in!relevant!media!to!obtain!values!within!the!dynamic!range!of!the!standard!curves.!Plates!were!subsequently!wrapped!and!stored!at!4°C!overnight.!Plates!were!washed!six!times!and!100µL!detection!antibody!added!to!each!well,!after!appropriate!dilution!(section!3.10)!in!10%!v/v!FCS!in!PBS!and!subsequently!incubated!for!2!hours!at!room!temperature.!After!a!further!6!washes!100µL!of!ExtrAvidin!Alkaline!Phosphatase!(Sigma),!diluted!5000Hfold!in!PBS/Tween,!was!added!to!each!well.!After!1!hour!at!room!temperature!and!3!washes!with!PBS/Tween!followed!by!three!washes!with!water,!100µL!of!the!substrate!pHNitrophenyl!phosphate!(SigmaFast™!Sigma)!was!added!to!each!well.!Plates!were!then!kept!shielded!from!light!until!developed!and!then!analysed!using!a!multiwell!scanning!spectrophotometer!(MultiskanEX!Microplate!Photometer,!Thermo!Scientific)!reading!absorbance!at!405nm.!For!some!assays!commercially!available!kits!were!used!and!the!instructions!within!adhered!to.!DuoSet®!ELISA!from!R&D!systems!were!used!to!assay!RANTES!and!ILH28A!according!to!the!manufacturer’s!instructions!up!until!conjugation!of!the!detection!antibody,!at!which!point!local!protocol!and!reagents!were!used!for!simplicity!and!reproducibility.!The!Verikine™!Human!Interferon!Beta!ELISA!kit!(PBL!interferon!source)!was!provided!with!precoated!multiwell!plates!and!used!in!complete!accordance!with!the!manufacturer’s!instructions!and!supplied!reagents.! !
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3.10 ELISA/antibody/dilutions/and/recombinant/standards/
Cytokine' Capture/Detection' Dilution' Top'
Standard'
Supplier'
IL'6'
Capture! 1/500! 2000pg/mL! BD!Detection! 1/500!
IL'8'
Capture! 1/500! 500pg/mL! BD!Detection! 1/500!
IL'10'
Capture! 1/500! 2000pg/mL! BD!Detection! 1/1000!
IL'28A'
Capture! 1/180! 8000pg/mL! R&D!Detection! 1/180!
IFNβ'
Capture! Varied!according!to!batch!and!accompanying!instructions!
4000pg/mL! PBL!Interferon!source!Detection!
CCL5/RANTES'
Capture! 1/360! 1000pg/mL! R&D!Detection! 1/360!!! !
!! Materials!and!Methods! !
74!
3.11 Human/in/vitro/experiments/
3.11.1 Viability/assays/
3.11.1.1 Live/Dead®,assay,The!Red!Live/Dead®!fixable!dead!cell!stain!kit!(Invitrogen)!was!used!as!it!permits!fixation!of!samples!with!PFA!prior!to!analysis.!The!reagent!is!a!fluorescent!reactive!dye!that!reacts!with!cellular!amines.!The!reagent!crosses!the!compromised!cell!membranes!of!dead!cells!and!binds!intracellular!amines!as!well!as!cell!surface!amines,!resulting!in!higher!signal!from!dead!cells!compared!to!live.!7.5!x!104!cells!were!seeded!into!24!well!plates!and!after!24!hours!treated!with!virus!at!various!doses.!Cells!were!harvested,!after!the!required!duration!of!infection,!with!PBS!and!trypsin!and!washed!in!PBS.!Cell!pellets!were!then!resuspended!in!1!ml!PBS!with!1!µL!of!Live/Dead!dye!reconstituted!according!to!the!manufacturer’s!instructions.!Cells!were!then!incubated!for!15!minutes!at!room!temperature!prior!to!a!further!wash!with!PBS!followed!by!a!wash!with!1%!v/v!FCS!in!PBS.!Cells!were!then!fixed!in!1%!PFA!and!stored!at!4°C!prior!to!flow!cytometry.!
3.11.1.2 Methylthiazolyldiphenyl8tetrazolium,bromide,,MTT,8000!cells!were!seeded!in!triplicate!into!96!well!plates!and!after!24!hours!treated!with!virus!at!various!doses.!After!the!required!duration!of!infection!20!µL!of!5mg/mL!MTT!diluted!in!PBS,!was!added!to!each!well.!After!4!hours!all!media!was!carefully!aspirated!from!plates,!without!disrupting!the!adherent!monolayer,!and!replaced!with!150!µL!reagent!grade!DMSO!(Fisher!sciences).!After!5!minutes!at!37°C,!to!allow!solubilisation,!plates!were!sealed!and!analysed!using!a!multiwell!scanning!spectrophotometer!(MultiskanEX!Microplate!Photometer,!Thermo!Scientific,!Rochester,!USA)!reading!absorbance!at!550!nm!and!viability!calculated!by!normalisation!to!100%!against!untreated!control!wells.!
3.11.2 Western/blots/Cell!pellets!and!cellHfree!supernatants!were!prepared!by!plating!3x106!melanoma!cells!in!T75!flasks!and!the!following!day!adding!virus!at!an!MOI!of!0,!0.1!or!2.5.!After!24,!48!and!72!hours!cells!and!supernatant!were!harvested.!CellHfree!supernatant!was!kept!at!H80°C!until!analysis.!Stacking!and!running!gels!were!prepared!using!constituents!as!prescribed!previously!(Sambrook,!1989)!and!poured!into!prefabricated!cassettes!(Invitrogen!Life!technologies).!20µL!cell!free!supernatants!made!up!1:1!with!Laemmli!buffer!were!loaded!into!sample!lanes!and!
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75!2!µl!of!protein!molecular!weight!markers!added!to!control!lanes!(Odyssey®!from!LIHCOR!Biosystems,!Lincoln,!USA).!Gels!were!run!using!the!XCell!SureLock™!Mini!Cell!system!(Invitrogen)!and!a!BioHRad!laboratories!PowerPac™!HC.!Gels!were!run!at!160H180V!for!around!60!minutes.!Protein!transfer!was!performed!at!25V!for!120!minutes,!using!Hybond™HC!super!membrane!(Amersham!Biosciences,!Little!Chalfont,!UK).!Membranes!were!blocked!in!Odyssey!blocking!buffer!(LIHCOR!Biosciences)!and!washed!with!three!changes!of!PBS/0.1%!v/v!Tween!between!stains.!Staining!for!HMGB1!was!performed!using!a!monoclonal!mouse!antiHhuman!HMGB1!antibody!(R&D!systems,!Abingdon!UK)!used!at!1H2µg/mL!in!a!1:1!mix!of!blocking!buffer!and!PBS/0.1%!Tween.!Goat!antiHmouse!conjugated!with!AlexaFluor!680!(Molecular!probes,!Invitrogen)!was!used!as!a!secondary!antibody!at!0.2µg/mL!.!The!LIHCOR!Odyssey®!InfraHred!imaging!system!was!used!for!analysis.!Actin!staining!was!performed!the!following!day!for!cell!lysates!using!murine!antiHβ!actin!(AbCam)!at!0.3µg/mL,!counterstained!with!IRDye800!conjugated!affinity!purified!polyclonal!Rabbit!antiHMouse!IgG!(Rockland,!Gilbertsville,!USA)!used!at!0.1µg/mL.!
3.11.3 Multilayer/models/The!method!was!adapted!from!methodology!used!to!mimic!small!molecule!passage!through!vascular!endothelium!(personal!communication!from!Dr!Roger!Phillips,!University!of!Bradford).!2x105!cells!were!seeded!into!ThinCert™!tissue!culture!inserts!for!multiwell!plates,!TW!(Greiner!BioHOne,!Stroudwater,!UK).!After!initial!optimizing!experiments!8.0µm!pore!size!TW!were!used!with!Mel624!cells.!TW!were!handled!using!sterilised!forceps!to!prevent!contamination.!For!5H6!days!media!was!replaced!daily!in!both!the!TW!and!the!underlying!well,!taking!care!not!to!disrupt!cells.!The!change!of!media!colour!was!noted!as!a!possible!indicator!of!cell!proliferation;!indirect!microscopy!was!of!limited!effectiveness!in!visualising!cells.!Integrity!of!the!multilayer!was!inferred!from!the!absence!of!obvious!holes!on!microscopy!and!the!ability!of!the!TW!to!maintain!a!column!of!media!above!the!fluid!level!in!the!underlying!well.!Virus!was!added!to!the!underlying!well!to!try!and!maintain!the!three!dimensional!architecture!in!the!face!of!the!disruption!caused!by!viral!infection.!
3.11.4 Confocal/Microscopy/TW!were!prepared!for!imaging!by!immersion!in!1%!PFA!overnight.!The!following!morning!TW!were!rinsed!in!PBS!by!gentle!immersion!in!sequential!containers!of!
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76!sterile!PBS!after!cautious!aspiration!of!residual!PFA.!The!TW!were!immersed!in!1%!FCS!in!PBS!and!blocked!for!two!hours.!TW!were!then!aspirated!and!immersed!for!5!minutes!in!300nM!DAPI!(Invitrogen)!diluted!in!PBS,!and!thoroughly!rinsed!in!serial!changes!of!PBS!as!above.!TW!were!imaged!on!glassHbottomed!culture!dishes!using!an!Eclipse!TE2000HE!microscope!and!the!data!analysed!using!EZHC1!FreeViewer!software!v3.5!(both!from!Nikon!Instruments!Europe,!Kingston,!UK).!
3.11.5 Isolation/of/human/peripheral/blood/mononuclear/cells/and//
magneticallyYactivated/cell/sorting/(MACS)/Human!buffy!coats!and!cones!were!supplied!by!the!National!Blood!Service!(NBS).!Fresh!blood!was!obtained!from!healthy!donors!according!to!existing!protocols!and!ethical!approval.!After!dilution!1:1!with!HBSS,!blood!was!layered!onto!LymphoPrep!(AxisHShield,!Kimbolton,!UK)!in!50mL!Falcon!tubes!and!spun!at!800g!for!25!minutes!without!brakes.!The!buffy!layer!was!then!collected!using!wide!tipped!pastettes!and!cells!were!washed!in!HBSS!and!pelleted!by!centrifugation!at!400g!for!ten!minutes.!A!final!wash!in!MACS!buffer!(1%!FCS!and!2!mM!EDTA!diluted!in!PBS),!or!HBSS!was!performed,!dependent!upon!the!intended!use,!and!the!cells!pelleted!as!above.!!If!required!PBMC!were!resuspended!in!25!mL!freezing!media!and!frozen!in!1!mL!aliquots!for!subsequent!use.!
3.11.6 Preparation/of/human/dendritic/cells//PBMC!were!prepared!as!above,!the!final!wash!being!performed!in!MACS!buffer.!The!cell!pellet!was!resuspended!in!80!µL!MACS!buffer!per!107!cells!and!incubated!with!5H10!µL!per!107!cells!(dependent!on!the!number!of!cells!required)!CD14!MicroBeads!(Miltenyi!Biotec,!Bisley,!UK)!for!15!minutes!at!4°C!then!washed!in!MACS!buffer.!After!resuspending!cells!in!500µL!MACS!buffer!per!108!cells!the!suspension!was!applied!to!LS!columns!(Miltenyi)!in!a!magnetic!field.!After!three!rinses!columns!were!removed!from!the!magnetic!field!and!CD14+!cells!harvested!by!forced!expulsion!of!5mL!MACS!buffer!through!the!columns,!into!15mL!Falcon!tubes.!CD14+!cells!were!counted!and!resuspended!at!2x106/mL!in!monocyte!media!and!grown!in!T25!flasks!for!5!days!prior!to!use.!!
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3.11.7 HLAYA2/phenotyping/of/blood/cells/The!HLAHA2!phenotype!was!tested,!where!necessary,!after!separation!as!described!above.!!105!separated!cells!were!added!to!each!of!two!FACS!tubes!then!washed!in!FACS!buffer.!2!µL!of!BB7.2!antibody!(CRUK)!was!added!to!one!tube!and!both!then!incubated!at!4°C!for!30!minutes.!Cells!were!then!washed!with!FACS!buffer!and!2!µL!of!a!goat!antiHmouse!FITCHconjugated!antibody!added!to!each!tube.!Cells!were!incubated!at!4°C!for!30!minutes!and!finally!washed!with!FACS!buffer,!then!fixed!in!1%!PFA!and!stored!at!4°C!prior!to!flow!cytometry.!!
3.11.8 DC/cultured/with/filtered/tumour/conditioned/media/(TCM)/DC!prepared!from!Buffy!coats!or!cones!as!described!above!and!after!5!days!of!culture!in!DC!media!were!cocultured!with!TCM.!TCM!was!prepared!by!plating!4x106!Mel888!in!T75!flasks!and!infecting!with!MV!at!an!MOI!of!0,!0.1!or!2.5!the!following!day.!48!hours!after!infection!the!media!was!harvested!and!centrifuged!to!pellet!any!floating!cells.!The!resulting!supernatant!was!then!filtered!through!0.2µm!cell!strainers!and!again!through!Viresolve!filters!(Millipore,!Watford,!UK)!to!remove!all!virions!prior!to!subsequent!experiments.!DC!were!harvested!after!5!days!and!resuspended!in!fresh!DC!media!at!a!cell!density!of!1x106/mL!and!2!mL!put!into!each!of!5!wells!in!6!well!plates.!2!mL!of!TCM!was!then!added!to!appropriate!wells.!2!mL!DMEM!or!2!mL!DMEM!with!lipopolysaccharide!(LPS)!at!250!ng/mL!were!used!as!controls.!The!following!day!DC!and!media!were!harvested!and!centrifuged,!the!supernatant!aliquoted!and!stored!at!H80°C.!DC!were!washed!with!FACS!buffer!then!stained!with!CD80!PE,!CD83!PE!CD86!PE,!CD40!PE,!Class!I!FITC!or!class!II!FITC!for!flow!cytometry.!
3.11.9 Preparation/of/DCYMel888/cocultures/DC!prepared!from!Buffy!coats!or!cones!as!described!above!and!after!5!days!of!culture!in!DC!media!were!cocultured!with!Mel888!for!priming!experiments.!4x106!Mel888!cells!were!seeded!in!T75!and!the!following!day!infected!with!MV!in!2mLs!Optimem,!at!an!MOI!of!0.1!or!1,!2.5!or!Optimem!alone!for!control.!After!2!hours!cells!were!rinsed!with!PBS!and!fresh!DMEM!replaced.!The!following!day!Mel888!cells!were!harvested,!washed!with!RPMI!and!counted.!Day!5!DC!were!harvested!and!washed!with!RPMI,!then!cocultured!at!a!ratio!of!3!Mel888!:!1!DC!in!fresh!DC!media.!Cocultures!were!then!incubated!overnight!in!T25!or!T75!flasks,!laid!flat!in!a!
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78!37°C!incubator!to!allow!Mel888!to!adhere.!For!phenotypic!studies!the!DC!prepared!as!above!were!washed!with!FACS!buffer!then!stained!with!CD80!PE,!CD83!PE!CD86!PE,!CD40!PE,!Class!I!FITC!or!class!II!FITC!for!flow!cytometry.!!
3.11.10 Preparation/of/priming/cultures/PBMC!were!isolated!as!described!above!and!cocultures!of!DC!with!Mel888/MVHMel888!established!as!above.!After!24!hours!of!DCHMel888!coculture,!nonHadherent!DC!were!harvested!and!cocultured!with!freshly!thawed!autologous!PBMC.!Cocultures!were!established!in!CTL!media!at!a!ratio!of!around!1!DC:20!PBMC!dependent!upon!the!number!of!cells!obtained!and!maintained!at!a!cell!density!of!2H4x106/mL.!ILH7!was!added!to!cocultures!at!5!ng/mL!of!media.!For!the!duration!of!cocultures!flasks!were!regularly!inspected!and!fresh!media!and!cytokines!added!as!required.!ILH2!was!added!at!30!U/mL!on!day!4!only.!After!one!week!PBMCHDC!cocultures!were!reHstimulated!with!DC!from!further!DCHMel888/MVHMel888!cocultures.!A!schematic!of!the!assay!is!shown!in!Figure!34,!page!135.!
3.11.11 CD107/assay/CD107a!and!CD107b!are!markers!normally!present!on!cytotoxic!granules!but!transiently!exposed!on!the!surface!of!cells!following!degranulation.!Based!on!the!method!of!Betts!et!al.!it!is!possible!to!identify!cells!that!degranulate!in!response!to!stimulation!by!culture!with!antiHCD107a!and!antiHCD107b!(both!BD!biosciences)!(Betts!et!al.,!2003).!Brefeldin!A!is!included!in!the!culture!to!prevent!recycling!of!exposed!CD107.!The!cells!of!interest!were!coHcultured!with!their!proposed!targets!at!a!1:1!ratio!in!either!CTL!media!or,!for!innate!experiments,!RPMI!with!10%!v/v!FCS,!in!the!presence!of!FITCHlabelled!antiHCD107!antibodies.!After!one!hour!incubation!at!37°!brefeldin!A!was!added!to!a!final!concentration!of!10!µg/mL!and!the!culture!continued!for!a!further!four!hours.!Samples!were!then!washed!with!FACS!buffer!prior!to!further!staining!with!either!antiHCD8!for!lymphocyte!assays!or!CD56!for!innate!studies.!Samples!were!then!fixed!in!1%!PFA!before!flow!cytometry.!
3.11.12 Intracellular/IFNγ/At!the!same!time!as!preparing!cocultures!for!CD107!assay!1:1!cocultures!of!effector!and!target!cells!were!prepared!in!suitable!media!and!incubated!at!37°.!After!one!hour!brefeldin!A!was!added!to!a!final!concentration!of!10!µg/mL!then!the!cells!
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79!incubated!for!a!further!four!hours.!Samples!were!washed!with!FACS!buffer!prior!to!staining!with!either!antiHCD8!for!lymphocyte!assays!or!CD56!for!innate!studies.!After!fixation!with!1%!PFA!cells!were!then!permeabilised!with!1mL!of!0.3%!w/v!saponin!(Sigma)!for!15!minutes!at!room!temperature.!Cells!were!washed!with!FACS!buffer!then!incubated!with!antiHIFNγ!diluted!in!0.1%!w/v!saponin!
3.11.13 Chromium/release/assay/The!chromium!release!assay!uses!target!cells!loaded!with!51Cr;!when!lysed!by!effector!cells!the!target!cells!release!51Cr!into!the!supernatant,!which!can!in!turn!be!detected!and!quantified!by!a!scintillation!counter.!!A!million!target!cells!were!harvested,!washed!and!centrifuged!to!form!a!cell!pellet!in!a!falcon!tube.!The!supernatant!was!discarded!and!around!100!μCi!of!51Cr!added!to!the!tube,!then!the!cells!incubated!for!one!hour!at!37°C.!Cells!were!then!washed!three!times!with!HBSS!to!remove!51Cr!that!had!not!been!taken!up!then!resuspended!in!CTL!media.!Effector!cells!were!added!to!wells!of!a!roundHbottomed!96!well!plate!(Nunc)!in!serial!halving!dilutions.!The!51CrHlabelled!target!cells!were!then!added!to!wells!containing!effector!cells,!resulting!in!a!range!of!effector:target!ratios!from!100:1!downwards.!Triplicate!wells!were!prepared!for!each!ratio.!In!experiments!examining!adaptive!THcell!responses!5000!unlabelled!K562!cells,!which!are!particularly!susceptible!to!innate!effectors,!were!added!to!every!well!to!competitively!exclude!innate!killing!of!loaded!targets.!For!each!cell!line!used,!and!for!each!experiment!performed!a!further!control!plate!was!prepared!to!quantify!maximum!and!minimum!target!lysis;!Labelled!targets!were!added!to!wells!containing!CTL!media!alone,!or!1%!triton!XH100!the!latter!a!detergent!which!causes!profound!disruption!of!cell!membranes.!Effector!cells!were!not!added!to!any!such!wells,!but!K562!were!included!when!used!in!sample!wells.!The!coculture!sample!plate!and!control!plate!were!incubated!at!37°C!for!four!hours!before!the!cells!were!pelleted!by!centrifugation.!50!μL!of!supernatant!was!then!transferred,!without!dislodging!the!pellet,!to!scintillation!plates!(Lumaplate,!Packard!Biosciences).!Once!the!scintillation!plates!had!dried!(at!least!overnight)!the!quantity!of!released!51Cr!was!determined!using!a!1450!Microbeta!Jet!Liquid!Scintillation!and!Luminescence!counter!(Wallac).!The!counts!per!minute!(CPM)!were!converted!to!percentage!specific!lysis!using!the!formula;!!"#$"%&'("!!"#$%&%$!!"##"$%!= 100!× !"#!"#$%& − !"#!"#$%&$'#(!!!"#"$!" ÷ !"#!"#$!%! − !"#!"#$%&$'#(! !
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3.12 Mouse/in/vitro/experiments/
3.12.1 Preparation/of/murine/cells/Tissues!harvested!from!mice!were!prepared!by!macerating!through!100!μm!cell!strainers!(BD!Falcon)!in!cold!PBS!followed!by!washing!with!cold!PBS.!Where!necessary!erythrocytes!were!removed!by!resuspension!for!2!minutes!in!5H10!mL!red!cell!lysis!buffer,!followed!immediately!by!2!washes!in!cold!PBS.!!
3.12.2 MACS/selections/THcells!were!isolated!from!splenocytes!with!a!negative!MACS!selection!method,!using!a!pan!THcell!isolation!kits!and!equipment!according!to!the!manufacturer’s!instructions!(Pan!THcell!Isoloation!Kit!II,!Miltenyi!Biotech).!Single!cell!suspensions!were!prepared!from!spleens!and!lymph!nodes!then!resuspended!in!MACS!buffer!and!incubated!with!a!cocktail!of!biotinylated!antibodies!with!a!broad!range!of!specificities,!other!than!CD8.!After!a!ten!minute!incubation!at!4°C!antiHbiotin!magnetically!labelled!antibodies!where!then!added!with!additional!MACS!buffer!and!the!cells!incubated!for!a!further!15!minutes!at!4°C.!The!cells!were!then!washed,!resuspended!in!MACS!buffer!and!the!suspension!passed!through!a!magnetic!column.!The!eluate!containing!THcells!was!collected,!the!cells!were!washed!twice!with!PBS!before!resuspension!in!PBS!at!107!cells!per!mL!for!intravenous!administration!to!mice.!!
3.12.3 TYcell/activation/Activated!THcells!were!prepared!by!preparing!single!cell!suspensions!from!spleens!and!lymph!nodes!then!treating!the!cells!with!red!cell!lysis!buffer.!After!two!washes!cells!were!resuspended!in!THcell!media!at!106!cells!per!mL,!supplemented!with!ILH2!and!relevant!antigen!(SIINFEKL!or!hgp100).!2!mL!of!the!cell!suspension!was!placed!into!each!well!of!24!well!plates!and!the!cells!incubated!for!up!to!7!days.!Cells!were!monitored!daily!and!media!refreshed!as!needed,!with!fresh!ILH2.!Activated!cells!proliferated!such!that!the!cells!needed!to!be!split!¼!after!2!days.!Cells!were!washed!with!cold!PBS!prior!to!administration!to!mice!on!the!fifth!or!sixth!day!after!initial!preparation.!!
3.12.4 Discrimination/of/host/lymphocytes/from/adoptively/transferred/cells/In!most!experiments!Thy1.2+!C57BL/6!mice!were!used,!but!in!order!to!assess!the!ability!of!adoptively!transferred!lymphocytes!to!reach!tumours!and!tumourHdraining!lymph!nodes!(TDLN)!a!further!experiment!was!prepared!in!which!Thy1.1!
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81!C57BL/6!were!inoculated!with!B16HOva!tumours!and!then!treated!with!lymphocytes!from!Thy1.2!OT1!mice.!At!the!time!of!euthanasia!tumours,!TDLN!and!spleens!were!harvested!from!the!recipient!mice!and!singleHcell!suspensions!prepared!as!before.!Cells!were!treated!with!red!cell!lysis!buffer!as!required,!then!washed!with!FACS!buffer.!0.5!μL#each#of#anti&Thy1.1&FITC,#anti&Thy1.2&PE#and#anti&
CD8a&PECy7#were#added#to#the#cells#for#20#minutes#at#4°C.#After#two#washes#with#FACS#
buffer,#cells#were#fixed#in#4%#PFA#prior#to#flow#cytometry.!
3.12.5 Intracellular/IFN/in/response/to/antigen/stimulation/Single!cell!suspensions!prepared!from!tumours,!tumourHdraining!lymph!nodes!and!spleens!were!resuspended!in!OT1!medium!at!an!approximate!concentration!of!2!x!106!cells!per!mL.!200!μL!was!added!to!wells!in!VHbottomed!96!well!plates.!Each!well!was!supplemented!with!0.4!μL!of!recombinant!peptide(human!gp100,!trp2,!SIINFEKL,!VSV),!along!with!2!μL!of!golgi!plug.!Cells!were!then!incubated!for!4!hours!at!37°C.!After!the!incubation!cells!were!washed!with!FACS!buffer!then!incubated!with!0.5!μL!of#anti&Thy1.1&FITC,#anti&Thy1.2&PE#and#anti&CD8a&PECy7!for!20!minutes!at!4°C,!prior!to!further!washing!with!FACS!buffer.!!Cells!were!then!permeabilised!with!the!BD!Cytofix/Cytoperm!kit,!used!in!keeping!with!the!manufacturer’s!instructions.!Briefly,!washed!cells!were!resuspended!in!the!kit!Cytofix/Cytoperm!reagent!for!20!minutes!at!4C,!then!washed!twice!with!PERM!wash!buffer.!Cells!were!then!resuspended!in!PERM!wash!buffer!and!stained!with!antiHIFNγ!for!30!minutes!at!4°C.!After!two!final!washes!cells!were!resuspended!in!4%!PFA!prior!to!flow!cytometry.!Isotype!controls!for!each!fluorophore!were!prepared;!as!were!positive!controls!in!order!to!establish!suitable!compensation!levels.!
3.13 / Mouse/In/vivo/experiments/All!mouse!protocols!were!reviewed!and!approved!by!the!Mayo!Foundation!Institutional!Animal!Care!and!Use!Committee!(IACUC).!All!mice!were!housed!in!the!Mayo!animal!care!facility.!Mice!obtained!from!other!facilities!were!housed!in!an!onHsite!quarantine!facility!prior!to!use.!!C57Bl/6!were!obtained!from!the!Jackson!laboratories!(Bar!Harbor,!ME,!USA)!and!used!at!ages!from!6H8!weeks!in!all!protocols.!Female!Thy1.2!mice!were!used!in!most!experiments,!but!female!Thy1.1!were!used!when!discrimination!between!host!and!adoptively!transferred!THcells!was!needed!(see!Figure!47,!page!160).!OT1!
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82!and!pmel!transgenic!mice!were!obtained!from!the!Vile!laboratory’s!own!breeding!programme.!All!animal!procedures!were!performed!after!requisite!inHhouse!training!and!either!directly!by,!or!under!the!supervision!of,!Mrs!Jill!Thompson,!veterinary!technician!to!Professor!Vile.!In!order!to!maintain!consistency!and!objectivity,!as!advised!by!the!ARRIVE!guidelines,!Mrs!Thompson!performed!the!majority!of!tumour!measurements!(Kilkenny!and!Altman,!2010).!
3.13.1 Basic/procedures/Tumours!were!established!in!the!right!flanks!of!animals!by!subcutaneous!injection!of!5x105!cells!resuspended!in!100!μL!PBS.!Cells!were!prepared!by!initial!harvest!with!trypsin!followed!by!three!washes!in!4°C!PBS!prior!to!resuspension!at!5x106!cells!per!mL.!!Tumours!were!measured!thrice!weekly!by!caliper!and!their!anteroHposterior!and!lateral!dimensions!recorded.!Mice!were!euthanized!if!the!tumours!exceeded!1!cm!in!any!dimension,!if!there!was!evidence!of!ulceration!or!impending!ulceration,!or!if!the!animal!showed!any!signs!of!distress.!Euthanisation!was!performed!by!CO2!inhalation!in!all!cases.!!
3.13.2 Therapeutic/administrations/Therapy!was!applied!intravenously,!intratumourally!or!by!the!intraperitoneal!route.!All!administrations!were!performed!by!Mrs!Thompson,!or!under!her!direct!supervision.!After!briefly!preHwarming!mice!using!a!heat!lamp!to!elicit!venodilation,!intravenous!access!was!obtained!by!placing!unsedated!mice!into!a!custom!jig!that!exposes!the!tail.!Venous!access!was!obtained!with!Kendall!monoject!28!gauge!tuberculin!syringes!(Tyco!healthcare).!Naïve!THcells,!both!OT1!and!pmel,!were!administered!intravenously!with!a!standard!dose!of!106!cells!in!100!μL!cold!PBS.!Activated!cells,!both!OT1!and!pmel,!were!administered!intravenously!with!a!standard!dose!of!107!cells!in!100!μL!cold!PBS.!A!higher!dose!was!used!for!activated!cells!because!of!their!lesser!potential!for!expansion!in!vivo.!SIINFEKL!was!administered!intravenously!with!a!standard!dose!of!0.1!mg!per!mouse!in!100!μL!PBS.!Intravenous!virus!(VSVHOva!or!VSVHGFP)!was!administered!at!a!standard!dose!of!5!x!108!pfu!Intratumoural!and!intraperitoneal!injections,!which!were!performed!using!Kendall!monoject!tuberculin!syringes,!were!limited!to!50!μL!and!100!μL!respectively.!
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83!Anaesthesia!was!achieved!using!inhalational!isofluorane!delivered!via!an!oxygenHdriven!clinicalHgrade!vapouriser!to!an!induction!chamber!or!nose!cone,!titrated!to!effect,!with!the!exception!of!intracranial!injections,!which!were!performed!using!intraperitoneal!anaesthesia!detailed!below.!
3.13.3 Radiotherapy/Mice!were!secured!for!external!beam!radiotherapy!in!a!mouse!jig!with!single!flank!shield!(Precision!Xray!Inc.,!North!Branford,!CT,!USA)!that!restrains!the!animals!without!the!need!for!anaesthesia!and!was!well!tolerated!(Travis!et!al.,!1982).!The!7!mm!thick!lead!shield,!with!a!semiHlunar!cutout!over!the!right!flank,!was!placed!over!the!jig!to!restrict!dose!to!the!tumour!and!adjacent!tissue.!300!kV!photons!were!delivered!from!a!Maxitron!300!kilovoltage!irradiator!(General!Electric,!no!longer!manufactured)!at!a!sourceHtoHsurface!distance!of!0.7!m!and!a!dose!rate!of!1.2!Gy/min.!Treatment!setup!was!calibrated!by!physicists!from!the!Mayo!clinic!radiation!oncology!department!prior!to!starting!experiments.!For!some!experiments!a!137Cs!source!was!used!in!a!Mark!I!model!25!irradiator!(J.L.!Shepherd!and!associates!San!Fernando!Ca,!USA).!For!locally!boosted!treatments!mice!were!placed!in!the!same!jig!as!described!above.!For!whole!body!treatments!mice!were!housed!in!1!L!beakers!on!a!rotating!platform!within!the!irradiator!housing!to!deliver!evenly!distributed!dose.!Experiments!using!the!137Cs!irradiator!were!performed!by,!or!under!direct!supervision!of,!Mr!Tim!Kottke,!as!US!federal!regulations!restrict!access!to!high!activity!sources.!!
3.13.4 Brachytherapy/Sealed!sources!containing!IodineH125!were!obtained!from!the!Mayo!departments!of!radiation!safety!and!radiation!oncology!after!use!in!patients!for!prostate!cancer!brachytherapy!or!ocular!melanoma.!No!patientHrelated!information!was!kept!after!the!sources!were!returned!to!radiation!safety.!The!location!and!use!of!each!source!was!recorded!and!details!kept!by!the!radiation!safety!department.!The!seeds!available!were!determined!by!clinical!necessity!and!so!different!activities!had!to!used!within!the!experiments!described.!An!equal!distribution!of!seed!activities!was!maintained!amongst!experimental!groups!unless!otherwise!indicated.!Silastic!plaques!were!prepared!from!sheets!of!2!mm!tissueHgrade!silastica!obtained!from!the!Mayo!engineering!department.!8!mm!diameter!discs!were!cut!using!a!customHmade!aluminium!punch.!125I!seeds!were!inserted!into!the!discs!by!creating!
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84!a!pilot!hole!with!20!gauge!hypodermic!needles.!For!some!experiments!the!plaques!were!overlain!with!a!centrally!placed!6mm!diameter!disc!of!1!mm!thick!lead!sheet,!secured!and!covered!with!adhesive!silastic!(Dow!Corning!adhesives,!Midland,!MI).!This!made!the!overall!thickness!of!the!plaque!3.5!mm!but!the!addition!of!lead!shielding!reduced!the!emergent!activity!by!90%,!with!resultant!benefits!to!personnel!exposure,!and!allowing!the!use!of!higher!activity!seeds.!After!preparation!the!plaques!were!autoclaved!prior!to!surgical!insertion.!For!insertion!of!plaques!mice!were!anaesthetized!with!inhalational!isofluorane.!After!cleaning!with!betadine!a!2!cm!craniocaudal!incision!was!made!medial!to!the!palpable!tumour.!A!pouch!was!prepared!overlying!the!tumour!using!blunt!dissection!and!the!plaque!inserted.!The!pouch!was!closed!using!surgical!clips!and!the!mouse!observed!until!seen!to!have!recovered!from!the!effects!of!anaesthesia.!After!insertion!of!plaques!mice!were!housed!in!a!dedicated!radiation!facility!within!the!animal!house,!until!the!plaques!were!removed.!Removal!was!performed!using!inhalational!isofluorane!anaesthesia.!Plaques!were!readily!extracted!with!minimal!dissection!and!the!incision!reclosed!with!surgical!clips.!Clips!were!removed!after!9!days,!once!the!wound!was!well!healed.!Computed!tomography!images!were!captured!using!a!highHresolution!microHSPECT/CT!system!(XHSPECT,!Gamma!Medica!Ideas,!Inc.,!Northridge,!CA).!MicroHCT!images!were!acquired,!without!SPECT!acquisition,!in!3!minutes!(600!ms,!360!images)!at!0.5!mA!and!60!kV.!Mice!were!anaesthetised!with!inhalational!isofluorane!throughout.!The!data!were!transferred!according!to!DICOM!(digital!imaging!and!communications!in!medicine)!protocols!to!the!radiation!oncology!physics!department!for!dosimetry!estimation.!An!initial!approximation!of!dose!to!tumours!from!one!seed!was!given!by!the!point!source!TGH43!formula,!wherein;!!"#$! !"#ℎ!"# = !!"#! "#$%!!"#$%&"ℎ!×! "#$!!"#$!!"#$%&#%!×!!"#$"%! "#$!!"#$%&'( ÷ !!!!The!dose!rate!constant!for!125I!is!0.965!cGy/hour/unit!and!radial!dose!fraction!approximates!to!unity.!!
3.13.5 Intracerebral/tumour/implantation./Mice!were!anaesthetized!with!a!combination!of!ketamine!(100!mg/kg)!and!Xylazine!(10!mg/kg)!(both!supplied!by!Mayo!pharmacy)!mixed!and!given!intraperitoneally.!Once!adequate!anaesthesia!was!confirmed!the!head!was!cleaned!
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85!with!betadine!and!the!eyes!covered!with!an!artificial!tear!preparation.!A!small!midline!incision!was!made!behind!the!eyes!to!the!level!of!the!ears.!Skin!was!bluntly!pushed!to!the!right!side!to!allow!access!to!the!site!for!the!burr!hole,!2!mm!anterolateral!to!the!bregma.!A!Dremel!multiHtool!(ACE!Hardware,!Rochester,!MN,!USA)!fitted!with!a!2!mm!cutting!bit!was!used!to!make!the!burr!hole!under!direct!vision.!Mice!were!then!transferred!to!a!stereotactic!jig!and!secured!by!tooth!hoop.!A!Hamilton!syringe!with!a!fixed!26!gauge!fine!bore!needle!was!then!guided!to!the!burr!hole,!until!the!needle!tip!was!seen!to!rest!on!the!meningeal!or!cerebral!surface.!The!syringe!was!then!driven!down!between!2H3!mm,!dependent!on!the!size!of!the!mouse,!and!infusion!of!cell!suspension!performed!at!1!μL!per!minute!with!an!additional!minute!after!completion!of!the!infusion.!The!needle!was!then!withdrawn!and!in!some!experiments!the!burr!hole!occluded!with!bone!wax!before!suturing!the!incision!with!4H0!vicryl!on!a!rbH1!curved!needle.!!Mice!were!monitored!and!warmed!by!heat!lamp!until!seen!to!have!fully!recovered!from!the!effects!of!anaesthesia.!Once!tumour!cells!had!been!implanted!mice!were!checked!daily!for!any!evidence!of!tumour!burden.!Specifically!impaired!gait,!persistent!hunching!or!emaciation!were!taken!as!evidence!of!unacceptable!tumour!burden!and!mice!displaying!such!symptoms!were!immediately!euthanized.!Tissue!was!extracted!for!histology!at!the!time!of!euthanasia!and!immediately!immersed!in!prefilled!pots!containing!30!mL!10%!neutral!buffered!formalin!(Fisher!Scientific)!then!sent!to!the!Mayo!animal!studies!histology!department!for!further!analysis.!
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4 Measles/virus/versus/melanoma/!
4.1 Introduction/The!Edmonston!strain!of!MV!has!been!studied!as!a!potential!OV!across!a!wide!range!of!preclinical!tumour!models!(Donnelly!et!al.,!2013).!Its!oncotropism!is!predominantly!due!to!overexpression!of!one!of!the!key!MV!receptors,!CD46,!on!the!surface!of!most!tumour!cells.!PreHclinical!promise!has!led!to!clinical!trials!in!myeloma,!ovarian!cancer,!glioma,!mesothelioma!and!lymphoma,!but!the!virus!had!not!previously!been!studied,!clinically!or!preHclinically,!in!melanoma!(Donnelly!et!al.,!2012a).!In!addition!to!direct!oncolysis!several!OV!have!been!demonstrated!to!cause!inflammatory!cell!death,!capable!of!enhancing!innate!antiHtumour!immunity!and!priming!adaptive!antiHtumour!immune!responses!(Prestwich!et!al.,!2008c).!Indeed!in!some!preHclinical!models!the!therapeutic!efficacy!of!OV!is!in!fact!predominantly!mediated!by!immune!sequelae,!rather!than!oncolysis!per!se!(Prestwich!et!al.,!2009b).!MV!stimulates!immune!responses!in!models!of!mesothelioma,!but!its!immune!effects!have!been!otherwise!little!explored!(Gauvrit!et!al.,!2008).!!The!experiments!described!below!first!sought!to!test!the!oncolytic!activity!of!MV!against!in!vitro!models!of!human!melanoma,!and!then!to!assess!the!immunological!effects!of!MV!treatment,!exploring!its!potential!as!a!therapeutic!agent!for!patients!with!melanoma.!! !
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4.2 Results/
4.2.1 CD46/expression/on/melanoma/cell/lines/wtMV!has!a!tropism!for!immune!cells!and!DC,!thought!in!part!to!contribute!to!the!immunosuppression!associated!with!the!measles!illness!(Grosjean!et!al.,!1997;!Permar!et!al.,!2006;!SchneiderHSchaulies!and!SchneiderHSchaulies,!2009).!NectinH4!has!recently!been!identified!as!a!receptor!for!the!wild!type!virus!and!is!likely!to!be!relevant!for!oncolytic!strains!too,!however!it!is!thought!to!be!more!important!for!exiting!the!cell!(Mühlebach!et!al.,!2011).!The!principle!receptor!to!which!wtMV!is!able!to!bind!is!CD150,!also!known!as!the!signalling!lymphocyte!activation!marker!(SLAM),!commonly!expressed!on!DC!and!lymphocytes!(Erlenhofer!et!al.,!2002;!Dhiman!et!al.,!2004).!By!contrast!the!Edmonston!strain!has!acquired!additional!tropism!for!CD46,!ubiquitously!expressed!on!nucleated!human!cells.!CD46!is!the!membrane!cofactor!receptor!which!serves!to!bind!and!neutralise!components!of!the!complement!pathway,!specifically!C3b!and!C4b,!acting!as!cofactor!for!their!proteolytic!degradation.!Its!function!therefore!is!to!regulate!complementHmediated!lysis,!preventing!inappropriate!attack!by!complement!proteins.!CD46!is!upregulated!on!several!human!malignancies,!presumably!as!a!defence!against!complement!mediated!lysis,!and!it!is!reported!that!this!is!one!of!the!mechanisms!of!MV!oncotropism!(Anderson!et!al.,!2004;!Ong!et!al.,!2006b).!CD46!binds!to!the!F!(fusion)!and!H!(haemagglutinin)!structural!proteins!of!MV,!and!the!resulting!trimer!undergoes!conformational!changes!that!lead!to!viral!entry!(Navaratnarajah!et!al.,!2008,!2009).!Subsequent!viral!transmission!between!cells!is!also!mediated!by!CD46;!an!infected!cell!will!produce!F!and!H!proteins!that!are!in!turn!expressed!on!its!surface.!These!surface!F!and!H!proteins!bind!CD46!on!adjacent!uninfected!cells,!which!leads!to!cellHtoHcell!fusion,!resulting!in!giant!multinucleated!syncytia!(Duprex!et!al.,!1999;!Duprex!and!Rima,!2002).!Experiments!with!cell!lines!transfected!to!express!varying!amounts!of!CD46!have!shown!that!the!efficiency!of!viral!entry!is!directly!related!to!levels!of!CD46!expression!(Ong!et!al.,!2006b).!In!contrast!the!phenomenon!of!cellHtoHcell!fusion!requires!a!threshold!level!of!CD46!expression,!but!increasing!levels!do!not!significantly!increase!the!efficiency!of!fusion.!Given!that!CD46!or!CD150!expression!on!melanoma!cells!would!be!a!requisite!for!successful!oncolysis!by!MV,!the!human!melanoma!cell!lines!Mel888,!Mel624,!MeWO!and!SkMel28!were!stained!with!FITCHlabelled!antiHCD46!or!antiHCD150!
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88!mAb!prior!to!flow!cytometry!to!determine!the!levels!of!surface!expression.!As!expected!no!cell!line!expressed!CD150!(data!not!shown)!but,!as!shown!in!Figure!9,!all!four!cell!lines!express!surface!CD46,!suggesting!possible!susceptibility!to!MV.! !
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! !
!Figure! 9.! CD46! expression! on!melanoma! cell! lines.!Melanoma! cell! lines! (Mel888,!Mel624,!MeWO!and! SkMel28)!were! examined! for! surface! expression! of! CD46,! a!MV! receptor,! by! flow! cytometry!after! staining! with! a! FITCHconjugated! monoclonal! antiHCD46! antibody.! A.! Representative!histograms! indicate! cells! stained! with! an! isotype! control! antibody! (filled! histograms),! and! cells!stained!with! antiHCD46! (open! histograms).! B.!Median! fluorescence! intensity! (MFI)!was! recorded!from!three!separate!experiments.!Error!bars!indicate!the!standard!error!of!the!mean!values!(SEM).!!!! !
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4.2.2 Morphological/changes/following/MV/treatment./The!characteristic!cytopathic!effect!(CPE)!of!MV!is!to!produce!giant!multinucleated!cells!or!syncytia.!Infected!cells!express!the!fusogenic!viral!proteins!F!and!H!on!their!surface!and!cellHtoHcell!fusion!ensues;!the!resulting!syncytia!may!contain!many!hundreds!of!nuclei.!These!appearances!were!first!described,!independently,!by!Warthin!and!Finkeldy!after!examination!of!enlarged!lymph!nodes!from!children!suffering!wtMV!infection;!those!authors!now!share!an!eponym!as!a!result!(Paik!et!al.,!2002).!!Cells!of!each!of!the!four!melanoma!lines!used!above!were!treated!with!MV!expressing!GFP!in!serumHfree!viral!infection!media!at!a!range!of!multiplicities!of!infection!(MOI).!48!hours!later!the!flasks!were!examined!for!evidence!of!CPE.!As!shown!in!Figure!10!there!were!clearly!visible!syncytia!amongst!Mel888!treated!with!MVHGFP,!indeed!the!plaques!were!visible!without!microscopy,!but!are!more!readily!seen!with!fluorescent!microscopy!as!demonstrated!in!Figure!11.!Figure!12!throughFigure!17!illustrate!similar!findings!amongst!the!other!cell!lines,!though!it!is!clear!that!the!speed!and!degree!of!infection!varies!between!cell!lines.!!! !
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! ! !Figure!10.!Cytopathic!effect!of!MV!upon!Mel888.!Mel888!cells!were!treated!with!MVHGFP!at!the!MOI!indicated!and!photographs!taken!using!phase!contrast!microscopy,!after!24,!48!and!72!hours.!! !
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! ! !Figure!11.!GFP!expression!in!Mel888!treated!with!MVHGFP.!Fluorescence!microscopy!of!the!same!fields!shown!in!Figure!10.!! !
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! ! !Figure!12.!Cytopathic!effect!of!MV!upon!Mel624.!Mel624!cells!were!treated!with!MVHGFP!at!the!MOI!indicated!and!photographs!taken!using!phase!contrast!microscopy,!at!24,!48!and!72!hours.!! !
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! ! !Figure!13.!GFP!expression!in!Mel624!treated!with!MVHGFP.!Fluorescence!microscopy!of!the!same!fields!shown!in!Figure!12.!! !
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! ! !Figure!14.!Cytopathic!effect!of!MV!upon!MeWO.!MeWO!cells!were!treated!with!MVHGFP!at!the!MOI!indicated!and!photographs!taken!using!phase!contrast!microscopy,!at!24,!48!and!72!hours.!! !
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! ! !Figure!15.!GFP!expression!in!MeWO!treated!with!MVHGFP.!Fluorescence!microscopy!of!the!same!fields!shown!in!Figure!14.!! !
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! ! !Figure! 16.! Cytopathic! effect! of! MV! upon! SkMel28.! SkMel28! cells! were! treated! with! MVHGFP! at! the! MOI!indicated!and!photographs!taken!using!phase!contrast!microscopy,!at!24,!48!and!72!hours.!! !
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! ! !Figure!17.!GFP!expression!in!SkMel28!treated!with!MVHGFP.!Fluorescence!microscopy!of!the!same!fields!shown!in!Figure!16.!! !
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4.2.3 Viability/assays/following/MV/treatment/To!obtain!objective!measures!of!MVHmediated!oncolysis!of!melanoma!cells!Live/Dead!flow!cytometry!assays!were!performed.!The!Live/Dead!reagent!is!a!commercially!available!product!that!is!based!on!similar!principles!to!the!more!familiar!propidium!iodide!stains;!it!is!a!nonHspecific!amineHbinding!dye!that!readily!binds,!but!does!not!cross,!cell!membranes.!Live!cells!with!intact!external!membranes!will!therefore!have!a!considerably!lower!fluorescence!when!compared!to!dead!or!dying!cells!with!disrupted!membranes.!MV!was!added!in!Optimem!without!serum!at!a!MOI!in!the!range!indicated,!to!cells!grown!overnight!in!24Hwell!plates,!and!after!one!hour!was!replaced!with!DMEM.!At!24,!48!and!72!hour!intervals!cells!were!harvested,!washed!and!stained!with!the!Live/Dead!reagent!in!accordance!with!the!manufacturer’s!instructions,!and!then!fixed!in!1%!PFA!prior!to!analysis!by!flow!cytometry.!After!gating!around!the!morphologically!intact!population!to!exclude!nonHspecific!binding!of!the!dye!by!cellular!fragments!and!doublets,!cells!were!separated!into!positive!or!negative!staining!by!comparison!with!untreated!controls!and!the!percentage!of!dead!cells!determined.!As!shown!in!Figure!18,!very!little!cell!death!was!seen!at!24!hours,!irrespective!of!MOI.!However!within!48!hours!an!increase!in!cells!stained!with!the!Live/Dead!reagent!was!seen,!indicating!that!all!four!melanoma!cell!lines!were!susceptible!to!MVHmediated!oncolysis!in!a!doseHdependent!fashion.!There!appeared!to!be!a!threshold!between!0.01!and!0.1!MOI,!below!which!no!increase!in!killing!compared!to!controls!was!seen.!Though!susceptibility!was!similar!between!cell!lines,!Mel624!appeared!slightly!more!resistant!to!the!oncolytic!effects!of!MV!than!the!other!lines,!despite!the!microscopic!and!macroscopic!appearances!(Figure!12).!
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!Figure!18.!Oncolytic!activity!of!MV!against!melanoma!cell!lines!(Live/Dead).!Tumour!cells!were!seeded!in!24!well!plates!and!the!following!day!treated!with!MV!at!the!MOI!indicated.!Oncolytic!activity!was!assessed!after!24,!48!and!72!hours!using!the!Live/Dead!discriminator!assay!and!the!proportion!of!dead!cells!quantified!by!flow!cytometry.!Results!shown!are!the!mean!of!5!independent!experiments!and!error!bars!indicate!the!SEM.!!!!!
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101!It!has!been!reported!that!MVHinfected!cells!forming!large!syncytia!may!remain!viable!for!extended!periods!whilst!cultured!with!adequate!numbers!of!intact!cells!(Herschke!et!al.,!2007).!This!suggests!that!some!MVHinfected!giant!cells,!fated!to!die,!may!maintain!their!cell!membrane!integrity!during!the!period!of!this!assay.!!The!yellow!tetrazolium!salt!3H[4,5HdimethylthiazolH2Hyl]H2,5Hdiphenyltetrazolium!bromide!(MTT)!freely!permeates!cell!membranes!and!is!subsequently!reduced!by!mitochondrial!dehydrogenases,!present!in!metabolically!functional!cells,!to!a!purpleHcoloured!formazan.!The!production!of!formazan!is!a!colourimetrically!detectable!and!quantifiable!change!which!indicates!the!number!of!metabolically!intact!cells!and!is!used!as!a!measure!of!cell!killing!H!the!MTT!assay!(Liu!and!Dalgleish,!2009).!The!MTT!assay!was!performed!to!corroborate!the!results!of!the!Live/Dead!assay!as!well!as!the!appearances!of!cytopathic!effect!following!MVHtreatment,!which!suggest!oncolytic!efficacy!of!the!virus.!!Melanoma!cell!lines!were!grown!in!96!well!plates.!The!following!day!MV!was!added!as!before!and!MTT!assay!performed!at!24,!48!and!72!hours!after!MV!treatment.!Results!were!obtained!by!measuring!absorption!at!550!nm.!The!percentage!of!cells!alive!in!treated!wells!was!calculated!based!on!relative!absorption;!untreated!wells!served!as!controls!and!were!assumed!to!be!100%!alive.!Results!of!the!MTT!assays!are!shown!in!Figure!19.!In!keeping!with!the!results!from!Live/Dead!assays!no!loss!of!survival!was!seen!at!24!hours!at!any!MOI!in!any!cell!line.!By!48!hours!after!infection!there!was!evidence!of!loss!of!viability!of!Mel624!and!Mel888;!MeWO!and!SkMel28!only!began!to!display!susceptibility!by!72!hours,!in!keeping!with!the!morphological!changes!described!above.!It!was!noted!that!levels!of!viability!were!higher!at!low!MOI,!and!this!prompted!concern!that!subHtherapeutic!MOI!appeared!to!stimulate!proliferation!of!melanoma.!In!further!experiments!cell!counts!confirmed!that!there!was!no!proliferation!in!cells!treated!at!any!MOI!compared!to!untreated!controls!(data!not!shown).!!!The!MTT!reagent!readily!permeates!intact!membranes!therefore!it!is!likely!that!the!increased!absorption!seen!at!low!MOI!actually!reflects!transiently!increased!metabolic!activity!within!surviving!MVHinfected,!multinucleated!giant!cells!(Liu!and!Dalgleish,!2009).!!Notably!there!was!some!discordance!between!the!degree!of!susceptibility!determined!by!Live/Dead!assay!when!compared!to!MTT;!i.e.!by!Live/Dead,!Mel624!
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102!appears!to!be!the!most!resistant!cell!line,!whereas!by!MTT!Mel624!is!the!most!susceptible.!This!presumably!reflects!the!fact!that!each!assay!measures!different!and!surrogate!markers!of!cell!killing,!and!the!discrepancy!due!to!inherent!variations!between!the!cell!lines.!Despite!the!limitations!of!each!assay!it!is!important!to!note!that!collectively!the!data!from!Live/Dead!assays,!MTT!assays,!and!the!morphological!changes!seen,!all!serve!to!assert!the!susceptibility!of!melanoma!cell!lines!to!oncolysis!by!MV.!Reassuringly!the!degree!and!timing!of!killing!observed!are!in!keeping!with!reports!of!oncolytic!efficacy!of!MV!in!several!other!nonHmelanoma!cancer!models!(Haralambieva!et!al.,!2007;!Myers!et!al.,!2008;!Dingli!et!al.,!2009;!Liu!et!al.,!2009;!Msaouel!et!al.,!2009;!Iankov!et!al.,!2010;!Li!et!al.,!2010).!Previous!experience!of!reovirus,!an!alternative!OV,!used!in!models!of!human!melanoma!suggests!that!MV!replication!in,!and!killing!of,!human!melanoma!cell!lines!is!slower!and!less!effective!than!reovirus,!though!with!the!caveat!that!comparisons!outwith!formal!headHtoHhead!testing!are!unreliable!(Errington!et!al.,!2008b).! !
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!Figure! 19.! Oncolytic! activity! of!MV! against!melanoma! cell! lines! (MTT).! Tumour! cells! were! seed! in! 96!well!plates!and!the!following!day!treated!with!MV!at!the!MOI!indicated.!Cell!viability!was!assessed!after!24,!48!and!72!hours!using!MTT!assay!and!the!proportion!of!metabolically!active!cells!quantified!by!optical!density,!with!viability!determined!in!relation!to!untreated!controls.!Results!shown!are!the!mean!of!4!separate!experiments!and!error!bars!indicate!the!SEM.!! !
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4.2.4 Viral/replication/!One!of!the!tenets!of!the!OV!approach!is!that!successful!viruses!will!reach!tumours!and!after!cell!entry!commandeer!cellular!machinery!to!initiate!viral!replication.!This!inHtarget!replication!has!been!suggested!to!be!vital!to!therapy,!although!others!have!argued!that!much!of!the!efficacy!of!OV!is!in!fact!due!to!effects!upon!the!immune!system!(Prestwich!et!al.,!2009a).!!Melanoma!cells!were!plated!in!triplicate!in!six!well!plates!and!after!24!hours!infected!at!an!MOI!of!0.1.!Cells!were!scraped!from!each!well!and!nonHadherent!cells!recovered!from!the!supernatant!media!by!centrifugation.!The!cells!were!then!subjected!to!three!cycles!of!freezing!and!thawing!to!release!virions!from!intact!cells!or!syncytia,!and!the!viral!suspension!was!titrated!by!serial!tenHfold!dilutions!on!Vero!cells!to!quantify!the!TCID50!(Tissue!culture!50%!infectious!dose)!according!to!the!method!of!Reed!and!Muench!(Reed!and!Muench,!1938).!As!illustrated!in!Figure!20,!melanoma!cells!treated!with!MV!at!an!MOI!of!0.1!yielded!logarithmic!increases!of!replicating!virus!by!48!hours!after!infection.!The!results!shown!are!representative!of!two!separate!experiments.!The!data!presented!so!far!assert!the!conventional!oncolytic!potential!of!MV!in!melanoma;!namely!that!the!virus!successfully!infects,!replicates!within!and!kills!melanoma!cell!lines.!Notably!however!this!is!likely!only!to!be!one!component!of!OV!efficacy!in!the!clinical!setting,!and!others!have!demonstrated!that!generation!of!an!antiHtumour!immune!response!is!requisite!for!therapy!in!some!in!vivo!models!of!OV!(Prestwich!et!al.,!2009b).!Therefore!the!inflammatory!potential!of!MV,!in!the!setting!of!melanoma,!was!examined.!! !
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!Figure!20.!Viral!replication.!Cells!from!each!melanoma!line!were!plated!in!24!well!plates!and!the!following!day!treated!with!MV!in!serumHfree!media!to!an!MOI!of!0.1.!At!the!time!points!indicated!adherent!and!nonHadherent!cells!were!harvested! then!subjected! to! three!cycles!of! freezing!and! thawing! then!added,!after!serial! tenHfold!dilutions,!to!Vero!cells!in!order!to!establish!the!viral!titre,!and!the!foldHincrease!calculated.!Results!shown!are!representative!of!two!separate!experiments.! !
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4.2.5 Characteristics/of/MVYinduced/melanoma/cell/death/As!would!be!expected,!the!use!of!MV!as!a!paediatric!vaccine!MV!stimulates!a!Th1Hskewed!inflammatory!cytokine!response!(Ovsyannikova!et!al.,!2003);!clearly!a!very!different!setting!from!oncolytic!virotherapy,!but!this!at!least!suggests!that!treatment!with!MV!may!generate!the!inflammatory!milieu!capable!of!enhancing!antiHtumour!immunity.!It!has!previously!been!shown!in!melanoma!cell!lines!that!cytokine!and!chemokine!release!following!OVHmediated!cancer!cell!death!contributes!to!the!generation!of!innate!and!adaptive!immune!responses!and!bystander!killing!(Errington!et!al.,!2008a,!2008b).!In!parallel!with!the!cytotoxicity!assays!described!above,!supernatant!media!was!collected!from!cells!24,!48!and!72!hours!after!treatment!with!MV!at!a!range!of!MOI.!This!tumourHconditioned!media!was!clarified!by!centrifugation!and!stored!at!H80°C!before!analysis!for!a!range!of!cytokines!by!ELISA,!the!results!of!which!are!shown!in!Figure!21!and!Figure!22.!The!release!of!chemokines!and!cytokines!varied!amongst!the!different!cell!lines!but!some!patterns!were!evident.!A!doseHdependent!increase!in!levels!of!IL6!was!seen!from!Mel888,!Mel624!but!to!low!absolute!levels,!and!to!a!somewhat!higher!level!with!MeWO!cells!(Figure!21).!IL6!is!often!described!as!a!pleiotropic!cytokine,!thought!to!be!involved!in!tumour!initiation!and!known!to!be!proHinflammatory,!but!its!precise!actions!in!the!context!of!melanoma!are!not!yet!clear!(Culig!and!Puhr,!2012;!Hoejberg!et!al.,!2012,!F.ErringtonHMais,!A.!Melcher!and!J.!NewtonHBishop,!personal!communications!2012).!IL8,!another!inflammatory!cytokine!that!has!been!implicated!in!the!recruitment!of!macrophages!and!neutrophils!to!the!tumour!microenvironment,!was!elicited!in!a!dose!dependent!fashion!from!all!four!cell!lines!tested!(Waugh!and!Wilson,!2008).!IL8!is!also!released!by!neutrophils!in!response!to!infection!with!MV!(Zhang!et!al.,!2012).!!RANTES!(Regulated!upon!Activation,!Normal!THcell!Expressed,!and!Secreted,!also!known!as!CCL5)!is!a!chemokine!involved!in!recruiting!several!species!of!immune!cells!including!cytotoxic!THcells!and!has!been!shown!to!enhance!the!ability!of!CD4+!THcells!to!stimulate!antiHtumour!responses!(Lapteva!and!Huang,!2010;!GonzálezHMartín!et!al.,!2012).!Mel888,!Mel624!and!SkMel28!all!released!RANTES!in!a!dose!dependent!fashion!following!treatment!with!MV!(Figure!21).!!
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107!IFN!are!the!prototypical!antiHviral!cytokines!and!nonHmalignant!human!epithelial!cells,!treated!with!an!alternative!strain!of!MV,!produced!IFN!in!response!to!cellHtoHcell!fusion!(Herschke!et!al.,!2007).!One!of!the!oncotropic!mechanisms!of!OV!often!cited!is!the!deficient!IFN!response!present!in!many!tumour!cells!(CritchleyHThorne!et!al.,!2009).!This!is!often!conflated!with!deficient!production!of!IFN!despite!previous!reports!to!the!contrary;!primary!cells!from!ovarian!cancer!patients,!and!myeloma!patients!produce!type!I!interferons!in!response!to!the!Edmonston!strain!of!MV,!though!at!considerably!lower!levels!than!shown!in!Figure!22!(Haralambieva!et!al.,!2007).!Production!of!IFNα,!IFNβ!and!IFNλ/IL28!has!previously!been!reported!in!a!lung!adenocarcinoma!cell!line,!following!treatment!with!wtMV,!and!was!apparently!mediated!by!TLR3!recognition!of!double!stranded!RNA!(Berghäll!et!al.,!2006).!Single!stranded!viral!RNA!is!recognised!by!TLR!7!and!8,!but!neither!are!thought!to!be!present!in!epithelial!or!endothelial!cells!(Tissari!et!al.,!2005).!MV!may!also!stimulate!IFN!production!by!other!mechanisms!as!it!has!been!shown!that!the!act!of!virus!fusing!with!a!cell!membrane!(specifically!a!virusHlike!peptide!based!on!HSVHtype!1)!can!elicit!an!IFN!response,!independently!of!subsequent!intracellular!viral!recognition!(Holm!et!al.,!2012).!!Accordingly!all!four!melanoma!cell!lines!released!significant!quantities!of!at!least!one!species!of!either!type!I!(α/β)'or!III!(λ)!IFN!(Figure!22).!The!production!of!type!I!IFN!by!tumour!cells!in!response!to!MV!has!previously!been!considered!to!be!potentially!deleterious!to!OV!therapy!as!cells!normally!respond!to!IFN!by!down!regulating!cellular!machinery!required!for!viral!synthesis!(Haralambieva!et!al.,!2007).!However!malignant!cells!commonly!have!defects!in!their!IFNHresponse!pathways!such!that!they,!more!than!adjacent!normal!tissue,!are!unlikely!to!benefit!from!IFNHmediated!protection,!theoretically!enhancing!the!therapeutic!index!(CritchleyHThorne!et!al.,!2009).!Moreover!type!I!IFN!have!direct!antiproliferative!and!cytotoxic!activity!against!melanoma,!and!are!in!clinical!use!in!some!treatment!centres!(Johns!et!al.,!1992;!Kubo!et!al.,!2008;!Mocellin!et!al.,!2010).!Type!I!IFN!have!been!used!clinically!to!treat!melanoma,!and!have!been!demonstrated!preclinically!to!be!critical!in!the!generation!of!innate!and!adaptive!responses!(Johns!et!al.,!1992;!Haralambieva!et!al.,!2007).!Though!they!act!through!different!receptor!pathways!the!type!III!IFN,!such!as!IL28,!seem!to!have!many!downstream!properties!in!common!with!the!type!I!IFN,!including!antiviral!and!antiproliferative!actions!(Uzé!and!Monneron,!2007).!IL28!
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108!has!antitumour!activity!against!murine!melanoma,!and!causes!upregulation!of!MHC!class!I!molecules!(Lasfar!et!al.,!2006).!In!a!mouse!model!of!melanoma,!in!which!it!was!previously!demonstrated!that!successful!virotherapy!is!dependent!upon!host!innate!and!adaptive!immune!responses,!IL28!was!produced!by!innate!effector!cells!in!response!to!virotherapy!with!VSV!and!blockade!of!IL28!abrogated!such!therapy!(Diaz!et!al.,!2007;!Wongthida!et!al.,!2010).!These!data!suggest!that!melanoma!cells,!normally!muted!in!their!communication!with!the!immune!system,!respond!to!treatment!with!MV!by!producing!a!range!of!cytokines!and!chemokines,!including!interferons!which!would!be!expected!to!have!autocrine!or!bystander!antitumour!effects.
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'Figure!21.!Cytokine!release!by!melanoma!after!treatment!with!MV.!Melanoma!cell!lines!were!plated!in!24!well!plates!and!treated!at!the!range!of!MOI!indicated.!After!48!hours!supernatant!media!was!collected!and!centrifuged!to!remove!nonHadherent!cells,!then!analysed!for!presence!of!the!cytokines!IL6,!IL8!and!RANTES!by!ELISA.!Results!shown!are!the!mean!of!two!(RANTES)!or!three!(IL6!&!IL8)!separate!experiments!and!error!bars!indicate!the!SEM!
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' !Figure!22.!IFN!release!by!melanoma!after!treatment!with!MV.Melanoma!cell!lines!were!plated!in!24!well!plates!and!treated!at!the!range!of!MOI!indicated.!After!48!hours!supernatant!media!was!collected!and!centrifuged!to!remove!nonHadherent!cells,!then!analysed!for!presence!of!the!cytokines!IFNα,!IFNβ!and!IFNλ!by!ELISA.!Results!shown!are!the!mean!of!two!separate!experiments!and!error!bars!indicate!the!SEM.!
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111!HMGB1!is!a!recently!recognised!and!potent!danger!signal,!capable!of!activating!DC!via!TLR4!and!MyD88!and!contributing!to!cancer!cell!susceptibility!to!conventional!therapies!(Scaffidi!et!al.,!2002;!Lotze!and!Tracey,!2005;!Apetoh!et!al.,!2007a;!Bianchi!and!Manfredi,!2007;!Klune!et!al.,!2008;!Tang!et!al.,!2010;!Huang!et!al.,!2011a).!At!the!time!of!these!experiments!there!was!no!widely!available!assay!with!which!to!perform!ELISA,!so!cell!free!supernatants!were!analysed!by!western!blot!instead.!The!assay!was!developed!to!exclude!the!possibility!that!simian!HMGB1!was!contaminating!supernatant!media!from!tumour!cell!cultures!after!treatment!with!MV!(prepared!as!it!was!from!lysates!of!the!African!green!monkey!kidney!cell!line;!Vero).!Virus!was!added!to!cells!after!dilution!in!serumHfree!media!and!after!one!hour!the!cells!were!rinsed!with!PBS!and!then!fresh!virusHfree!FCSHsupplemented!media!restored.!As!shown!in!Figure!23!there!was!no!detectable!HMGB1!in!the!supernatant!media!immediately!after!the!wash!steps!described!above.!Moreover,!although!HMGB1!was!readily!detectable!in!the!viral!stock,!the!dilutions!used!in!experiments!reduced!the!concentration!of!HMGB1!below!the!detection!limit!of!the!assay!described.!Subsequent!experiments!involving!treatment!with!MV!were!performed!by!adding!virus!for!one!hour,!and!then!rinsing!and!replacing!with!fresh!virusHfree!media.!CellHfree!supernatants!were!prepared!for!western!blotting!by!diluting!1:1!with!Laemmli!buffer!and!stained!blots!analysed!by!infrared!fluorescence.!!Figure!24!demonstrates!that!at!48!hours!after!treatment!with!MV!there!was!detectable!HMGB1!in!the!supernatant!of!Mel888,!Mel624!and!MeWO,!and!traces!present!from!SkMel28.!By!contrast,!uric!acid,!another!established!danger!signal,!was!not!detected!in!the!supernatant!of!any!of!the!cells!at!any!MOI!using!a!commercially!available!ELISA!kit!(data!not!shown).!The!release!of!cytokines,!chemokines,!IFN!and!danger!signals!suggests!that!melanoma!lesions!infected!by!MV!will!generate!an!inflammatory!milieu,!capable!of!modifying!the!immune!balance.!
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!Figure!23.!Detection!of!HMGB1!by!Western!blot.!Optimisation!of!HMGB1!detection!assays!was!necessary! to!exclude!inadvertent!detection!of!HMGB1!present!in!the!viral!stock!as!a!result!of!preparation!using!simian!cell!lines.! Lane! 2,! adjacent! to! the!marker! bands! demonstrates! that! simian!HMGB1! is! present! (with! an! effective!molecular!weight!of!25H30!kDa)!and!crossHreacts!with!the!antiHhuman!HMGB1!antibody!used!for!subsequent!experiments.!However!after!dilution!in!either!plain!or!complete!media!(lanes!3!and!4!respectively)!the!levels!of!simian! HMGB1! fall! below! the! detectable! threshold,! and! a! rinsing! step! (lane! 5)! was! also! used! in! all! MV!treatments.!The!prominent!bands!in!lanes!3!and!6!are!albumin!(MW!67!kDa).!! !
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Figure!24.! !HMGB1!release!from!cells!following!treatment!with!MV.!CellHfree!supernatant!was!collected!from!melanoma! cells! 48! hours! after! treatment! with! MV! at! MOI! between! 0.01! and! 5! in! serumHfree! media.! The!supernatant!was!prepared!for!western!blot!by!mixing!1:1!with!Laemmli!buffer!prior!to!loading!onto!SDSHPAGE!gel,! along! with!marker! proteins! (M)! and! supernatant! from! untreated! cells! (C).! After! running! and! transfer,!membranes! were! airHdried! for! 30! minutes,! soaked! in! blocking! buffer! for! 45! minutes,! then! incubated! with!mouse!antiHhuman!HMGB1!monoclonal!antibody!overnight!at!4°C.!The!following!day!blots!were!washed!three!times! then! incubated! with! a! secondary! goat! antiHmouse! antibody! conjugated! to! AlexaFluor! 680! prior! to!imaging! using! the! LIHCOR! odyssey! infrared! imaging! system.! ! Results! shown! are! illustrative! of! two! separate!experiments.! !
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4.2.6 Human/melanoma/primary/cells/High!risk!melanoma!of!the!arm!commonly!recurs!in!the!axillary!lymph!nodes!(Burmeister!et!al.,!2012).!These!recurrences!carry!a!grave!prognosis!but!are!often!resected!to!aid!palliation.!Tissues!from!such!procedures!performed!in!Leeds!were!obtained!shortly!after!surgery!and!used!to!prepare!single!cell!suspensions!in!order!to!generate!human!melanoma!primary!cells.!Given!the!widely!understood!limitations!of!relying!entirely!on!immortalised!cell!lines,!these!primary!cells!were!used!to!further!examine!the!oncolytic!activity!of!MV!(Abbott,!2003).!Contemporaneously!resected!lesions!were!histologically!confirmed!as!melanoma,!and!cells!used!were!found!to!express!intracellular!gp100!and!melanHA!by!flow!cytometry!(or!previously!by!immunohistochemistry;!(Errington!et!al.,!2008b))!and!have!morphology!in!keeping!with!melanoma!(Figure!25).!!As!shown!in!Figure!26!the!primary!cells!were!permissive!to!MV!infection,!displaying!GFP!after!treatment!with!MVHGFP.!Although!syncytia!were!visible!they!were!less!obvious!than!seen!in!the!established!cell!lines,!and!CPE!took!considerably!longer!to!evolve.!This!presumably!reflects!the!much!longer!cell!doubling!time!of!primary!cells;!passage!times!for!the!primary!cells!was!in!the!order!of!weeks,!cf.!circa!2!days!for!Mel888.!Live/Dead!assays!were!performed!as!before,!albeit!at!later!time!points,!and!confirmed!the!susceptibility!of!melanoma!to!the!oncolytic!activity!of!MV.!Cell!free!supernatants!from!MVHtreated!primary!cells!were!also!used!for!ELISA;!the!limited!number!of!cells!available!precluded!the!wide!panel!of!cytokines!examined!in!figures!Figure!21!through!Figure!23,!however!MVHtreated!cells!from!two!of!three!donors!tested!produced!RANTES,!in!keeping!with!the!results!seen!using!cell!lines.!Primary!cells!from!one!donor!produced!considerable!amounts!of!IL6!in!response!to!MV!treatment.!IL8!was!produced!by!cells!from!all!three!donors!at!levels!little!affected!by!MV.!Thus!human!melanoma!primary!cells,!isolated!and!grown!in!tissue!culture!are!susceptible!to!killing!by!MV,!consistent!with!the!results!seen!using!immortalised!human!melanoma!cell!lines.!Despite!the!challenges!involved!in!working!with!human!primary!cells,!compared!to!established!cell!lines,!these!data!suggest!that!the!effect!of!MV!are!not!attributable!to!the!artifice!associated!with!cell!lines,!affirming!the!apparent!susceptibility!of!human!melanoma!to!MV.!!The!variability!of!killing!seen!amongst!cell!lines,!and!between!donors!suggests!that!there!are!tumourHassociated!factors!that!determine!MVHvulnerability;!for!that!
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115!reason!Zimmerman!et!al!have!reported!a!method!using!precision!cut!tumour!slices!for!ex!vivo!testing!of!MV!efficacy!as!a!way!of!improving!patient!and!virus!selection!(Zimmermann!et!al.,!2009).!! !
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!
Figure!25.!Human!melanoma!primary!cells.!Freshly!resected!nodal!metastases!were!used!to!prepare!single!cell!suspensions!then!plated!in!order!to!establish!human!melanoma!cell!primaries.!A.!Whilst!at!low!passage!(third!or!fourth)!these!cells!were!observed!to!have!morphology!in!keeping!with!cells!of!the!melanoma!cell!lines.!Cells!from!three!of!four!primary!cell!lines!were!permeabilised!with!0.1%!saponin!then!stained!with!(B)!antiHgp100,!or!(C)!antiHmelanHA!and!analysed!by!flow!cytometry.!Grey!histograms!show!isotype!controls.!Representative!results!from!one!of!three!donors!are!shown!
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! !
!Figure!26.!The!effects!of!MV!upon!human!melanoma!primary!cells.!Primary!cells!were!treated!with!MV!or!MVHGFP!at!a!range!of!MOI.!A.!Cytopathic!effects!were!seen!after!treatment!with!MVHGFP!by!bright!field!microscopy.!B.!Illumination!with!UV!illustrates!both!the!central!syncytia!with!blebbed!membranes,!but!also!GFPHexpressing!syncytia! at! the! periphery! of! the! image,! that! are! not! immediately! obvious! in! the! brightHfield!micrograph.! C.!Live/Dead! assays,! performed! as! described! in! Figure! 18,! but! at! prolonged! time! points,! confirmed! a! doseHdependent!loss!of!cell!viability!after!treatment!with!MV!(day!9!results!are!the!mean!values!from!three!donors!and!error!bars!indicate!the!SEM).!D.!Supernatants!were!collected!and!analysed!by!ELISA!for!the!presence!of!the!cytokines!shown.!Results!from!each!of!the!three!donors!are!shown.!!
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4.2.7 3Ydimensional/culture/models/Assays!using!cells!in!monolayer!culture!are!readily!performed!and!reproduced,!but!are!well!recognised!to!bear!significant!caveats!(Lee!et!al.,!2007).!In!vivo!tumours!exist,!on!the!whole,!in!threeHdimensional!structures!and!have!cellHtoHcell!interactions!throughout!their!membrane.!These!interactions!may!obscure!viral!receptors!or!impede!viral!transmission.!Initially!freshly!resected!melanoma!tissues!were!used!to!prepare!fine!slices!that!can!be!maintained!in!culture;!this!was!based!on!the!previous!report!of!the!use!of!hepatic!tumour!slices,!however!melanoma!tumour!have!different!physical!characteristics!and!the!technique!proved,!after!several!efforts!at!optimisation,!unhelpful!(Zimmermann!et!al.,!2009).!Spheroids!or!multilayer!models!are!increasingly!being!described!in!preclinical!therapy!studies,!including!oncolytic!viruses.!Adenoviral!infection!of!ovarian!cancer!cell!lines!was!fourHfold!more!productive!in!a!monolayer!model!when!compared!to!a!spheroid!model!(Lam!et!al.,!2007).!Studies!of!ovarian!cancer!cells!prepared!from!ascites,!normally!susceptible!to!oncolysis!by!a!myxoma!virus,!showed!that!the!same!cells!formed!into!spheroids!became!resistant!to!the!virus!(Correa!et!al.,!2012).!Moreover!studies!of!the!melanoma!cell!line!NA8!show!that!basal!gene!expression!varies!considerably!when!the!cells!are!grown!in!monolayer!compared!to!spheroids!(Ghosh!et!al.,!2005)!.!Levels!of!IL8!and!CXCL1!expression!were!particularly!upregulated!in!cells!in!the!spheroid!configuration.!Methodology!in!use!to!test!the!penetration!of!candidate!molecules!through!vascular!endothelium!was!adapted!to!perform!qualitative!assessments!of!the!ability!of!MV!to!infect!cells!cultured!in!a!threeHdimensional!system!(Evans!et!al.,!2009).!!A!schematic!illustration!of!the!model!is!shown!in!Figure!27.! !
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!Figure!27.!Multilayer!model!of!melanoma.!Mel624! cells!were! added! to! transwells! immersed! in!media.!After!three!to!five!days!the!cells!impaired!fluid!exchange!across!the!transwell!membrane!such!that!additional!media!applied!to!the!transwell!did!not!equilibrate!with!the!underlying!well!(Δ!Fluid! level),!and!this!was!coincident!with!changes!in!the!colour!of!media;!at!which!point!the!multilayer!models!were!deemed!ready!for!treatment!with!MV.!After!early!experiments!MV!was!added!to!the!lower!chamber!to!avoid!cytopathic!effect!threatening!the! integrity! of! the!multilayer.! (Inset)!H&E! stained! transverse! slice! through! the!multilayer.! The! base! of! the!multilayer,! which! rested! on! the! transwell! membrane,! is! more! densely! ordered! than! the! rather! friable!appearance!of!the!upper!aspect.!This!multilayer!had!been!treated!with!MVHGFP!and!a!syncytium!is!visible! in!the!very!centre!of!the!image!above!the!green!line.!!! !
!Measles!virus!versus!Melanoma!
120!Given!the!thickness!of!cells!in!a!multilayer!model!conventional!microscopy!is!of!no!use!in!examining!cells.!It!was!possible!to!extract!the!multilayer!by!cutting!the!membrane!from!the!transwell!and!then!mounting!in!wax.!This!allowed!for!transverse!microtome!sectioning!of!the!multilayer!(Figure!27)!but!the!procedure!was!extremely!delicate!and!several!multilayers!were!lost!or!damaged!using!this!process.!Instead!confocal!microscopy!allowed!for!the!intact!transwell!to!be!placed!on!a!microscopy!stage,!without!the!need!for!extraction!or!manipulation!of!the!multilayer!within.!The!greater!penetrative!ability!of!laser!light!used!in!confocal!microscopy!overcomes!the!limitations!faced!by!conventional!microscopy!in!terms!of!light!path.!Transwells!containing!Mel624!were!prepared!and!MVHGFP!added!to!the!underlying!wells.!48!hours!after!infection!the!transwells!were!immersed!overnight!in!1%!PFA!then!stained!with!DAPI!one!hour!prior!to!confocal!imaging.!Representative!images!in!Figure!28!illustrate!that!multiHlayered!Mel624!cells!remained!permissive!to!MV!infection.!Syncytia!were!formed!that!extend!vertically!throughout!the!thickness!of!the!multilayer!and!adopt!complex!pedunculated!structures!not!otherwise!seen!in!conventional!twoHdimensional!models.!These!large!syncytia!contained!several!dozen!DAPIHstained!nuclei,!hinting!at!the!number!of!cells!subsumed!within.!These!admittedly!qualitative!data!further!assert!the!oncolytic!activity!of!MV!in!melanoma.!The!ability!of!MV!to!infect!in!a!direct!cellHtoHcell!manner!may!circumvent!any!impediment!to!virion!movement!caused!by!cell!to!cell!junctions!(Sattentau,!2008).! !
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!Figure!28.!MV!efficacy!in!a!multilayer!model!of!melanoma.!Confocal!microscopy!of!Mel624!plated!in!transwells!48! hours! after! treatment! with! MVHGFP! and! having! been! counterstained! with! DAPI! reveals! complex!multinucleated!syncytia,!the!largest!of!which!(middle!image)!contain!several!dozen!nuclei.!Lateral!renderings,!produced!as!a!composite!of!a!zHstack!of!horizontal!images,!reveal!that!the!syncytia!extend!for!the!full!thickness!of!the!multilayer.!
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4.2.8 Actions/of/MV/on/elements/of/the/innate/immune/system/Reovirus!has!previously!been!shown!to!enhance!innate!tumour!killing!by!NK!cells!and!whole!populations!of!PBMC!(Errington!et!al.,!2008a;!Adair!et!al.,!2012).!Studies!of!oncolytic!VSV!and!reovirus!have!demonstrated!the!critical!necessity!of!innate!stimulation!to!mediate!therapeutic!efficacy!(Prestwich!et!al.,!2009a).!In!order!to!investigate!similar!phenomena!following!treatment!with!MV,!PBMC!from!healthy!donors!were!prepared!from!fresh!blood!and!cultured!overnight!in!the!presence!of!MV!at!an!MOI!of!1.!The!following!day!the!ability!of!treated!versus!untreated!PBMC!to!kill!radioactively!labelled!(51Cr)!Mel888!targets!was!assayed!at!a!range!of!PBMC!to!target!ratios.!As!shown!in!!Figure!29!MVHtreated!PBMC!killed!Mel888!far!more!effectively!than!untreated!PBMC.!As!expected!the!killing!was!not!specific!to!melanoma,!and!similar!results!were!noted!when!the!ovarian!cancer!cell!line!SkovH3!was!used!as!targets.!NK!cells!are!the!archetypal!innate!effectors,!and!as!shown!in!!Figure!29!there!was!upregulation!of!CD69!expression!amongst!the!CD3HCD56+!fraction!of!PBMC,!following!overnight!treatment!with!MV.!CD69!is!associated!with!activation!of!lymphocytes,!and!enhancement!of!their!cytotoxic!potential.!Levels!of!DNAM1,!NKG2D!and!CCR7!on!NK!cells!did!not!change!with!MVHtreatment!(data!not!shown).!Having!identified!evidence!of!NK!cell!activation,!after!treatment!with!MV,!further!demonstration!of!their!role!in!the!enhanced!innate!killing!of!tumour!targets!was!sought!using!the!CD107!assay!of!degranulation!in!response!to!targets.!CD107a!and!CD107b!are!proteins!normally!resident!on!the!inner!membrane!of!cytotoxic!granules!(Betts!et!al.,!2003;!Betts!and!Koup,!2004).!At!the!time!of!degranulation!these!markers!are!transiently!exposed!on!the!surface!of!cells,!before!recycling!pathways!scavenge!the!residues.!With!the!use!of!protein!transport!inhibitors!such!as!brefeldin!CD107a/b!accumulates!on!the!surface!of!degranulating!cells!and!can!be!detected!using!fluorescently!tagged!antibodies.!PBMC!from!healthy!donors!were!treated!overnight!with!MV!and!the!following!day!coHcultured!with!Mel888!targets.!After!1!hour!of!coHculture!brefeldin!A!was!added!to!the!media,!prior!to!a!further!four!hours!of!culture.!Cells!were!then!harvested!and!stained!for!flow!cytometry.!As!seen!in!Figure!30!the!population!of!cells!that!expressed!CD107a!or!b!in!response!to!melanoma!targets!was!predominantly!CD3HCD56+,!consistent!with!NK!cells,!and!this!degranulation!was!enhanced!amongst!PBMC!that!had!been!treated!with!MV!
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123!overnight.!Notably!there!was!no!evidence!of!degranulation!in!response!to!MV!in!the!absence!of!targets.!!It!is!worth!noting!that!though!these!data!examine!an!element!of!the!innate!immune!system,!clearly!there!are!multiple!other!effectors.!Neutrophils,!for!example,!are!known!to!respond!both!directly!to!MV!and!to!MVHinfected!tumours,!and!in!one!model!at!least!contribute!significantly!to!the!innate!antiHtumour!efficacy!seen!following!MV!treatment!(Grote!et!al.,!2003;!Zhang!et!al.,!2012).!In!keeping!with!previous!reports!of!the!effects!of!OV!upon!innate!effector!cells!these!data!demonstrate!phenotypic!and!functional!changes!in!NK!cells!following!treatment!with!MV.!!
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A'
!Figure! 29.! Stimulation! of! innate! effectors! by!MV.! PBMC! from! healthy! donors!were! cultured! overnight! after!treatment!with!MV!at!an!MOI!of!1.!A.!The!following!day!the!PBMC!were!coHcultured!with!51CrHlabelled!Mel888!at!ratios!of!PBMC!to!Mel888!as!indicated.!After!4!hours!the!cellHfree!serum!was!assayed!for!chromium!release!to! assess! cytolytic! function.! Results! shown! are! the! mean! from! three! healthy! donors,! assayed! in! separate!experiments.!Error!bars!indicate!the!SEM.!B.!PBMC!treated!overnight!with!MV!at!an!MOI!of!1!were!stained!with!CD56,!CD3!and!CD69.! Levels! of! surface!CD69!expression! in!CD3HCD56+! cells!with!or!without! treatment! are!shown!from!one!donor!representative!of!the!four!tested!in!separate!experiments.!!! !
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!!!Figure!30.!Stimulation!of!NK!cells!by!MV.!PBMC!from!healthy!donors!were!cultured!overnight!after!treatment!with!MV!at!an!MOI!of!1.!The!following!day!the!PBMC!were!coHcultured!with!either!Mel888!or!no!targets,!in!the!presence!of!brefeldin!A!and!antiHCD107a!and!b.!After!4!hours!the!cells!were!stained!with!antiHCD56!and!antiHCD3!then!analysed!by!flow!cytometry.!A.!Representative!dot!plots!from!one!healthy!donor.!B.!Mean!values!from!3!healthy!donors,!error!bars!indicate!SEM.!!
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4.2.9 Actions/of/MV/on/Dendritic/cells/wtMV!infection!can!be!profoundly!immunosuppressive;!most!of!the!deaths!that!occur!due!to!wtMV!are!due!to!secondary,!often!bacterial,!infections!(Permar!et!al.,!2006;!SchneiderHSchaulies!and!SchneiderHSchaulies,!2009).!Several!explanations!for!the!immunosuppression!are!espoused!but!the!predilection!of!wtMV!to!infect!immune!cells!is!often!stressed.!wtMV!has!a!solitary!tropism!for!CD150,!a!marker!overexpressed!on!DC!and!lymphocytes,!and!carriage!by!infected!DC!is!a!critical!early!step!in!measles!infection!(Griffin!and!Oldstone,!2009).!The!effects!of!wtMV!upon!DC!have!been!argued!to!be!critical!in!the!development!of!the!immunosuppression!associated!with!the!measles!illness,!specifically!impairing!IFN!pathways!and!CD40Hmediated!maturation!of!DC!(Grosjean!et!al.,!1997;!De!Witte!et!al.,!2006).!By!contrast!MV!(rather!than!wtMV)!has!been!given!to!patients!in!the!context!of!several!clinical!trials!and!immunosuppression!has!not!been!reported!as!an!adverse!event.!Similarly!the!strain!of!MV!in!use!both!in!these!experiments,!but!also!in!OV!therapy!trials,!is!derived!from!the!Edmonston!strain!and!has!been!used!extensively!as!a!paediatric!vaccine!H!given!that!context!the!safety!profile!of!MV!is!such!that!toxicity!to!immune!cells!is!unlikely.!Moreover!Gauvrit!et!al.!using!a!similar!strain!of!MV!reported!that!DC!efficiently!phagocytose!MVHinfected!tumour!cells,!undergoing!maturation!as!a!result!(Gauvrit!et!al.,!2008).!The!effects!of!MV!and!MVHtreated!melanoma!cells!upon!CD14Hderived!DC!were!therefore!investigated.!DC!prepared!from!healthy!donor!PBMC!were!treated!with!MV!at!a!range!of!MOI,!and!assayed!after!24!and!48!hours!by!Live/Dead!staining.!As!shown!in!Figure!31!DC!were!robust!in!the!face!of!MVHinfection,!even!to!MOI!of!2.5.!In!fact!it!was!striking!that!maturation!by!a!standard!dose!of!LPS,!commonly!used!as!a!DC!maturation!agent,!possibly!caused!more!death!of!DC!than!MV!treatment.! !
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!!Figure!31.!Susceptibility!of!DC!to!treatment!with!MV.!DC!were!prepared!from!PBMC!by!CD14+!MACS!selection!and!culture!for!7!days!with!GMHCSF!and!IL4.!!DC!were!then!treated!with!MV!at!the!MOI!indicated!or!LPS!at!250!ng/mL.! After! 24! and! 48! hours! the! DC!were! analysed! by! flow! cytometry! after! staining! with! the! Live/Dead!reagent.! Results! shown! are! the! mean! of! experiments! using! blood! from! three! healthy! donors.! Error! bars!indicate!the!SEM.!! !
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128!DC!treated!with!MV!were!additionally!assessed!for!phenotypic!evidence!of!maturation.!In!order!to!successfully!stimulate!THcell!responses,!DC!must!present!antigen!in!a!suitable!MHC!context!along!with!costimulatory!molecules;!in!the!absence!of!a!second!stimulatory!signal!antigen!presentation!will!lead!to!anergic!responses.!The!principle!THcell!receptor!for!the!second!signal!is!CD28,!which!recognises!dimers!of!CD80!and/or!CD86!(also!known!as!B7.1!and!B7.2!respectively).!This!second!signal!is!requisite!for!a!cytotoxic!T!cell!response,!although!other!signals!are!also!required!(Joffre!et!al.,!2009),!thus!the!upregulation!of!CD80!and!CD86!on!DC!is!a!vital!element!of!the!development!of!antitumour!responses.!!Levels!of!CD80!and!CD86!were!increased!following!treatment!with!MV,!though!CD40!was!not!affected,!in!experiments!performed!using!DC!prepared!from!9!healthy!donors!(data!not!shown).!Therefore!the!strain!of!MV!in!use!as!an!oncolytic!agent,!in!contrast!to!wtMV,!is!not!toxic!to!DC.!!In!order!to!model!the!impact!of!MV!upon!DC!within!the!tumour!microenvironment,!where!malignant!cells!may!be!hypothesised!to!generate!a!suppressive!milieu!that!could!overcome!any!stimulatory!capacity!of!MV,!DC!were!cultured!in!the!presence!of!supernatant!from!Mel888!cells,!or!MVHtreated!Mel888.!These!supernatant!tumourHconditioned!media,!characterised!in!Figure!21!through!Figure!24,!were!filtered!to!exclude!virus!and!then!applied!to!DC!overnight,!and!the!expression!of!phenotypic!markers!analysed!the!following!day.!DC!were!initially!prepared!by!culture!in!media!supplemented!with!IL4!and!GMHCSF!for!up!to!seven!days,!but!were!then!cultured!without!cytokines!once!tumourHconditioned!media!(TCM)!was!added.!!As!seen!in!Figure!32!MHC!expression,!both!class!I!and!II,!was!increased!in!the!presence!of!TCM,!though!there!was!minimal!difference!between!the!effect!of!TCM!from!untreated!Mel888!when!compared!to!MVHMel888;!TCM!from!untreated!Mel888!did!not!alter!levels!of!CD80!or!CD86,!implying!that!TCM!conditions!DC!for!antigen!sampling!and!presentation!which!will!likely!lead!to!anergy!in!the!absence!of!a!suitable!second!signal.!However!CD80!and!CD86!were!both!consistently!upregulated!in!response!to!MVHMel888!TCM!in!experiments!performed!with!DC!from!4!healthy!volunteers.!By!filtering!the!TCM!the!direct!action!of!MV!upon!DC!was!excluded,!demonstrating!that!Mel888!treated!with!MV!produce!a!pattern!of!cytokines!that!induce!phenotypic!maturation!of!DC,!including!expression!of!
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129!markers!involved!in!the!costimulatory!signal.!Although!this!suggests!that!the!suppressive!action!of!melanoma!TCM!is!overcome!by!the!effects!of!MV!upon!melanoma!cells,!it!is!possible!that!cellHtoHcell!inhibition!could!still!functionally!suppress!DC.!Therefore!in!order!to!exclude!contact!mediated!inhibition!of!DC!maturation,!Mel888!or!MVHtreated!Mel888!were!coHcultured!with!DC!overnight.!It!should!be!noted!that!in!this!assay!the!direct!effects!of!MV!upon!DC!cannot!be!excluded,!though!as!demonstrated!above!(Figure!18,!Figure!19!and!Figure!20)!there!is!limited!viral!replication!or!killing!of!Mel888!within!a!24Hhour!period,!and!only!limited!expression!of!viral!proteins!(Figure!11).!Those!caveats!notwithstanding,!it!was!apparent!that!direct!coHculture!with!untreatedHMel888!causes!downregulation!of!CD86,!whereas!coHculture!with!MVHMel888!is!able!to!overcome!the!inhibitory!effects!of!the!melanoma!cell,!and!CD86!is!increased!fourHfold!from!untreated!DC!(Figure!33).!!CD83,!a!further!marker!of!DC!maturation,!was!upregulated!by!coculture!with!MVHMel888,!but!not!by!TCM,!indicating!the!differential!effects!of!soluble!mediators,!compared!to!contactHmediated!effects.!!The!expression!of!CD40,!involved!in!sustaining!DC!activation!and!function,!did!not!change!in!response!to!TCM!but!was!upregulated!by!coHculture!with!MVHMel888!(Gommerman!and!Summers!deLuca,!2011).!The!precise!sequence!of!events!by!which!matured!DC!are!able!to!stimulate!THcell!responses!remains!the!subject!of!intense!research.!The!process!of!DC!maturation,!as!evinced!by!the!upregulation!of!surface!markers!that!play!a!critical!role!in!antigen!presentation,!is!certainly!a!key!step!and!appears!to!be!enhanced!by!MVHtreatment.!!! !
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!Figure! 32.! Effects! of! MVHtreated! melanoma! supernatant! on! DC.! Mel888! were! treated! with! MV! at! the! MOI!indicated!and!after!24!hours!the!supernatant!collected!and!filtered!to!remove!nonHadherent!cells!and!virus.!DC!were! cultured!with! the! resulting!TCM!overnight! and! the! following!day! levels!of! surface!phenotype!markers!measured!by!flow!cytometry.!A.!Representative!flow!cytometry!plots!of!CD80!and!CD86!expression.!B.!Mean!fold! changes! in! marker! expression! relative! to! DC! cultured! in! standard! melanoma! cell! media,! from! results!obtained!from!the!DC!of!four!healthy!donors.!Error!bars!indicate!the!SEM.!!!
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!
!Figure!33.!Effects!of!MVHtreated!melanoma!cells!on!DC.!Mel888!were!treated!with!MV!at!the!MOI!indicated!and!harvested!after!24!hours.!DC!were!cultured!with!Mel888!or!MVHtreated!Mel888!overnight!and!the! following!day!levels!of!surface!phenotype!markers!measured!by!flow!cytometry.!A.!!Representative!flow!cytometry!plots!of!CD80!and!CD86!expression.!B.!Mean!fold!changes!in!marker!expression!relative!to!DC!cultured!in!standard!melanoma!cell!media,!from!results!obtained!from!the!DC!of!four!healthy!donors.!Error!bars!indicate!the!SEM!! !
CD
 80
CD
 83
CD
 86
CD
 40
0
1
2
3
4


	

	

	

	



















	


CD80!
CD86!
DC!+!0.1MV!Mel888!DC!+!2.5MV!Mel888!Untreated!DC!DC!+!Mel888!!Isotype!
LPSHmatured!DC!
A'
B'
!Measles!virus!versus!Melanoma!
132!
4.2.10 Actions/of/MV/upon/the/Adaptive/antiYtumour/immune/response/In!addition!to!direct!oncolysis,!it!has!been!posited!that!OV!can!generate!therapeutic!antiHtumour!immunity!(Prestwich!et!al.,!2009a).!Any!cancer!cell!death!may!release!tumour!associated!antigens!but!in!the!presence!of!suppressive!cytokines,!regulatory!THcells!and!tumourHassociated!macrophages,!such!antigen!is!unlikely!to!be!usefully!processed!by!antigen!processing!cells!such!as!DC!(Golden!et!al.,!2012).!By!contrast!OVHmediated!cell!death!may!alter!the!tumour!microenvironment!in!ways!that!favour!the!generation!of!an!immune!response.!As!shown!above!MVHmediated!cell!death!is!associated!with!the!release!of!chemokines!and!cytokines!that!can!recruit!and!activate!immune!effector!cells.!HMGB1!is!a!danger!signal!that!can!act!on!DC!through!the!TLR4/MyD88!pathway,!and!may!prompt!DC!to!direct!their!response!towards!activation,!rather!than!anergy,!and!is!induced!by!MV.!It!has!previously!been!reported!that!intravenously!administering!reovirus!to!mice!bearing!syngeneic!melanoma!not!only!reduces!tumour!burden,!but!also!primes!an!adaptive!immune!response!against!melanomaHassociated!antigen!(Prestwich!et!al.,!2008b)!.!The!same!authors!also!demonstrated,!using!human!in!vitro!models,!that!reovirusHtreated!melanoma!cells!were!able!to!activate!DC,!which!in!turn!crossHprimed!THcell!responses!against!melanoma!antigens.!Similar!results!have!been!obtained!in!a!model!of!human!mesothelioma!but!have!not!otherwise!been!reported!in!melanoma!(Gauvrit!et!al.,!2008).!!To!test!the!hypothesis!that!MVHtreated!melanoma!cells!could!activate!DC!and!in!turn!prime!a!THcell!response!against!melanoma!antigens!longHterm!coHcultures!were!established;!the!procedure!for!these!experiments!is!detailed!below!and!represented!schematically!in!Figure!34.!PBMC!were!isolated!from!the!buffy!coats!as!before.!Depending!on!cell!numbers!around!80%!were!divided!amongst!20!cryovials!for!immediate!storage!at!H80C.!The!remaining!20%!were!subjected!to!CD14+!selection!and!cultured!in!IL4!and!GMHCSF!for!five!days!in!order!to!generate!DC.!On!the!fifth!day!of!culture!the!DC!were!split,!and!cultured!with!either!Mel888,!or!Mel888!that!had!been!treated!with!MV!at!an!MOI!of!0.1!or!1,!48!hours!earlier.!DC!were!cultured!with!the!Mel888!or!MVHMel888!at!a!ratio!of!1!DC!to!3!melanoma!cells!for!24!hours.!The!nonHadherent!cells!were!then!harvested,!while!the!melanoma!remained!adherent!to!the!flask.!These!DC,!hereafter!DCHMel!or!DCHMVHMel,!were!subsequently!coHcultured!with!a!proportion!of!their!autologous!PBMC.!Each!coHculture!was!established!in!cytotoxic!T!lymphocyte!(CTL)!media!with!IL2,!
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133!and!IL7.!The!remaining!PBMC!were!used!to!prepare!further!DC,!which!again!were!loaded!with!either!Mel888,!or!MVHtreated!Mel888,!and!these!DC!then!used!to!reHstimulate!the!PBMC/CTL!in!culture.!After!two!weeks!in!culture,!and!two!stimulations!by!autologous!DC!the!PBMC!were!then!subjected!to!various!assays!of!THcell!function!as!described!below.!!
4.2.10.1 CD107,assays,As!described!above,!surface!expression!of!CD107!indicates!degranulation!in!response!to!targets,!therefore!CD107!assays!were!used!to!assess!the!response!of!PBMC,!prepared!as!shown!in!Figure!34,!to!tumour!targets.!PBMC!stimulated!with!DCHMel888!served!as!controls!to!those!stimulated!with!DCHMVHMel888.!Cells!from!each!condition!were!coHcultured!with!either!Mel888!or!an!irrelevant!tumour!target,!SkovH3,!both!free!from!MV,!or!no!targets!at!all!(blanks).!!After!one!hour!of!coHculture!brefeldin!A!was!added,!and!after!a!further!4!hours!the!cells!stained!for!CD8!and!CD107a!or!b,!and!analysed!by!flow!cytometry.!The!assay!requires!relatively!few!effector!cells,!and!so!was!performed!after!one!week!of!coHculture,!immediately!prior!to!the!second!stimulation!with!loaded!DC,!and!a!week!later!at!completion!of!the!experiment.!As!shown!in!Figure!35!the!CD8+!cells!from!PBMC!treated!with!DCHMVHMel888!were!more!positive!for!CD107,!even!in!the!absence!of!targets,!but!there!was!a!twoHfold!increase!in!responses!against!Mel888!compared!to!SkovH3!cells.!Following!the!second!stimulation!there!was!an!even!clearer!enhancement!in!melanomaHspecific!responses!from!the!MVHtreated!condition!than!the!controls.!Representative!data!from!two!donors!are!shown!in!Figure!35,!and!are!representative!of!results!from!experiments!performed!with!12!donors,!in!9!of!whom!there!was!evidence!of!a!specific!antiHMel888!response.!Notably!the!degree!of!response!varied!amongst!donors,!as!illustrated.!Some!donors!had!evidence!of!response!after!the!first!stimulation,!whilst!others!remained!negative!until!the!second.!!
4.2.10.2 Intracellular,IFNγ,IFNγ!is!produced!by!THcells!when!the!THcell!receptor!binds!its!cognate!antigen,!and!indicates!THcell!activation.!Accordingly!after!two!weeks!of!coHculture!PBMC!were!analysed!for!an!IFNγ!response!to!melanoma!or!irrelevant!SkOV!targets!by!intracellular!staining.!Cells!were!prepared!as!described!above!and!after!the!fourHhour!coHculture!were!permeabilised!and!stained!for!IFNγ!prior!to!flow!cytometry.!
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134!As!shown!in!Figure!36!there!was!up!regulation!of!IFNγ!response!in!CD8+!cells!that!had!been!exposed!to!DCHMVHMel888,!when!compared!to!the!control!condition.!Moreover!this!upregulation!was!specific!to!Mel888!targets,!as!it!was!not!seen!against!SkOV!cells.!
!
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!!
!Figure!35.!Priming!assays:!Surface!expression!of!CD107!following!treatment!with!MV.!DC!were!coEcultured!at!a!ratio!of!3:1!for!24!hours!with!Mel888!that!had!or!had!not!been!treated!with!MV!(MOI!of!0,!0.1!or!1)!for!48!hours.!These!DC!were!then!cultured!with!autologous!PBMC!for!one!week!and!then!identically!prepared!DC!used!to!reEstimulate!the!PBMC!cultures.!After!one!and!two!weeks!the!PBMC!were!used!in!CD107!assay!and!analysed!by! flow!cytometry.!A.!Representative!FACS!plot.! Illustrating!gating!strategy.!B.!Results! from!two! separate! donors! after! one! and! two!weeks! of! coEculture.! Results! shown! are! illustrative! of! those! seen!from!9!of!12!donors.!
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!Figure! 36.! Priming! assays:! IFNγ! response! following! treatment!with!MV.! ! PBMC!prepared! as! described! in!Figure!35!were!used!after!two!weeks!culture!to!assay!IFNγ!production!in!response!to!tumour!targets.!PBMC!were! coEcultured! with! fresh! Mel888! targets,! or! SkovE3! cells,! or! blank! media! alone,! and! the! media!supplemented!with!brefeldin!A.!After!four!hours!the!cells!were!fixed,!then!permeabilised!and!stained!with!an!antiEIFNγ!antibody!prior!to!analysis!by!flow!cytometry.!The!proportion!of!CD8+!cells!that!were!positive!for! IFNγ!was!quantified.!The!results!above!are! from!two!separate!donors;! from!12!donors!a!specific! IFNγ!response!to!Mel888!was!identified!in!six!assays.!! !
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4.2.10.3 Chromium.release.assay.In!order!to!formally!assess!the!cytolytic!function!of!CD8+!TEcells!prepared!as!described!above,!chromium!release!assays!were!also!performed.!Mel888!and!irrelevant!SkovE3!targets!were!labelled!with!51Cr!and!then!coEcultured!with!PBMC,!prepared!as!above.!In!order!to!extinguish!the!impact!of!nonEspecific!cell!killing!by!innate!effector!cells!present!within!the!PBMC,!the!coEcultures!were!prepared!with!unlabelled!K562!to!serve!as!redundant!targets.!The!coEcultures!were!prepared!at!a!range!of!effector!to!target!ratios!(E:T)!and!after!4!hours!the!quantity!of!released!51Cr!determined!by!scintography.!The!proportion!of!killing!was!determined!by!comparison!with!targets!similarly!cultured!in!the!absence!of!effector!cells,!but!with!or!without!detergent,!the!former!serving!to!indicate!the!level!of!release!concordant!with!100%!killing.!Figure!37!shows!results!from!five!donors!tested!in!independent!experiments.!In!one!donor!no!enhancement!of!killing!was!seen,!but!in!the!remaining!four,!whilst!there!was!little!or!no!killing!of!relevant!targets!by!PBMC!that!had!been!coEcultured!with!DCEMel,!by!contrast!coEculture!with!DCEMVEMel888!enhanced!killing!of!Mel888!to!varying!degrees.!There!was!no!meaningful!killing!of!SkovE3!by!any!donor’s!PBMC,!with!or!without!MVEtreatment,!indicating!that!a!melanomaEspecific!response!was!generated!(data!not!shown).!Data!from!Figure!35!through!Figure!37!also!demonstrate!that!in!some!donors!the!degree!of!Mel888Especific!enhancement!was!greater!when!the!tumour!cells!used!for!priming!were!treated!with!MV!at!an!MOI!of!0.1!rather!than!1.!This!observation!was!not!consistent!across!all!donors!however,!and!in!the!small!sample!of!donors!in!which!both!MOI!were!tested!it!is!impossible!to!draw!reliable!conclusions!on!the!nature!of!the!difference.!It!is!possible!that!the!lower!dose!(which!was!more!or!as!effective!in!three!of!the!four!positive!donors)!is!able!to!generate!an!ideal!amount!of!cytokines,!chemokines!and!danger!signals,!as!well!as!innate!activation,!without!over!stimulating!and!prematurely!exhausting!the!generation!of!an!adaptive!TEcell!response.! !
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4.2.10.4 Pentamer.staining.Tetramers!and!pentamers!of!antigenic!epitopes!presented!in!MHC!molecules,!labelled!with!fluorophore!have!enabled!detection!of!defined!antigenEspecific!TEcells,!having!circumvented!the!challenge!presented!by!the!low!avidity!of!the!TEcell!receptor.!One!limitation!is!that!they!present!antigenic!epitopes!on!specific!MHC!molecules,!and!are!therefore!HLAErestricted.!Most!tetramers!and!pentamer,!and!indeed!identified!epitopes,!are!restricted!to!HLAEA2!in!humans;!the!structure!of!HLAEA2!has!been!solved!to!a!high!resolution!thus!allowing!empirical!design!of!epitopes!and!other!associated!reagents.!!In!order!to!quantify!the!development!of!a!TEcell!response!specific!for!a!defined!melanoma!antigen,!and!presumably!indicative!of!a!broader!repertoire!of!TEcells!specific!for!a!range!of!melanoma!antigens,!priming!assays!were!repeated!using!blood!from!HLAEA2!+ve!donors.!Around!30%!of!local!donors!are!HLAEA2!+ve!but!untested!at!the!point!of!donation.!Buffy!coats!received!were!therefore!tested!for!HLAEA2!status!by!flow!cytometry.!The!subset!that!were!positive!were!maintained!in!culture!with!the!intention!of!completing!two!stimulations!by!loaded!DC,!however!at!that!time!problems!with!bacterial!and!fungal!contamination!prevented!successful!completion!of!the!assay.!!Others!have!used!MARTE1!pentamers!to!demonstrate!that!reovirus!stimulated!cross!priming!by!DC!loaded!with!reovirus!infected!Mel888!(Prestwich!et!al.,!2008b).!Furthermore!Gauvrit!et!al.!performed!similar!assays!in!an!in!vitro!model!of!human!mesothelioma!and!demonstrated!small!increases!in!mesothelin!pentamer!positivity!after!CTL!were!primed!with!DC!loaded!with!MVEtreated!mesothelioma!cells!(Gauvrit!et!al.,!2008).!Thus!despite!the!absence!of!pentamer!assays!the!data!presented!in!Figure!35!through!Figure!37,!taken!in!the!context!of!previous!reports!of!priming!enhanced!by!OV,!strongly!assert!that!MV!treatment!of!melanoma!generates!an!inflammatory!environment!that!enhances!DC!function!and!generates!a!melanomaEspecific!TEcell!response.!!! !
!! Measles!virus!versus!Melanoma! !
140!
!!!Figure! 37.! Priming! assays:! Lysis! of! melanoma! by! CTL! in! response! to! MV! treatment.! PBMC! prepared! as!described!above!were!tested!for!their!ability!to!lyse!tumour!targets.!Control!refers!to!PBMC!coEcultured!with!DCEMel,!0.1!and!1!refer!to!PBMC!coEcultured!with!DCE0.1MVEMel!and!DCE1MVEMel!respectively.!PBMC!were!coEcultured! for! four! hours!with! 51CrElabelled!Mel888! or! 51CrElabelled! SkovE3,! in! the! presence! of! K562! to!exclude!the!effects!of!innate!effector!cells.!Results!from!all!five!donors!tested!are!shown.!MelanomaEspecific!killing!was!enhanced!by!MV!in!four!out!of!five!donors!tested.!! !
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4.3 Discussion+Melanoma!cell!lines!express!CD46!at!a!level!that!is!permissive!both!to!viral!entry!and!cellEtoEcell!fusion,!as!illustrated!by!the!development!of!the!classical!cytopathic!effect,!giant!multinucleated!syncytia.!Objective!killing!assays!confirm!the!dose!dependent!killing!of!melanoma!cells,!both!immortalised!and!human!primary!cells.!In!a!three!dimensional!model!of!Mel624!cellEtoEcell!contact!does!not!preclude!viral!transmission,!perhaps!due!to!the!ability!of!MV!to!spread!by!triggering!fusion!of!infected!cells!with!their!uninfected!neighbours.!The!rate!and!degree!of!killing!observed!are!consistent!with!that!seen!with!MV!in!other!tumour!models,!and!with!other!oncolytic!viruses!used!in!models!of!melanoma.!!!Although!the!models!used!provide!evidence!of!the!efficacy!of!MV,!it!and!other!OV!are!unlikely!to!achieve!meaningful!clinical!therapy!purely!on!the!basis!of!direct!oncolysis;!in!vitro!cell!killing!after!direct!application!of!virus!at!an!MOI!of!5!would!be!hard!to!mimic!in!patients.!Moreover!if!the!fraction!of!cells!killed!in!such!a!situation!is!around!50%,!then!the!cell!doubling!time!of!most!tumours!is!likely!to!overcome!OV!as!therapy.!Increasingly!there!is!recognition!that!the!efficacy!of!those!viruses!that!have!succeeded!is!due!in!large!part!to!their!ability!to!cause!an!inflammatory!tumour!cell!death!and!recruit!antiEtumour!immune!responses,!rather!than!purely!being!dependent!on!oncolysis!(Prestwich!et!al.,!2008c).!In!clinical!testing!of!OncoVEX,!a!herpes!simplex!virus!engineered!to!express!GMECSF,!some!patients!benefitted!from!regression!of!untreated!tumours,!suggesting!the!generation!of!successful!antiEtumour!immunity!(Senzer!et!al.,!2009).!Therefore!the!nature!of!MVEinduced!melanoma!death!was!examined!and!its!impact!on!elements!of!the!innate!and!adaptive!immune!system!explored.!!The!death!caused!by!MV!was!inflammatory!in!nature,!releasing!a!panel!of!cytokines,!including!type!1!and!3!IFN.!IFN!have!previously!been!shown!to!activate!innate!and!adaptive!immune!responses!(Bonjardim,!2005).!Melanoma!cells!appear!to!be!unresponsive!to!the!antiviral!effects!of!IFN,!based!on!their!susceptibility!and!viral!replication!despite!IFN!production;!amongst!the!four!established!cell!lines!tested!there!was!no!evidence!of!reduced!viral!replication!or!cell!death!in!the!lines!that!produced!most!IFN.!In!the!tumours!of!patients!it!could!
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be!postulated!that!adjacent!nonEtransformed!cells!will!presumably!respond!to!IFN,!thus!enhancing!the!therapeutic!index!of!MV!as!a!treatment.!Moreover!IFN!are!known!to!have!direct!activity!against!melanoma!(Johns!et!al.,!1992).!Three!of!four!established!cell!lines!released!the!potent!danger!signal!HMGB1!after!treatment!with!MV.!To!investigate!the!effects!of!this!inflammatory!death!tumourEconditioned!media!from!MVEtreated!melanoma!was!applied!to!DC!and!was!observed!to!upregulate!surface!markers!suggesting!DC!adopt!an!activated!phenotype.!Furthermore!MV!enhanced!tumour!killing!by!the!key!innate!effector!cells,!NK!cells.!Finally!in!a!model!of!adaptive!immune!priming!MVEtreated!melanomas!were!able,!with!the!assistance!of!DC,!to!prime!melanomaEspecific!immune!responses.!!Though!it!would!be!appealing!to!extend!the!data!presented!above!into!animal!models,!better!to!assess!the!effect!of!a!complete!immune!system,!no!useful!model!exists.!Mice!have!been!used!extensively!for!research!with!MV!though!predominantly!in!the!context!of!immune!deficient!backgrounds!and!bearing!xenograft!tumours.!Moreover!CD46!is!not!a!native!murine!protein,!limiting!the!applicability!of!mice!for!studying!the!immune!consequences!of!MV!therapy.!A!transgenic!mouse!model!expressing!CD46!exists,!and!has!been!used!for!MV!study,!but!is!on!an!IFN!deficient!background,!therefore!limiting!its!applicability!to!further!study!of!the!data!described!within!this!chapter!(Ungerechts!et!al.,!2007b)!.!!!The!data!described!have!been!published!and!have!generated!interest!in!developing!clinical!trials!to!test!the!ability!of!MV!to!help!patients!with!melanoma!(Skelly,!2012;!Donnelly!et!al.,!2013).!The!body!of!existing!preclinical!and!early!phase!clinical!toxicity!data!pertaining!to!MV,!both!published!and!pending!publication,!strongly!indicates!the!safety!and!tolerability!of!MV!(both!MVECEA!and!MVENIS!have!been!used!clinically);!therefore!there!is!no!need!to!repeat!early!phase!safety!testing!of!MV!in!melanoma!patients!(Msaouel!et!al.,!2009;!Donnelly!et!al.,!2012a).!There!remain,!however!challenges!in!assessing!the!pharmacokinetics!and!pharmacodynamics!of!MV.!!
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A!key!limitation!to!successful!OV!has!been!delivery!of!virus.!Two!of!the!viruses!studied!as!OV!are!almost!universally!encountered!during!childhood!in!the!western!world;!MV!is!a!commonly!used!vaccine,!reovirus!is!thought!to!cause!no,!or!only!minor!and!selfElimiting,!illness!during!most!childhoods.!As!a!consequence!most!prospective!patients!will!have!preEexisting!antibodies!to!these!agents.!Even!if!a!virus!is!chosen!that!is!not!a!commonly!encountered!human!pathogen,!such!as!herpes!or!vaccinia,!antibodies!will!be!present!on!second!and!subsequent!administrations!(Donnelly!et!al.,!2012c).!Given!these!concerns!many!of!the!initial!clinical!trials!of!OV!were!performed!using!direct!administration!of!virus,!generally!intratumoural!injections,!in!an!attempt!to!circumvent!concerns!about!unsuccessful!delivery.!The!phase!II!trial!of!OncoVex,!an!engineered!type!I!herpes!simplex!virus,!demonstrated!promising!efficacy!in!melanoma!patients!and,!along!with!the!subsequent!phase!III!trial,!demonstrated!that!the!practical!challenges!involved!in!administering!frequent!injections!to!multiple!metastatic!lesions!can!be!overcome!(Senzer!et!al.,!2009).!Despite!that,!direct!administration!of!OV!has!obvious!limitations.!Not!all!lesions!can!be!safely!accessed!in!all!patients,!particularly!not!on!multiple!occasions.!Moreover!surgery!and!radiotherapy!are!known!to!be!effective!local!treatments;!instead!the!challenge!is!to!address!systemic!metastatic!and!micrometastatic!disease.!Two!studies!have!demonstrated!that!intravenously!administered!virus!can!reach!target!tissues.!Breitbach!et!al.!report!a!phase!I!study!of!JX594!in!which!23!patients!with!a!variety!of!solid!tumours,!including!four!with!melanoma,!were!found!to!have!evidence!of!viral!protein!expression!in!tumour!biopsies!taken!8E10!days!after!intravenous!viral!administration!(Breitbach!et!al.,!2011).!Adair!et!al.!identified!replicating!virus!within!liver!metastases!resected!a!week!or!more!after!reovirus!administration!(Adair!et!al.,!2012).!Most!importantly!virus!was!recovered!despite!preEexisting!antiEreovirus!antibodies!that!were!identified!in!all!patients.!Furthermore!it!was!demonstrated!that!virus!was!carried!by!the!white!blood!cells!and!platelets,!shielding!virus!from!neutralising!antibodies.!These!two!important!studies!support!the!principle!of!systemically!administered!OV,!though!further!work!is!required!to!characterise!the!nature!of!systemic!viral!carriage!as!well!as!pursuing!ancillary!treatments!that!could!enhance!it.!!!
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Given!the!results!of!the!preclinical!experiments!presented!within!this!chapter!a!clinical!trial!was!designed!in!order!to!commence!testing!of!MV!in!human!melanoma.!Several!phase!I!studies!of!MV!have!been!performed,!by!a!range!of!routes!of!administration,!and!none!has!shown!doseElimiting!toxicity!(personal!communication!M.!Federspiel!and!S.!Russell!2012).!Although!other!viruses,!such!as!reovirus,!have!been!shown!to!have!activity!against!melanoma!and!stimulate!antiEtumour!immune!responses,!a!potential!advantage!of!MV!is!that!its!genome!is!readily!amenable!to!modifications!to!enhance!targeting!of!the!virus,!or!‘arm’!the!virus.!Initial!studies!made!use!of!a!MV!engineered!to!express!human!carcinoEembryonic!antigen!(CEA).!CEA!is!an!inert!protein!secreted!by!a!number!of!tumours,!mainly!gastrointestinal.!MVECEA!was!designed!to!allow!for!pharmacokinetic!studies!following!viral!administration,!by!measuring!serum!levels!of!CEA!using!widely!available!routine!assays.!Subsequent!preclinical!developments!directed!the!solitary!manufacturing!facility!(Mayo!Clinic,!USA)!to!switch!to!the!production!of!MV!expressing!the!human!sodium!iodine!symporter!gene!(NIS).!NIS!encodes!a!human!protein!found!in!the!thyroid!involved!in!iodine!uptake.!Preclinical!studies!demonstrated!that!MVENIS!could!be!tracked!in!vivo!by!administering!iodine!or!technetium,!both!of!which!are!readily!taken!up!by!cells!expressing!the!NIS!protein,!and!performing!gamma,!PET!or!SPECT!imaging!(Myers!et!al.,!2007).!MVENIS!has!also!been!used!preclinically!in!combination!with!131I,!with!the!aim!of!accumulating!sufficient!levels!of!131I!within!virallyEinfected!tumour!cells!to!cause!bystander!killing!of!adjacent!uninfected!tumour!cells!(personal!communication!E.!Galanis,!2012).!Thus!MVENIS!has!promise!both!in!terms!of!imaging!viral!spread!and!enhancing!OV!efficacy.!The!study!proposed!was!developed!at!the!joint!ESOEESMOEAACR!clinical!trials!workshop!in!Flims!2012.!In!brief,!the!study!is!designed!as!a!twoEstage!phase!0!protocol,!as!illustrated!in!Figure!38.!An!initial!cohort!of!5!patients!who!have!been!found!to!have!metastatic!melanoma!involving!the!inguinal!or!axillary!lymph!node!basins!will!be!recruited!shortly!prior!to!planned!surgical!resection.!One!week!prior!to!surgery!patients!will!have!intratumoural!injections!of!MVENIS,!followed!over!the!subsequent!week!by!two!99Tc!SPECT!scans.!If!any!evidence!of!viral!protein!expression,!i.e.!NIS!expression!leading!to!focal!tracer!uptake,!can!be!seen!on!SPECT!in!the!first!five!patients!undergoing!intratumoural!injection,!then!further!
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patients!will!be!recruited!to!complete!two!cohorts,!intravenous!versus!intratumoural!MVENIS.!This!study!will!aim!to!validate!SPECT!as!a!pharmacokinetic!marker!for!subsequent!studies.!Additionally!blood!will!be!collected!from!patients!over!the!course!of!the!study!and!examined!for!evidence!of!antiEtumoural!immune!responses,!which!may!serve!as!pharmacodynamic!readouts!in!the!future.!!!
!Figure!38.!Proposed!trial!design.!Schematic!representation!of!proposed!trial!design!examining!the!ability!of!99TcEenhanced!SPECT!to!detect!NIS!protein!expression!following!intratumoural!or!intravenous!administration!in!melanoma!patients!with!inguinal!or!axillary!lymphadenopathy
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5 Enhancing+the+combination+of+adoptive+cell+therapies+and+
virotherapies+with+the+addition+of+local+radiotherapy+
5.1 Introduction+Rather!than!simply!being!a!cytotoxic!therapy,!radiotherapy!(RT)!has!been!shown,!in!vitro!and!in!vivo,!to!enhance!the!immunogenicity!of!cancer!cells(Reits!et!al.,!2006;!Bernstein!and!Hodge,!2012).!Though!its!effects!on!immune!cells!are!more!heterogeneous,!several!clinical!studies!have!shown!that!conventional!RT!protocols!lead!to!increased!numbers!of!circulating!tumour!antigenEspecific!TEcells!(Schaue!et!al.,!2008;!Tabi!et!al.,!2010).However,!radiotherapy!is!little!used!in!the!treatment!of!melanoma,!partly!because!there!is!nihilism!born!of!traditional!radiobiological!assessments!of!the!radioresistance!of!melanoma!(Stevens!and!McKay,!2006;!Jahanshahi!et!al.,!2012).!!Radiotherapy!in!the!form!of!total!body!irradiation!is!used!in!the!current!adoptive!cell!therapy!protocols!at!the!NCI!for!metastatic!melanoma(Rosenberg!and!Dudley,!2009).!In!that!setting!RT!is!thought!principally!to!act!by!depleting!host!lymphocytes!that!would!otherwise!act!as!a!competitive!‘sink’!for!activating!cytokines.!Total!body!irradiation,!and!indeed!the!entire!conditioning!regimen!in!use!for!ACT,!is!extremely!toxic,!which!limits!the!range!of!patients!that!can!be!treated!in!such!protocols.!Accordingly!many!groups!are!pursuing!methods!to!enhance!ACT!without!the!need!for!prohibitively!toxic!preEtreatment!(Cho!et!al.,!2012).!Moreover!alternative!immunotherapeutic!approaches!can!be!effective!against!melanoma!in!more!clinically!practicable!formats,!such!as!the!monoclonal!antibody,!ipilimumab!(Hodi!et!al.,!2010).!!In!the!following!experiments!the!potential!immuneEenhancing!effects!of!palliativeEdose!radiotherapy!were!explored.!Single!fraction!treatments!of!up!to!8!Gy!are!used!in!many!tumour!sites,!including!melanoma;!doses!of!8!Gy!are!associated!with!minimal!toxicity!and!are!readily!clinically!implemented.!Although!such!doses!are!inadequate!to!control!tumours,!they!may!enhance!therapy!by!killing!tumour!cells,!releasing!antigen!and!danger!signals,!and!causing!changes!on!and!within!tumour!cells!that!render!them!more!visible!and!vulnerable!to!cells!of!the!immune!system!(Bernstein!and!Hodge,!2012).!
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It#was#therefore#hypothesised#that#the#addition#of#sub3radical#doses#of#external#
beam#radiotherapy#to#established#tumours#would#elicit#immunologically#relevant#
changes#within#that#tumour#and#its#stroma,#that#would#enhance#therapy#with#the#
combination#of#adoptively#transferred#T3cells#and#oncolytic#virus.##
Although#ACT#routinely#uses#autologous#tumour3infiltrating#lymphocytes#with#a#
range#of#T3cell#receptors,#such#therapy#is#difficult#to#model#preclinically.#The#use#of#a#
model#antigen#system#is#a#pragmatic#solution#that#allows#hypotheses#to#be#tested#
using#reproducible#and#reliable#model#systems.#Accordingly#the#experiments#
presented#below#use#B16#melanoma#cells,#derived#from#a#C57BL/6#mouse,#that#have#
been#transfected#to#stably#express#the#chicken#protein#ovalbumin#(B163Ova).#OT1#
mice#are#transgenic#animals#in#which#lymphocytes#express#a#T3cell#receptor#that#
recognises#a#peptide#sequence#from#ovalbumin,#SIINFEKL.#Although#a#synthetic#
antigen#system#such#as#the#B163Ova/OT1#dyad#can#be#criticised#for#being#artificial#it#
has#the#advantages#of#being#well#characterised#and#associated#with#a#range#of#widely#
available#reagents#that#facilitate#analysis.#Pmel#transgenic#mice,#whose#T3cells#
recognise#epitopes#within#the#gp100#melanoma3associated#antigen,#known#to#be#
present#in#human#melanoma#and#melanocytes,#as#well#as#B16#melanoma#
(Rommelfanger#et#al.,#2012).#Pmel#T3cells#were#therefore#also#used,#in#order#to#
examine#responses#against#a#more#relevant#TAA.#Furthermore#recent#efforts#at#
enhancing#ACT#have#included#clinical#testing#of#T3cells#with#specificity#to#a#single#
epitope#(whether#by#engineering#the#TCR#or#transfecting#lymphocytes#with#a#
chimeric#antigen#receptor#(Porter#et#al.,#2011;#Restifo#et#al.,#2012)),#which#arguably#
enhances#the#potential#applicability#of#these#model#antigen#systems.### #
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5.2 Results+
5.2.1 Combinations+of+systemic+oncolytic+virus,+ACT+and+RT+To!test!the!potential!synergies!between!RT,!ACT!and!OV,!B16EOva!tumours!were!established!in!C57Bl/6!mice!and!therapy!started!7!days!after!tumour!implantation.!Mice!were!then!treated!with!8!Gy!orthovoltage!(150!kV)!external!beam!radiotherapy!to!the!tumour,!with!or!without!intravenous!VSVEOva,!and!with!or!without!intravenous!naïve!OT1!TEcells.!The!OT1!TEcells!used!in!this!and!all!following!experiments!were!prepared!by!harvesting!the!lymph!nodes!and!spleens!of!OT1!mice!and!performing!negative!selection!using!a!pan!TEcell!isolation!kit!to!yield!untouched!and!highly!pure!TEcells.!Tumours!were!measured!thrice!weekly,!and!the!mice!euthanized!if!the!tumours!exceeded!1!cm!in!any!dimension,!or!began!to!ulcerate.!As!shown!in!Figure!39,!8!Gy!RT!caused!tumour!growth!delay,!when!compared!to!untreated!mice,!and!consequently!briefly!prolonged!survival!(Figure!40).!Treatment!with!iv!VSVEOva!caused!brief!tumour!regression,!followed!by!rapid!regrowth.!The!combination!of!RT!and!VSVEOva!led!to!some!tumour!regressions,!but!the!tumours!recurred.!Intravenously!administered!naïve!OT1!TEcells!did!not!yield!any!tumour!regressions,!nor!improvement!in!survival,!and!the!combination!of!RT,!OT1!and!VSVEOva!did!not!yield!and!significant!improvements.!Notably!some!mice!treated!with!8!Gy!developed!moist!desquamation!within!the!treatment!field,!particularly!at!the!skin!fold!between!the!right!hind!limb!and!abdomen.!Although!these!reactions!settled!spontaneously,!and!did!not!impair!mobility!or!feeding,!it!was!decided!that!for!subsequent!experiments!the!dose!applied!should!be!reduced!to!4!Gy.!As!shown!in!Figure!41,!a!repeat!of!the!experiment!shown!in!Figure!39!and!Figure!40,!treatment!with!4!Gy!still!resulted!in!delayed!tumour!growth,!but!without!alteration!in!survival!(Figure!42).!No!skin!reactions!were!seen!in!any!subsequent!experiment!using!an!applied!dose!of!4!Gy!from!the!orthovoltage!source.!When!the!results!of!both!experiments!(Figure!40!and!Figure!42)!are!considered!there!was!no!obvious!enhancement!of!either!virotherapy!or!ACT!with!the!addition!of!RT,!and!the!triple!combination!was!not!synergistic.!!
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Figure! 39.! Combination! of! 8! Gy,! ACT! and!virotherapy.!days!after!injection!of!B16EOva!8!Gy! was! applied! to! tumours! followed! on!successive!days!by! iv!naïve!OT1! lymphocytes!and!iv!VSVEOva.!Tumour!growth!was!recorded!in! two! perpendicular! axes.! Vertical! bars!indicate! the! treatments! given! to! each! group!(n=8);!8!Gy!local!RT!E!dashed!grey!Naïve!OT1!–!solid!maroon!iv!VSVEOva!–!solid!green! !
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Figure!40.!Survival!following!combinations!of!8!Gy,!ACT!and!virotherapy.!Mice!from!the!experiment!illustrated!in!Figure!39!were!euthanized!when!tumours!reached!1!cm!in!any!dimension.!Survival!and!median!survival!for!each!group!are!indicated!above.! !
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!!Figure! 41.! Combination! of! 4! Gy,! ACT! and!virotherapy.!7!days!after! injection!of!B16EOva!4!Gy! was! applied! to! tumours,! followed! on!successive! days! by! iv! naïve! OT1! lymphocytes!and!iv!VSVEOva.!Tumour!growth!was!recorded!in!two! perpendicular! axes.! Vertical! bars! indicate!the!treatments!given!to!each!group!(n=8);!4!Gy!local!RT!E!dashed!grey!Naïve!OT1!–!solid!maroon!iv!VSVEOva!–!solid!green!
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!
!Figure! 42.! Survival! following! combinations! of! 4! Gy,! ACT! and! virotherapy.! Mice! from! the! experiment!illustrated! in! Figure! 41! were! euthanized! when! tumours! reached! 1! cm! in! any! dimension.! Survival! and!median!survival!for!each!group!are!indicated!above.!!! !
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5.2.2 Optimal+timings+of+combination+therapy+That!the!effects!of!radiotherapy!take!time!to!evolve!is!well!established,!and!the!time!taken!varies!according!to!fraction!size,!dose!rate!and!parameters!within!the!tissue!of!interest.!Thus!it!was!hypothesised!that!immunologically!relevant!effects!of!external!beam!RT!occur!in!a!specific!and!limited!time!frame.!The!corollary!of!which!is!that!the!experiments!described!above!may!have!failed!to!demonstrate!synergy!because!a!window!of!synergistic!potential!was!missed!in!the!schedule!as!applied.!In!order!to!test!this!hypothesis,!mice!were!treated!with!4!Gy!on!day!7!as!before,!and!then!received!naïve!OT1!at!a!range!of!intervals!thereafter!(days!8,!11,!13!and!15),!followed!on!subsequent!days!by!intravenous!SIINFEKL!with!the!aim!of!optimally!activating!OT1!with!their!cognate!antigen.!As!shown!in!Figure!43!there!was!a!delay!in!tumour!growth!and!an!improvement!in!survival!(Figure!44)!when!the!cellular!therapy!was!delayed!until!day!11!or!15!(4!and!6!days!after!RT!respectively).!However!no!such!improvements!were!seen!with!day!13!OT1,!an!incongruity!that!suggests!that!the!apparent!improvements!seen!in!day!11!and!15!groups!were!in!fact!spurious.!In!a!subsequent!experiment,!using!VSVEOva!in!place!of!SIINFEKL,!no!delay!of!tumour!growth!(Figure!45),!nor!survival!(Figure!46),!was!seen!when!the!interval!between!ACT!and!RT!was!prolonged.!The!rate!of!tumour!growth!prevented!later!time!points!being!used,!as!mice!would!have!needed!to!be!euthanized!before!receiving!ACT!or!virotherapy.!! !
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Figure!43.!Optimising!the!timings!of!therapy.!7!days! after! injection! of! B16EOva! 4!Gy! was!applied! to! tumours,! followed,! after! varying!intervals,! by! naïve! OT1! TEcells! and!intravenous! SIINFEKL.! Tumour! growth! was!recorded! in! two! perpendicular! axes.! Vertical!bars! indicate! the! timings! of! the! treatments!given!to!each!group!(n=8);!4!Gy!local!RT!E!dashed!grey!Naïve!OT1!–!solid!maroon!iv!SIINFEKL!–!solid!green! !
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!Figure!44.!!Optimising!the!timings!of!therapy!(survival).!Mice!from!the!experiment!illustrated!in!Figure!43!were!euthanized!when!tumours!reached!1!cm!in!any!dimension.!Survival!and!median!survival!for!each!group!are!indicated!above.!!!!! !
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Figure! 45.! Optimising! the! timings! of! therapy.! 7!days!after!injection!of!B16EOva!4!Gy!was!applied!to!tumours,!followed,!after!varying!intervals,!by!naïve!OT1! TEcells! and! intravenous! VSVEOva.! Tumour!growth! was! recorded! in! two! perpendicular! axes.!Vertical!bars!indicate!the!timings!of!the!treatments!given!to!each!group!(n=8);!4!Gy!local!RT!E!dashed!grey!Naïve!OT1!–!solid!maroon!iv!VSVEOva!–!solid!green!!
4Gy
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                            Day 8 OT1       
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                          Day 11 OT1
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                           Day 13 OT1
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                        Day 15 OT1
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
4Gy
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                                     
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                          Day 11 OT1
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                           Day 13 OT1
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
                        Day 15 OT1
0 20 40 60
0
2000
days since tumour challenge
vo
lu
m
e
!! Radiotherapy! !
157!
!Figure!46.!Optimising!the!timings!of!therapy!(survival).!Mice!from!the!experiment!illustrated!in!Figure!45!were!euthanized!when!tumours!reached!1!cm!in!any!dimension.!Survival!and!median!survival!for!each!group!are!indicated!above.!! !
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5.2.3 The+persistence+of+adoptively+transferred+TFcells++The!effectiveness!of!ACT!may!be!limited!by!several!factors!(Dudley!and!Rosenberg,!2003;!SanchezEPerez!et!al.,!2007):!
• Limited!persistence!or!survival!of!cells!
• Failure!to!generate!memory!
• Failure!of!cells!to!reach!tumour!or!draining!lymph!nodes!
• Failure!to!overcome!tumourEmediated!suppression!
• Resistance!of!tumour!cells!to!killing!mechanisms.!To!examine!some!of!these!parameters,!mice!bearing!B16EOva!were!treated!with!combinations!of!RT,!ACT!and!virotherapy,!and!euthanized!after!elective!intervals.!Tumours,!tumourEdraining!lymph!nodes!(TDLN)!and!spleens!were!then!harvested!and!examined!by!flow!cytometry.!VSVEGFP,!rather!than!VSVEOva,!was!used!to!avoid!conflation!of!antiEviral!responses,!as!distinct!from!antiEtumour!responses,!raised!against!ovalbumin.!!The!persistence!of!adoptively!transferred!cells!was!examined!by!flow!cytometry;!in!this!experiment!congenic!C57BL6!mice!bearing!the!Thy1.1!marker!were!used,!allowing!for!discrimination!of!host!lymphocytes!from!Thy1.2!donor!OT1!cells.!Adoptively!transferred!Thy1.2+ve!cells!were!detected!within!the!TDLN!of!all!treated!mice,!however!at!low!frequencies!and!declining!over!time!(Figure!47).!Moreover!no!difference!in!frequency!or!persistence!was!apparent!when!OT1!were!administered!with!virotherapy,!RT,!or!both.!No!Thy1.2!cells!were!detected!in!tumours!or!spleens!(data!not!shown),!suggesting!that!the!absolute!number!of!cells!persisting!to!day!12,!i.e.!four!days!after!administration,!or!trafficking!to!the!tumour!was!low.!Cells!prepared!for!use!in!the!experiments!shown!in!Figure!47!were!also!cultured!ex!vivo!for!four!hours!with!one!of!a!panel!of!antigenic!epitopes,!and!then!examined!for!the!presence!of!intracellular!IFNγ,!indicating!TEcell!recognition!of!a!cognate!antigen!(Figure!48).!Epitopes!from!the!TAA!trp2!and!gp100!were!included!to!address!the!possibility!of!epitope!spreading,!wherein!tumour!cell!killing!by!adoptively!transferred!effector!cells!releases!TAA!and!danger!signals!that,!enhanced!by!adaptiveEtoEinnate!cross!talk,!license!DC!to!prime!de!novo!adaptive!responses.!Consistent!with!the!finding!of!Thy1.2+!donor!cells!at!day!12,!
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an!IFNγ!response!to!SIINFEKL!was!detected!within!TDLN;!no!response!was!seen!in!cells!from!the!tumour!or!spleen,!from!mice!of!any!treatment!group!(data!not!shown).!Notably!there!was!no!apparent!enhancement!of!the!response!to!SIINFEKL!by!the!addition!of!RT!or!virotherapy!to!ACT,!when!examining!the!results!from!duplicate!mice.!At!day!14!the!production!of!intracellular!IFNγ#in#response!to!SIINFEKL!remained!higher!than!untreated!cells.!Moreover!mice!that!had!been!treated!with!VSV!(groups!C!and!D,!indicated!by!triangles)!appeared!to!have!a!response!to!the!viral!epitope!not!seen!in!the!virus!naïve!groups.!In!addition!at!day!14!some!mice!developed!a!response!against!the!TRP2!antigen,!though!it!must!be!noted!that!the!frequency!of!cells!detected!was!low,!as!was!the!absolute!difference!in!frequencies!when!compared!to!the!unstimulated!cells.!By!days!16!and!19!the!frequency!of!cells!that!stained!positive!for!intracellular!IFN!was!too!low!(in!keeping!with!the!results!seen!in!Figure!47)!to!be!able!draw!meaningful!conclusions.!Clearly!the!data!presented!in!Figure!47!and!Figure!48!do!not!preclude!other!factors!limiting!the!efficacy!of!ACT,!but!accepting!the!caveats!described!above,!it!appears!that!a!significant!impediment!to!therapy!using!naïve!OT1,!not!overcome!by!the!addition!of!RT,!is!the!limited!trafficking!of!OT1!cells!too,!and!persistence!within,!tumours!and!TDLN.!In!the!context!of!clinical!ACT!for!melanoma!it!is!thought!that!native!host!lymphocytes!can!denigrate!the!efficacy!of!adoptively!transferred!cells!by!competing!for!cytokines.!If!local!RT!is!able!to!stimulate!an!inflammatory!response!from!tumours,!including!chemokines!that!could!recruit!immune!effector!cells,!then!host!lymphocytes!may!also!act!as!a!chemokine!sink,!inhibiting!recruitment.!Current!ACT!protocols!include!total!body!irradiation!in!order!to!deplete!lymphocytes!and!reduce!the!effect!of!the!cytokine!‘sink’!–!a!similar!approach!may!therefore!be!useful!in!this!model.!
! !
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Figure!47.!Persistence!of!adoptively! transferred!cells.!A.!Schematic! illustrating! that!mice!bearing!B16EOva!tumours! were! treated! with! combinations! of! RT,! OT1! and! VSVEGFP,! and! two! mice! from! each! group!euthanized!on!days!12,!14,!16,!19!and!21.!If!tumours!reached!1!cm!in!any!dimension!mice!were!euthanized!earlier! than! the! preEplanned! schedule.! B.! TumourEdraining! lymph! nodes! were! removed! from! mice!immediately! after! euthanasia! and! analysed! for! the! presence! of! adoptively! transferred! TEcells! by! flow!cytometry;!donor!mice!were!Thy1.2!+ve!and!recipients!Thy1.1,!allowing!for!discrimination!of!donor!TEcells!from!host.!No!Thy1.2!+ve!cells!were!detected! in! the! tumour!or!spleens!of!mice! from!any!group!(data!not!shown).!!! !
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Figure! 48.! IFN!production! from!TDLN!CD8+!TEcells.! Tumour! draining! lymph!nodes!were! harvested! from!mice!bearing!B16EOva!tumours!after!12,!14,!16,!19!or!21!days,!and!following!treatment!with!combinations!of! OT1,! VSVEGFP! and! 4Gy.! Cells! were! cultured! ex! vivo! for! four! hours! in! the! presence! of! the! peptides!indicated!and! the! cells! then!analysed! for! intracellular! IFNγ.!Results! indicate! the!percentage!of!CD8+!cells!that!were!also!positive!for!IFNγ!in!each!mouse.!Note!that!the!axes!are!logarithmic.!Peptide!stimulation!and!staining!were!performed!on! the!day!of!harvest!and!FACS!analysis! the! following!day.!Two!mice!per!group!were!harvested!on!each!day,!according!to!predefined!allocation;!when!unplanned!euthanasia!was!required!on!an!analysis!day!the!additional!mice!were!included!in!that!day’s!analysis.!! !
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5.2.4 Total+body+irradiation+Local!radiotherapy!has!been!demonstrated!to!elicit!changes!within!the!tumour!and!its!stroma!that!could!have!immunologically!relevant!consequences.!Irradiation!of!the!whole!body!(or!total!body!irradiation,!TBI)!has!long!been!known!to!have!immunological!consequences.!Early!experience!of!the!bombings!of!Hiroshima!and!Nagasaki,!as!well!as!inadvertent!industrial!radiation!exposures,!revealed!that!doses!of!around!4!E!5!Gy!lead!to!death!in!50%!of!humans!(Hall!and!Giaccia,!2011).!In!most!such!cases!death!occurs!within!60!days!due!to!the!haematopoietic!syndrome,!in!which!precursor!cells!are!sterilised!by!the!radiation!and!pancytopenia!ensues.!Notably!the!lethal!dose!in!mice,!though!likely!to!vary!between!strains,!is!estimated!to!be!in!the!region!of!7!Gy.!!The!most!recently!reported!conditioning!regimen!for!clinical!ACT!includes!TBI;!12!Gy!in!six!fractions!over!three!days,!or!a!single!2!Gy!fraction!(Rosenberg!et!al.,!2011).!In!this!context!TBI!is!thought!to!act!by!depleting!host!lymphocytes,!that!would!otherwise!compete!with!adoptively!transferred!lymphocytes!for!endogenous!cytokines,!in!turn!allowing!the!transferred!cells!to!proliferate.!TBI!may!also!act!by!depleting!Tregs,!and!the!gastrointestinal!toxicity!of!TBI!is!likely!to!result!in!the!release!of!potent!danger!signals!such!as!LPS!into!the!circulation!which!would!serve!to!activate!APC!and!lymphocytes!(Somosy!et!al.,!2002).!Whole!body!irradiation!would!be!expected!to!enhance!the!efficacy!of!ACT!and!virotherapy!by!depleting!host!lymphocytes,!allowing!for!greater!proliferation!of!adoptively!transferred!naïve!TEcells,!by!reducing!competition!for!cytokines,!and!enhancing!the!immunogenicity!and!susceptibility!of!tumour!cells.!Accordingly!mice!bearing!B16EOva!tumours!were!treated!with!OT1!cells!and!intravenous!VSVEOva,!on!sequential!days!after!4!Gy!applied!to!the!tumour!or!4!Gy!to!the!whole!body.!As!shown!in!Figure!49!and!Figure!50,!there!was!no!benefit!from!the!addition!of!RT!to!ACT!and!virotherapy.!Notably!TBI!failed!to!achieve!better!tumour!control,!or!survival,!when!compared!to!local!radiotherapy.!Given!that!local!and!whole!body!radiotherapy!would!be!expected!to!have!very!different!patterns!of!immunological!effects!and!those!patterns!might!be!complementary,!in!a!subsequent!experiment!mice!were!treated!with!4!Gy!TBI,!with!or!without!an!additional!4!Gy!applied!to!the!tumour!alone,!in!combination!with!ACT!and!virotherapy!(Figure!51!&!Figure!52).!No!additive!benefit!was!derived!from!the!
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combination!RT!approach!when!compared!to!OT1!and!VSVEOva!alone.!Notably,!despite!two!4!Gy!fractions!encompassing!the!tumour,!separated!by!at!most!2!hours,!no!mice!developed!skin!reactions,!as!had!previously!been!seen!with!8!Gy.!This!is!presumably!due!to!some!early!repair!during!the!interval!between!the!treatments,!and!the!skin!sparing!effect!of!the!higher!energy!photons!of!the!137Cs!source!used!for!TBI.!!Although!the!escalated!dose!was!well!tolerated!no!benefit!was!seen!when!compared!to!the!combination!of!ACT!and!virotherapy!without!RT.!!
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!Figure! 49.! Whole! body! versus! local! irradiation.! 7! days! after! injection! of! B16EOva! 4!Gy! was! applied! to!tumours!using!an!orthovoltage!machine,!or!to!the!whole!animal!using!a!137Cs!source,!followed!on!successive!days!by!naïve!OT1!TEcells! and! intravenous!VSVEOva.!Tumour! growth!was! recorded! in! two!perpendicular!axes.!Vertical!bars!indicate!the!treatments!given!to!each!group!(n=8);!4!Gy!local!RT!E!dashed!grey!4!Gy!whole!body!RT!E!solid!grey!Naïve!OT1!–!solid!maroon!iv!VSVEOva!–!solid!green!
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!Figure!50.!Survival!following!whole!body!versus!local!irradiation.!Mice!from!the!experiment!illustrated!in!Figure!49!were!euthanized!when!tumours!reached!1!cm!in!any!dimension.!Survival!and!median!survival!for!each!group!are!indicated!above.!
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!Figure!51.!Combinations!of!whole!body!and! local! irradiation.!7!days!after! injection!of!B16EOva!mice!were!exposed! to!4!Gy! to! the!whole!body!using! a! 137Cs! source,! and! immediately! thereafter!4!Gy! to! the! tumour,!delivered!by!orthovoltage!source.!Naïve!OT1!TEcells!and! intravenous!VSVEOva!were!administered!on!days!eight!and!nine!respectively.!Tumour!growth!was!recorded!in!two!perpendicular!axes.!Vertical!bars!indicate!the!treatment!given!to!each!group!(n=8).!4!Gy!local!RT!E!dashed!grey!4!Gy!whole!body!RT!E!solid!grey!Naïve!OT1!–!solid!maroon!iv!VSVEOva!–!solid!green!!
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!Figure!52.!Survival! following!combinations!of!whole!body!and!local! irradiation.!Mice!from!the!experiment!illustrated!in!Figure!51!were!euthanized!when!tumours!reached!1!cm!in!any!direction.!Survival!and!median!survival!for!each!group!are!indicated!above.! !
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5.2.5 Pmel+++VSVFgp100+Transgenic!Pmel!mice!express!a!TEcell!receptor!(Vα1/Vβ13)!specific!for!an!epitope!within!gp100!when!presented!on!MHC!class!I!molecules.!As!gp100!is!a!TAA,!rather!than!tumourEspecific!antigen,!it!is!found!on!normal!melanocytes!as!well!as!melanoma.!Combinations!of!adoptively!transferred!Pmel!TEcells!with!VSV!expressing!gp100!have!recently!been!reported!to!cure!a!proportion!of!established!B16EOva!tumours,!though!necessitating!multiple!administrations!(Rommelfanger!et!al.,!2012).!External!beam!RT!was!therefore!combined!with!Pmel!lymphocytes!(prepared!in!the!same!way!as!OT1!TEcells)!and!VSVEgp100!to!test!the!hypothesis!that!RT!could!enhance!subtherapeutic!doses,!making!the!treatment!more!practicable!and!clinically!applicable.!!B16EOva!tumours!were!established!in!C57Bl/6!mice!and!therapy!started!7!days!after!tumour!implantation.!Mice!were!then!treated!with!external!beam!radiotherapy!to!the!tumour,!with!or!without!intravenous!naïve!Pmel!TEcells!the!following!day,!and!intravenous!VSVEgp100!a!day!later.!Additionally!the!effect!of!local!RT!was!compared!with!TBI,!in!concert!with!Pmel!and!VSVEgp100,!with!tumour!growth!curves!shown!in!Figure!53!and!survival!in!Figure!54.!As!shown!in!Figure!54!these!data!demonstrate!that!the!addition!of!local!RT!to!the!combination!of!VSVEgp100!and!Pmel!increased!median!survival!(from!23!to!30!days).!To!confirm!these!findings!this!combination!was!also!tested!in!the!experiment!shown!in!Figure!55,!confirming!the!enhanced!survival!seen!when!local!RT!was!added!to!Pmel!and!VSVEOva!(18!to!28!days).!!These!survival!data!(local!RT!+!Pmel!+!VSVEgp100)!were!tested!for!evidence!of!statistical!significance!using!GraphPad!Prism.!The!95%!confidence!interval!of!the!hazard!ratios!from!each!experiment!spanned!unity;!(2.5!{0.8E7.6}!&!2.7!{0.7E9.8}).!When!the!survival!data!were!combined!the!hazard!ratio!was!2.34!with!a!95%!confidence!interval!of!1.03!–!5.32.!LogErank!test!of!the!pooled!survivals!produced!a!p!value!of!0.04,!though!no!adjustment!was!made!for!the!multiple!groups!tested!in!each!experiment.!!The!effect!of!TBI!was!inconsistent!in!the!same!pair!of!experiments;!although!TBI!appeared!to!improve!survival!in!Figure!54,!no!such!benefit!was!seen!in!the!experiment!shown!in!Figure!55!!
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The!effect!of!RT!on!adoptively!transferred!activated!TEcells!was!also!studied.!Naïve!TEcells!in!combination!with!systemic!adjuvant,!such!as!an!oncolytic!virus!expressing!the!cognate!antigen,!are!thought!to!have!greater!potential!for!expansion!once!administered!and!to!be!less!prone!to!exhaustion!and!activationEinduced!death!than!activated!lymphocytes!(Rommelfanger!et!al.,!2012).!Despite!this,!most!reports!of!ACT!have!used!activated!lymphocytes!for!transfer,!and!therefore!a!comparison!of!RT!with!naïve!or!activated!was!undertaken.!The!data!presented!in!Figure!55!andFigure!56!were!obtained!in!one!experiment.!Pmel!lymphocytes!prepared!as!above!were!activated!by!culture!with!IL2!and!gp100!peptide!for!four!days!before!administration!to!mice.!The!median!survival!of!each!group!is!shown!in!Figure!56.!RT,!local!or!TBI,!enhanced!survival!by!ten!days!when!combined!with!activated!Pmel!and!VSVEgp100,!in!keeping!with!the!data!obtained!using!naïve!lymphocytes!(Figure!54).!The!increased!survival!following!the!addition!of!RT,!either!local!or!TBI,!was!not!a!statistically!significant!difference!(LogErank!test).!There!did!not!appear!to!be!any!benefit!from!activated!TEcells!compared!to!naïve.!!! !
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!Figure!53!Local!or!whole!body!RT!plus!Pmel!and!VSVEgp100.!7!days!after! injection!of!B16EOva!mice!were!exposed!to!4!Gy!to!the!whole!body!using!a!137Cs!source,!or!4!Gy!to!the!tumour,!delivered!by!orthovoltage!source.! Naïve! Pmel! TEcells! and! intravenous! VSVEgp100! were! administered! on! days! eight! and! nine!respectively.!Tumour!growth!was!recorded!in!two!perpendicular!axes.!Vertical!bars!indicate!the!treatment!given!to!each!group!(n=8).!4!Gy!local!RT!E!dashed!grey!4!Gy!whole!body!RT!E!solid!grey!Naïve!Pmel!–!solid!orange!!iv!VSEgp100!–!solid!mauve!
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!Figure!54!Survival!following!local!or!whole!body!RT!plus!Pmel!and!VSVEgp100.!Mice!from!the!experiment!illustrated!in!Figure!53!were!euthanized!when!tumours!reached!1!cm!in!any!direction.!Survival!and!median!survival!for!each!group!are!indicated!above! !
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NAÏVE!Radiotherapy! Pmel! VSVEgp100! Local! Whole!body!! ! !! 16!
 !! ! 14!
 !! !! 18!
! ! ! 18! 14!
! ! !! 21! 14!
!! !! ! 18! 14!
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+Figure!55.!Local!or!whole!body!RT!plus!naïve!Pmel! and! intravenous!VSVEgp100.!7!days!after! injection!of!B16EOva!mice!were!exposed!to!4!Gy!to!the!whole!body!using!a!137Cs!source,!or!4!Gy!to!the!tumour,!delivered!by! orthovoltage! source.!Naïve!Pmel!TEcells! and! intravenous!VSVEgp100!were! administered!on!days! eight!and! nine! respectively.! Mice!were! euthanized!when! tumours! reached! 1! cm! in! any! direction.! The!median!survival!for!each!group!is!indicated!in!A!(n=8!per!group).!The!survival!of!relevant!groups!is!also!plotted!in!B!&! C;! others!were! excluded! for! clarity.! The! groups! shown!were! treated! in! the! same! experiment! as! those!shown!in!Figure!56.!!
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ACTIVATED!Radiotherapy! Pmel! VSVEgp100! Local! Whole!body!! ! !! 16!
 !! ! 18!
 !! !! 21!
! ! ! 18! 14!
! ! !! 21! 14!
!! !! ! 25! 28!
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+Figure!56.!Local!or!whole!body!RT!plus!activated!Pmel!and!intravenous!VSVEgp100.!7!days!after!injection!of!B16EOva!mice!were!exposed!to!4!Gy!to!the!whole!body!using!a!137Cs!source,!or!4!Gy!to!the!tumour,!delivered!by!orthovoltage!source.!Activated!Pmel!TEcells!and!intravenous!VSVEgp100!were!administered!on!days!eight!and! nine! respectively.! Mice!were! euthanized!when! tumours! reached! 1! cm! in! any! direction.! The!median!survival!for!each!group!is!indicated!in!A!(n=8!per!group).!The!survival!of!relevant!groups!is!also!plotted!in!B!&! C;! others!were! excluded! for! clarity.! The! groups! shown!were! treated! in! the! same! experiment! as! those!shown!in!Figure!55! !
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5.2.6 Brachytherapy+The!results!illustrated!earlier!suggest!that!local!radiotherapy!or!TBI!have!minimal!effects!on!therapy!with!ACT!and!OV.!It!is!possible!that!4!Gy!as!an!applied!dose!may!have!been!inadequate!to!achieve!the!immunologically!relevant!changes!that!others!have!reported!at!higher!doses.!As!described!above,!it!was!not!possible!to!use!higher!doses!delivered!by!an!orthovoltage!source!without!causing!significant!skin!toxicity.!Therefore!brachytherapy!was!considered!as!an!alternative!method!of!irradiation!that!would!allow!higher!doses!to!be!delivered!to!the!tumour.!Brachytherapy!is!the!use!of!sealed!radioactive!sources!placed,!interstitially!or!into!potential!cavities,!adjacent!to!tumour.!In!common!use!in!the!midEtoElate!20th!century!for!a!wide!range!of!tumours,!more!recently!advances!in!external!beam!technology!have!largely,!though!not!completely,!supplanted!the!use!of!brachytherapy!in!many!tumour!sites.!Ongoing!applications!of!the!technique!include:!
o IntraEvaginal!brachytherapy!for!cervical!cancer!
o Prostatic!brachytherapy!!
o RetroEorbital!plaques!for!ocular!melanoma!
o Intraoperative!adjuvant!brachytherapy!for!breast!cancer!
o Intravascular!brachytherapy!for!nonEmalignant!disease.!The!necessity!for!operative!procedures!of!varying!complexity!along!with!the!evolution!of!conformal!radiotherapy!reduced!the!indications!for!brachytherapy,!however!some!significant!advantages!remain.!The!source!can!be!sited!under!direct!vision!or!image!guidance,!in!close!proximity!to!tumours,!allowing!for!confident!localisation!of!dose.!Furthermore!brachytherapy!sources!essentially!act!as!point!sources!thus!dose!varies!as!a!function!of!the!inverse!square!of!the!distance!from!the!source.!This!allows,!in!many!situations,!excellent!sparing!of!nearby!tissues!at!risk!whilst!delivering!very!high!dose!to!adjacent!tumour.!Sealed!sources!of!125I,!recycled!from!prostatic!brachytherapy,!were!mounted!inside!silastic!discs!(7!mm!Ø,!3!mm!thickness)!(Figure!57A).!These!‘plaques’!served!to!make!the!seeds!easier!and!safer!to!handle,!but!also!helped!secure!the!source!in!place!over!tumours,!reducing!migration!of!the!seeds!within!the!subcutaneous!space.!Extensive!work!was!done!with!the!radiation!safety!group!to!
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address!concerns,!both!Federal!and!Institutional,!about!seed!loss;!seeds!not!mounted!in!plaques!are!5!mm!long!with!a!diameter!under!1!mm.!In!later!experiments!plaques!were!prepared!with!a!half!mm!thick!disc!of!lead!mounted!on!one!side!to!improve!radiation!safety.!The!tenth!value!layer!of!photons!emerging!from!125I!is!around!a!tenth!of!a!mm!of!lead,!and!estimates!with!a!GM!tube!confirmed!that!the!unilateral!shielding!considerably!reduced!the!exposure!rate.!!In!order!to!test!the!feasibility!of!the!procedure,!including!the!surgical!placement!of!the!plaques,!two!mice!bearing!day!7!B16EOva!tumours!were!anaesthetised!with!inhalational!isofluorane!(one!C57BL6!and!one!OT1).!Once!adequate!anaesthesia!was!achieved!a!1!cm!craniocaudal!incision!was!made!overlying!the!subcutaneous!tumour!and!a!small!pocket!established!by!blunt!dissection.!Plaques!containing!dummyEseeds!were!inserted!and!the!incision!closed!with!surgical!staples.!These!mice!were!then!used!to!obtain!CT!images!for!the!purposes!of!dosimetry!estimates!(Figure!57B).!After!4!days!the!plaques!were!removed!under!anaesthesia.!In!this!and!subsequent!experiments!it!was!noted!that!the!mice!tolerate!the!plaques;!there!was!no!evidence!of!excessive!selfEgrooming,!barbering,!or!gnawing!at!the!plaque!site,!either!by!the!mouse!or!its!cage!mates.!The!CT!data!acquired!was!used!to!prepare!dosimetry!estimates!for!subsequent!experiments!(Figure!57C).!!In!order!to!assess!the!effect!of!brachytherapy!in!this!model!active!plaques!were!inserted!in!mice!bearing!established!7Eday!B16EOva!tumours.!The!dose!delivered!to!tumour!varies!according!to!the!activity!of!125I!present!within!the!sealed!source,!and!the!duration!of!the!exposure.!Plaques!were!therefore!left!in!place!for!2,!4,!7!or!9!days!before!removal.!Tumour!growth!could!not!be!recorded!while!plaques!were!in!place,!predominantly!due!to!the!unnecessary!radiation!exposure!to!personnel!that!would!be!entailed.!Survival,!however,!was!recorded!and!as!shown!in!Figure!58!the!doses!delivered!did!not!result!in!changes!in!survival!between!the!treated!groups,!or!mice!bearing!dummy!plaques!as!controls.!Although!these!doses!clearly!were!inadequate!to!control!tumours,!it!was!hypothesised!that!given!the!nature!of!the!inverse!square!rule!there!would!be!regions!of!the!tumour!exposed!to!ablative!doses,!capable!of!evincing!tumour!antigens!and!danger!signals.!Further!from!the!source,!the!dose!would!be!too!low!
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to!ablate!tumour,!but!perhaps!adequate!to!alter!the!tumour!cells!in!immunologically!relevant!ways.!Therefore!a!further!experiment!was!performed!in!which!mice!bearing!B16EOva!tumours!were!treated!with!active!plaques!for!48!hours!followed,!after!plaque!removal,!by!intravenous!ACT!and!virotherapy.!As!illustrated!in!Figure!59,!little!difference!in!survival!was!seen!in!mice!treated!with!the!triple!combination!and!those!receiving!ACT!and!virotherapy!without!brachytherapy.!!Comparison!of!the!effect!of!a!dose!from!a!single!fraction!of!EBRT,!delivered!over!7!minutes,!with!that!delivered!over!48!hours!by!brachytherapy,!is!limited!by!the!important!effect!of!dose!rate!on!the!efficacy!of!a!given!dose;!when!dose!is!delivered!at!a!low!rate!intracellular!repair!mechanisms!abrogate!the!effects!of!irradiation,!lowering!the!effective!dose.!However!it!is!likely!that!the!dose!achieved!in!areas!of!the!tumour!directly!adjacent!to!the!plaque!was!high!enough!(in!excess!of!40!Gy,!Figure!57C)!to!quell!such!concerns.!
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!Figure!57.!Development!of!brachytherapy.!A.!IodineE125!seeds,!used!in!prostatic!brachytherapy!are!0.8mm!in!diameter!and!4mm!long.!They!were!secured!in!silastic!discs!to!aid!handling!and!subcutaneous!placement.!B.!Silastic!plaques!bearing!dummy!pellets!were!implanted!into!a!C57Bl/6!mouse!bearing!a!7Eday!established!B16EOva! tumour.! The! following!day! the!mouse!was! anaesthetised! and! scanned! in! a!microCT.! These! data!were!then!transmitted!to!the!radiotherapy!physics!department!and!planning!software!used!to!estimate!the!dose!distribution.!B.!The!10!Gy!isodose!is!portrayed!as!a!rendered!sphere.!C.!Isodose!curves!are!shown!in!a!transverse!slice.!The!key!indicates!doses!delivered!over!96!hours!in!cGy!(1!Gy!=!100!cGy)!
A!
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!Figure!58.!The!effect!of!brachytherapy!on!B16EOva!tumours.!C57Bl/6!mice!bearing!7!day!established!B16EOva!were!anaesthetised!and!either!dummy!or!active!125I!plaques!inserted!over!the!tumour.!After!intervals!of!2,! 4,! 7! or! 9! days! the! plaques!were! removed.!Mice!were! euthanized!when! tumours! reached! 1! cm! in! any!direction.!The!survival!of!each!group!is!plotted.!The!median!survival!for!each!group!is!indicated!below!(n=8)!
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!Figure!59!Brachytherapy!in!combination!with!virotherapy!and!adoptive!cell!therapy.!C57Bl/6!mice!bearing!6!day!established!B16EOva!were!anaesthetised!and!either!dummy!or!active! 125I!plaques! inserted!over! the!tumour.! After! 48! hours! the! plaques! were! removed.! Naïve! OT1! TEcells! and! intravenous! VSVEOva! were!administered! on! days! 9! and! 10! respectively.! Mice!were! euthanized!when! tumours! reached! 1! cm! in! any!direction.!The!survival!of!key!groups! is!plotted;!others!were!excluded! for!clarity.!The!median!survival! for!each!group!is!indicated!below!(n=8).!
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5.3 Discussion+Radiotherapy!is!an!effective!treatment!for!many!cancers,!and!has!effects!beyond!simply!inducing!apoptosis!or!mitotic!catastrophe!in!radiosensitive!tumour!cells!and!the!immune!effects!of!RT!are!being!explored!by!several!groups(Bernstein!and!Hodge,!2012).!In!the!experiments!presented!above!combinations!of!adoptive!cell!therapy!and!antigenEexpressing!virus!were!not!significantly!enhanced!by!palliativeEdose!external!beam!RT,!or!by!brachytherapy.!This!is!in!contrast!to!the!previous!reports!of!successful!synergies!between!RT!&!FltE3!ligand!(which!causes!expansion!of!DC!numbers!in!vivo)!and!RT!plus!CTLAE4!blockade!(which!unshackles!TEcell!responses),!albeit!in!different!models!and!using!a!range!of!doses!(Chakravarty!et!al.,!1999,!2006;!Demaria!et!al.,!2004,!2005).!Reits!et!al.!demonstrated!that!tumours!irradiated!in!vivo!were!more!susceptible!to!killing!by!CTL!and!that!the!combination!of!CTL!and!RT!(10!Gy!as!a!single!fraction)!controlled!tumours!and!cured!mice(Reits!et!al.,!2006).!However,!the!CTL!used!in!that!publication!were!taken!from!a!cell!line!maintained!in!vitro!culture,!and!were!activated!in!vitro!prior!to!use.!There!are!studies!that!have!reported!immunological!effects!of!RT!that!would!be!deleterious!to!immunotherapy,!rather!than!beneficial;!Merrick!et!al.!found!that!irradiating!DC!in!vitro!diminished!their!ability!to!prime!TEcell!responses,!though!others!have!reported!contrasting!results(Liao!et!al.,!2004;!Merrick!et!al.,!2005;!Huang!et!al.,!2011b).!Moreover!the!effects!of!local!RT!will!be!predominantly!upon!tumour!cells!and!surrounding!stroma.!As!most!effector!cells!or!APC!would!be!expected!to!reside!outside!the!field!of!palliative!RT,!so!the!direct!effect!of!RT!upon!them!is!less!relevant!in!the!context!of!single!fraction!treatments;!these!effects!will!of!course!become!important!when!conventionally!fractionated!treatments,!which!can!last!several!weeks,!are!considered.!Overall!the!published!literature!suggests!that!RT!could!be!used!to!enhance!immunotherapies,!though!of!course!the!effect!of!any!publication!bias!involved!cannot!be!quantified.!!!The!lack!of!synergy!documented!above!contrasts!with!other!reports!that!have!identified!beneficial!effects!of!RT,!generally!with!higher!doses!of!RT.!This!suggests!that!strategies!in!melanoma,!clinical!or!preEclinical,!to!take!advantage!of!the!reported!immune!effects!of!RT!may!best!explore!higher!dose!and!higher!doseErate!forms!of!RT.!For!example!it!would!be!reasonably!straightforward!to!
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design!a!study!in!which!patients!due!to!receive!palliative!RT!for!a!metastatic!lesion,!to!a!dose!of!8Gy,!also!received!a!cancer!vaccine!or!immunomodulatory!treatment.!However,!based!on!the!data!above,!it!may!be!more!prudent!to!investigate!combinations!with!higher!doses!of!RT,!despite!the!challenges!to!recruitment!and!implementation!that!would!be!entailed.!Although!the!data!presented!above!suggest!no!synergy!between!RT!and!immunotherapies!targeting!the!synthetic!ovalbumin!antigen!(OT1!+!VSVEOva),!there!was!evidence!(Figure!54!E!Figure!56)!of!effective!combination!of!RT!and!gp100Eimmunotherapy!(Pmel!+!VSVEgp100).!The!two!models!are!very!different,!and!one!role!of!RT!in!the!latter!may!be!to!increase!expression!of!gp100!on!tumour!cells,!however!this!hypothesis!could!not!be!addressed!in!the!time!available.!Further!work!is!needed!to!confirm!and!explain!the!intriguing!disparity!between!the!two!immunotherapy!dyads.!!The!emergence!of!ipilimumab!as!the!first!effective!therapy!for!melanoma!coincides!with!growing!use!of!stereotactic!body!radiotherapy!(SBRT)!for!oligometastatic!disease.!The!Mayo!clinic’s!experience!of!SBRT!for!melanoma!patients!has!been!one!of!almost!universal!local!control!(Dr!Sean!Park,!personal!communication!2012).!Hypothesising!that!the!hypofractionated!doses!involved!in!SBRT!would!result!in!the!release!of!TAA!and!danger!signals,!a!protocol!was!developed!(by!the!author,!along!with!Dr!Sean!Park,!Dr!Kenneth!Olivier!and!Dr!Svetomir!Markovic)!in!which!patients!undergoing!SBRT!for!oligometastatic!melanoma!will!have!blood!collected!before,!during!and!after!treatment.!The!blood!will!be!used!for!pentamerEbased!and!functional!assays,!as!well!as!ELISA!of!cytokine!and!chemokine!levels,!in!order!to!monitor!inflammatory!and!melanomaEantigen!specific!responses!as!a!consequence!of!treatment!with!SBRT.!The!protocol!was!approved!by!the!institutional!review!board!and!is!currently!open!to!accrual.!Others!are!already!testing!the!combination!of!SBRT!and!ipilimumab,!on!the!logical!hypothesis!that!SBRT!may!direct!immune!responses!against!melanoma!that!will!be!enhanced!by!the!blockade!of!CTLAE4!(Clinical!trials.gov!and!personal!communication!Dr!Voichita!BarEAd!2012).!!Advances!in!radiotherapy!have!taken!a!relatively!unusual!path!when!compared!to!many!other!clinical!treatments.!Technological!advancements!(IMRT,!IGRT,!Stereotactic!RT,!ARCEtherapy!etc.)!have!been!predominantly!tested!and!
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developed!in!the!clinical!and!‘in!silico’!settings,!with!relatively!little!animal!testing!undertaken(Bentzen,!2008;!Verhaegen!et!al.,!2011).!In!terms!of!modelling!dose!distribution!within!tumours!or!normal!tissue,!small!animals!are!clearly!of!little!value!to!radiation!oncologists!and!medical!physicists;!the!C57Bl/6!mice!used!within!this!chapter!had!an!anteriorEposterior!thoracic!dimension!of!under!1.5!cm,!whereas!the!depth!of!maximum!dose!from!a!6!MV!photon!beam!is!around!2!cm.!If!high!dose!and!hypofractionated!radiotherapy!approaches!are!to!be!accurately!modelled!in!mice,!and!in!particular!the!immunological!consequences!thereof,!then!newer!technology!will!be!needed!than!the!erstwhile!clinicalEgrade!equipment!used!in!the!bulk!of!this!chapter.!A!small!range!of!precision!platforms!is!now!commercially!available!which!will!allow!strategies!combining!immunotherapies!and!modern!RT,!including!the!ability!to!deliver!imageEguided!hypofractionated!RT!to!mice,!to!be!tested!and!refined!preEclinically,!in!parallel!with!ongoing!clinical!developments!(Song!et!al.,!2010;!Verhaegen!et!al.,!2011).!!
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6 Developing+a+model+of+intracranial+melanoma+
6.1 Introduction+Melanoma!metastasises!to!the!brain!more!commonly!than!most!cancers!and!augurs!a!grim!prognosis!when!it!does!so.!Autopsy!studies!suggest!brain!metastases!may!occur!in!up!to!75%!of!patients!with!advanced!disease,!though!they!are!diagnosed!in!far!fewer!(Fisher!and!Larkin,!2012).!In!those!diagnosed!preEmortem!there!is!often!significant!morbidity!associated!with!intracranial!disease,!and!with!the!subsequent!treatments.!Melanoma!brain!metastases!are!felt!to!be!at!high!risk!of!haemorrhage,!and!catastrophic!intracerebral!bleeds!may!well!be!the!terminal!event!in!a!significant!proportion!of!patients.!!The!emergence!of!stereotactic!radiotherapy!techniques,!and!particularly!stereotactic!radiosurgery,!have!considerably!changed!the!management!of!brain!metastases,!appearing!to!offer!good!local!control!for!patients!with!oligometastatic!disease!(Linskey!et!al.,!2010).!!Commonly!brain!metastases,!whether!symptomatic!or!detected!by!trialEmandated!screening,!are!an!exclusion!criterion!in!studies!of!systemic!therapy.!However!there!are!reports!suggesting!Ipilimumab!and!adoptive!cell!therapies!may!have!some!efficacy!within!the!brain!(Hong!et!al.,!2010;!Margolin!et!al.,!2012).!Any!novel!therapy!for!melanoma!will!ideally!be!effective!against!brain!metastases,!and!moreover!will!need!to!be!able!to!access!the!lesions.!Furthermore!many!cell!types!of!the!CNS!share!a!neural!crest!origin!with!melanocytes!and!melanomas,!and!may!share!antigens!(Bridle!et!al.,!2010).!Successful!immunotherapy!for!melanoma!has!been!reported!to!result!in!vitiligo!and!dermatitis;!therefore!a!model!of!melanoma!in!the!brain!will!also!allow!for!study!of!the!risk!of!more!significant!neurological!autoimmune!toxicities.!
6.1.1 The+BloodFbrain+barrier+(BBB)+The!brain!was!first!recognised!to!have!some!separation!from!the!rest!of!the!circulation!following!the!work!of!Paul!Ehrlich.!When!he!injected!a!range!of!aniline!dyes!into!the!blood!stream!the!brain!alone!remained!unstained.!Conversely!dyes!injected!into!the!cerebrospinal!fluid!(CSF),!by!Ehrlich’s!student!
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Edwin!Goldmann,!stained!the!brain!but!didn’t!appear!to!have!access!to!the!other!organs.!In!contrast!to!other!vascular!structures!the!capillaries!of!the!brain!are!connected!by!particularly!tight!junctions,!and!reside!on!thick!basement!membranes,!beyond!which!the!VirchowERobin!space!and!foot!processes!of!the!glia!limitans!provide!further!impediments!to!cellular!and!humoral!access!(Wilson!et!al.,!2010).!Although!disruption!of!the!BBB!is!often!asserted!in!the!presence!of!tumours!(and!occasionally!described!as!the!bloodEtumour!barrier,!BTB)!there!is!evidence!that!it!may!remain!intact!and!able!to!impede!therapeutic!access,!particularly!in!the!case!of!microscopic!disease.!The!widespread!use!of!trastuzumab!for!breast!cancers!that!overexpress!human!epidermal!growth!factor!receptor!2,!has!revealed!the!limited!ability!of!trastuzumab!to!cross!the!BBB,!as!successful!control!of!visceral!disease!has!unmasked!unfettered!intracranial!disease!(Stemmler!and!Heinemann,!2008).!Preclinical!models!suggest!that!monoclonal!antibodies!are!unable!to!cross!the!intact!BBB,!although!active!immunotherapeutic!approaches!may!be!more!effective!(Sampson!et!al.,!2000;!Cranmer!et!al.,!2005).!!Bechmann!et!al!argue!eloquently!in!their!review!that!in!its!strictest!sense!the!BBB!refers!to!the!barrier!to!solute!diffusion!from!capillaries!within!the!brain,!and!should!therefore!not!be!used!to!refer!to!impediments!of!lymphocyte!trafficking!(Bechmann!et!al.,!2007).!They!also!highlight!the!importance!of!the!perivascular!or!VirchowERobin!space!(lying!between!the!two!basement!membranes!of!the!glia!limitans!and!the!vascular!smooth!muscle)!(VRS)!as!a!means!of!lymphatic!drainage!for!the!brain!parenchyma!and!a!repository!of!macrophages.!Notably!VRS!do!not!occur!about!capillaries!but!are!found!instead!at!the!pre!and!post!capillary!vessels,!and!are!the!site!of!leukocyte!passage!when!it!occurs.!Rather!than!crossing!the!solute!BBB,!immune!cells!instead!access!the!brain!parenchyma!by!traversing!venule!walls!to!enter!the!VRS,!and!from!there!cross!the!barrier!afforded!by!the!glia!limitans.!!For!the!sake!of!simplicity!for!the!remainder!of!this!thesis!BBB!will!be!used!to!describe!the!collective!impediments!faced!by!the!immune!system!in!accessing!targets,!rather!than!delineating!the!specific!solute!barrier,!in!keeping!with!the!approach!adopted!by!other!authors!(Savarin!et!al.,!2010).!! !
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The!immune!privilege!of!the!brain,!though!mediated!in!large!part!by!the!physical!barriers!described!above,!has!parallels!with!that!of!established!tumours.!Cells!within!the!brain!express!low!levels!of!MHC!I!and!II,!and!antigen!presenting!cells!are!scarce.!The!foot!processes!of!astrocytes!bordering!the!VRS!constitutively!express!the!death!ligand!CD95L!to!deter!cells!that!have!reached!the!VRS!from!proceeding!into!the!parenchyma!(Wilson!et!al.,!2010).!!What!is!clear!is!that!despite!such!immunosuppressive!attributes!the!brain!remains!capable!of!recruiting!immune!responses!when!necessary.!In!mouse!models!of!CNS!infections!CD8+!TEcells!access!the!brain!parenchyma!under!the!direction!of!chemokines!and!cytokines!produced!by!infected!cells,!and!the!resulting!upregulation!of!adhesion!molecules!on!CNS!vascular!epithelial!cells!(Wilson!et!al.,!2010).!!!Preclinical!models!that!are!able!to!mimic!the!challenges!to!successful!therapy!of!brain!metastases!have!been!developed!in!a!number!of!cancers.!This!chapter!describes!the!development!and!early!application!of!a!model!melanoma!that!would!allow!investigation!of!a!range!of!melanoma!treatments!otherwise!being!explored!by!the!group!(Diaz!et!al.,!2007;!Kottke!et!al.,!2011a,!2011b;!Rommelfanger!et!al.,!2012).!!
6.1.2 Existing+models+of+intracranial+disease+The!conventionally!used!melanoma!cell!lines!do!not!spontaneously!metastasise!when!injected!subcutaneously!but!several!methods!exist!to!model!intracranial!disease,!each!with!their!own!advantages!and!limitations!(Cranmer!et!al.,!2005).!!!!
• Intracardiac!administration!(ICD)!Direct!injection!of!tumour!cells!into!the!left!ventricle!bypasses!the!pulmonary!circulation,!with!a!reasonable!proportion!of!the!inoculum!reaching!the!carotid!circulation.!It!is!a!relatively!easy!technique,!as!most!veterinary!technicians!can!readily!adapt!their!existing!technique!of!cannulating!the!heart!for!terminal!bleeds.!However!sufficient!tumour!cells!will!evade!the!carotid!arteries!that!other,!nonEcranial,!metastases!will!form,!and!cardiac!deposits!are!common.!!!
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• Intracarotid!artery!administration!(ICA)!!By!performing!a!unilateral!neck!dissection!the!internal!carotid!artery!can!be!visualised!and!cannulated.!The!vessel!must!be!ligated!after!the!procedure,!and!subsequent!brain!perfusion!relies!on!the!patency!of!the!circle!of!Willis.!The!procedure!reduces,!significantly!but!incompletely,!the!frequency!of!extraEcranial!tumour!growth!but!is!an!extremely!challenging!procedure;!the!mouse!common!carotid!is!generally!less!than!half!a!millimetre!in!external!diameter!and!fine!microsurgical!skills!are!required.!Moreover!the!procedure!is!time!consuming!and!only!a!limited!number!of!mice!can!be!prepared!per!day!((Lorger!and!FeldingEHabermann,!2010)!and!personal!communication!Dr!M.!Lorger!2012).!!
• Intracranial!injection!(i.c.)!Direct!inoculation!of!tumour!cells!into!the!brain!is!relatively!straightforward.!!The!mouse!skull!can!readily!be!penetrated,!freehand!with!conventional!hypodermic!needles!but!considerable!variation!in!the!position!of!inoculation!can!ensue!((Cranmer!et!al.,!2005)!and!personal!communication!Mrs!J.!Thompson!2011).!The!use!of!a!stereotactic!frame!improves!interEprocedural!consistency!and!others!have!described!their!experience!with!the!method!in!detail!(Carlson!et!al.,!2011).!!
• Subcutaneous!tumour!metastasis!The!immediate!criticism!of!each!of!the!methods!outlined!above!is!that!they!do!not!mimic!metastatic!evolution!that!occurs!in!nature.!Accordingly!others!have!passaged!melanoma!lines!in!mice!by!serial!i.c.!administration!followed!by!brief!in!vitro!culture!to!select!neurotropic!cells!(Cranmer!et!al.,!2005).!These!cells,!apparently!capable!of!developing!brain!metastases!following!subcutaneous!injection,!are!not!available!from!the!conventional!tissue!culture!repositories.!!
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After!consideration!of!each!of!the!available!options,!and!discussion!with!colleagues!with!some!familiarity!with!the!issues,!it!was!decided!that!direct!intracranial!injection!was!the!most!appropriate!method!to!develop,!specifically!adapting!the!method!reported!by!Dr!J.!Sarkaria’s!group!at!the!Mayo!clinic!(Carlson!et!al.,!2011).!In!particular!it!was!important!to!be!able!to!use!the!cell!lines!on!which!previous!data!were!obtained!and!for!which!the!lab’s!existing!reagents!and!methods!would!be!most!applicable.!!In!order!to!estimate!the!appropriate!group!size!for!planned!experiments!a!power!calculation!was!performed!by!the!Mayo!clinic!biostatistical!team.!Previous!reports!indicate!a!median!survival!of!untreated!tumourEbearing!mice!of!14.6!days,!with!a!standard!deviation!of!2.5!(Thomas!et!al.,!2011).!Therefore!based!on!a!two!sample!binomial!test!of!proportions!a!group!size!of!6!is!required!to!have!a!90%!chance!of!detecting!that!the!proportion!of!mice!alive!at!day!14!is!at!least!13%!higher!in!the!experimental!arm!than!the!control!arm;!i.e.!this!equates!to!a!median!survival!of!21!days!in!the!treated!group,!a!hazard!ratio!of!1.5.!However!the!above!cited!study!reported!heterogeneous!group!sizes!suggesting!the!standard!deviation!of!uncensored!groups!may!exceed!2.5;!accordingly,!and!concordant!with!the!experience!of!existing!therapeutic!strategies,!a!group!size!of!8!is!required!to!reliably!detect!clinically!meaningful!differences!between!therapy!groups.!!This!group!size!affirms!the!need!to!use,!in!initial!experiments!at!least,!the!i.c.!method!of!establishing!tumours.!
6.1.3 Adaptation+of+a+previously+described+method+The!procedure!developed!was!adapted!from!the!experience!of!colleagues!who!have!considerable!experience!of!i.c.!administrations!of!human!xenograft!tissues!in!nude!mice!E!relevant!details!are!described!below!(Carlson!et!al.,!2011).!Mice!were!anaesthetised!with!intraperitoneal!ketamine!and!xylazine!in!order!to!minimise!movement!caused!by!intercostal!movements.!Once!the!efficacy!of!analgesisa!was!confirmed!an!incision!was!made!craniocaudally!over!the!midline!of!the!dorsal!aspect!of!the!skull.!A!burr!hole!was!then!made!at!the!right!bregma.!The!mouse!was!positioned!on!a!stereotactic!frame!and!a!Hamilton!syringe!with!mounted!needle!driven!2E3!mm!into!the!brain!parenchyma!(Figure!60).!Tumour!
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inoculum!was!administered!1!µL!per!minute!to!a!maximum!volume!of!3!µL.!After!a!further!minute!the!needle!was!withdrawn!and!the!incision!sutured!closed.!! !
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Figure! 60.! Stereotactic! injection! of! tumour! cells.! Mice! were! anaesthetised! with! intraperitoneal!ketamine! and! xylazine.!The! skull!was! exposed!and!a!burr!hole!made!over! the! lateral! bregma.!A!stereotactic! frame! was! used! to! inject! tumour! inoculum! 2E3! mm! below! the! dura! into! the! right!cerebral!hemisphere.!Injections!were!performed!at!1uL!per!minute!and!the!needle!left!in!place!for!2!minutes!after!the!injection.!The!scalp!incision!was!sutured!closed!and!mice!were!observed!in!a!warmed!environment!until!fully!recovered!from!the!procedure!and!effects!of!the!anaesthesia.!!!
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6.2 Results+
6.2.1 Characteristics+of+the+model+The!method!of!intracranial!administration!described!above!has!been!used!to!implant!human!glioma!primary!cells!into!nude!mice;!Carlson!et!al.!routinely!administer!105!cells!(Carlson!et!al.,!2011).!The!doubling!times!of!human!primary!cells!derived!from!glioma,!compared!to!the!murine!melanoma!line!B16,!are!very!different;!therefore!in!order!to!select!a!suitable!dose!for!further!experiments,!an!initial!experiment!was!performed!in!order!to!titrate!the!appropriate!number!of!tumour!cells!required!for!i.c.!installation,!such!that!tumours!would!develop!in!a!reliable!fashion.!!Mice!were!injected!with!doses!of!B16EOva!between!5000!and!500,000!cells,!and!euthanized!upon!development!of!any!concerning!signs!of!neurological!embarrassment.!Figure!61A!indicates!survival!following!i.c.!injection.!Notably!no!mice!died!during!the!procedure!or!anaesthesia,!nor!in!the!10!days!thereafter.!!Amongst!the!groups!given!higher!doses!of!tumour,!extracranial!growth!of!tumour!was!apparent!in!several!mice,!though!survival!was!not!significantly!different!between!mice!with!or!without!extracranial!growth,!and!neurological!signs!were!still!used!as!the!indication!to!euthanize!in!all!mice.!At!the!lowest!cell!dose!used,!3!mice!did!not!develop!neurological!symptoms!and!were!euthanized!40!days!after!i.c.!injection.!Following!euthanasia!the!brains!of!those!three!mice!were!examined!and!no!macroscopic!tumour!deposits!could!be!identified.!Accordingly!104!cells!were!administered!in!all!subsequent!experiments.!In!Figure!61B!the!untreated!groups!from!subsequent!experiments!were!compared,!demonstrating!the!consistency!of!tumour!growth!between!experiments.!The!median!survival!of!untreated!mice!was!17!days!after!inoculation!and!all!mice!developed!tumours.!!! !
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Figure!61.!Characteristics!of!the!intracranial!melanoma!model.!A:!Eight!mice!per!group!were!injected!with!doses! of! B16EOva! from! 5x103! to! 5x105! and! monitored! for! signs! of! neurological! impairment.! B:! Having!selected!104!as!the!optimal!dose!for!subsequent!experiments,!untreated!control!groups!from!four!separate!experiments!were!compared,!revealing!broadly!similar!outcomes,!and!a!pooled!median!survival!of!17!days!(total!32!mice).!!
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6.2.2 Tolerability+Given!the!nature!of!the!procedure,!periprocedural!deaths!were!anticipated,!but!thankfully!little!seen.!Since!implementation!519!mice!have!undergone!i.c.!injections!and!only!5!deaths!have!occurred!within!7!days!of!the!procedure.!The!cocktail!of!ketamine!and!xylazine!causes!prolonged!anaesthesia,!with!recovery!times!of!1E2!hours;!all!5!mice!appeared!to!die!as!a!result!of!the!sedation,!rather!than!the!procedure.!By!the!day!after!i.c.!procedures!mice!behave!normally,!feeding!and!drinking!without!impediment!and!with!no!detectable!behavioural!changes.!!
6.2.3 Monitoring+tumour+burden+In!conventional!mouse!models!tumours!are!established!subcutaneously,!often!in!the!flank.!This!makes!the!tumours!easily!palpable!and!easily!measureable.!Providing!the!cell!line!used!grows!consistently!it!is!therefore!possible!to!monitor!tumour!growth!and!euthanize!the!mice!before!the!tumour!is!large!enough!to!cause!symptoms!or!suffering.!Clearly!this!is!not!possible!for!intracranial!disease.!!!Given!the!thin!skull!of!mice!ultrasound!may!be!able!to!penetrate!sufficiently!to!allow!crude!tumour!measurements,!which!would!in!turn!allow!for!anticipatory!rather!than!reactive!euthanasia.!Mice!were!therefore!taken!for!highEfrequency!ultrasound,!8!days!after!i.c.!inoculation!of!104!B16EOva!into!the!right!cerebellum.!As!illustrated!in!Figure!62!tumours!were!readily!apparent!adjacent!to!the!falx!cerebri.!Although!the!procedure!takes!only!a!couple!of!minutes!to!obtain!the!images!shown,!the!mice!need!to!be!anaesthetised!in!order!to!secure!them!for!images!of!adequate!quality,!therefore!the!technique!is!not!practical!as!a!dayEtoEday!method!for!monitoring!tumour!burden.!!In!the!absence!of!a!practical!measure!of!tumour!burden!mice!were!instead!monitored!daily!for!evidence!of!neurological!impairment!or!behavioural!changes.!Lateralising!signs!did!not!develop,!even!in!mice!with!large!tumours!within!the!brain.!Instead!hunching,!reduced!mobility!and!signs!of!selfEneglect!were!taken!as!indicators!of!tumour!burden!and!used!to!indicate!when!to!euthanize!the!mouse.!Mice!were!inspected!7!days!a!week!to!ensure!that!tumours!were!not!allowed!to!progress!to!the!point!that!they!caused!distress!to!the!animals.!!! !
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!
!Figure!62.!High!frequency!ultrasound!of!intracranially!injected!B16!melanoma.!Ultrasound!appearances!of!B16EOva!tumours!established!by!intracranial! !injection.!Mice!were!injected!with!104!B16EOva!tumour!cells!(from!experiment!indicated!in!Figure!61)!into!the!right!cerebral!hemisphere!and!after!eight!days!imaged!by!high! frequency! ultrasound.! Two! mice! were! imaged! as! a! preliminary! test! of! the! imaging! modality! and!reprepesentative!screen!captures!taken!in!the!central!axes!of!the!tumours,!from!each!mouse!are!presented.!The!blue!bars!indicate!the!size!of!the!tumours,!3.57!mm!and!2.74!mm!respectively.!!
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6.2.4 Immunohistochemistry+Further!to!characterise!the!tumours!established!by!i.c.!injection,!brains!were!extracted!from!all!mice!at!the!time!of!euthanasia!and!immersed!overnight!in!formalin!to!aid!subsequent!handling.!In!addition!to!macroscopic!visual!examination,!tumours!from!two!mice!per!group!were!selected!at!random!and!conveyed,!intact!and!in!formalin,!to!the!Mayo!research!histology!department!in!Scottsdale!Arizona.!These!representative!brains!were!prepared!by!the!histopathology!service!and!after!H&E!staining!analysed!by!a!clinical!histopathologist!(Dr!Ronald!Marler,!DVM,!PhD).!Tumours!were!visible!macroscopically!as!black!melanoma!deposits!within!the!substance!of!the!brain!parenchyma.!Some!tumours!extended!along!the!track!of!the!inoculation!needle!and!grew!exophytically,!occasionally!extending!through!the!burr!hole!and!becoming!subcutaneous!masses.!In!subsequent!inoculations,!using!an!optimised!tumour!dose!these!phenomena!abated,!and!instead!tumours!became!established!either!as!discreet!lesions!in!the!right!cerebrum!or!adopted!a!more!diffuse!pattern,!often!developing!along!the!surface!of!the!cerebellum.!The!site!of!inoculation!lies!immediately!above!the!right!ventricle!of!the!brain;!therefore!tumours!are!likely!to!have!extended!into,!or!have!been!directly!inoculated!in,!the!cerebrospinal!fluid!and!then!tracked!bilaterally!to!areas!around!the!brain.!Initial!histopathological!assessment!after!H&E!staining!confirmed!that!the!macroscopic!deposits!were!melanoma!lesions,!generally!behaving!as!spaceEoccupying,!rather!than!infiltrative!lesions.!
6.2.5 Magnetic+resonance+imaging+Magnetic!resonance!imaging!(MRI)!has!been!reported!to!be!a!useful!imaging!modality!to!assess!intracranial!tumours!(Prabhu!et!al.,!2000).!In!addition!to!providing!high!resolution!anatomical!data,!the!growing!repertoire!of!MRI!scan!sequences!can!be!used!to!obtain!additional!data!about!the!effects!of!treatment!on!parameters!such!as!the!permeability!of!the!blood!brain!barrier!(Cao!et!al.,!2005;!Harry!et!al.,!2010!and!personal!communication!Dr!A.!Johnson!2011).!Clinical!trials!have!identified!that,!in!contrast!to!many!conventional!cancer!therapies,!the!efficacy!of!immunotherapies!may!not!be!best!assessed!by!size!criteria!such!as!the!widely!used!RECIST!system.!Accordingly!the!use!of!MRI!was!piloted!alongside!
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the!development!of!the!intracranial!model!as!an!imaging!method!that!might!provide!further!useful!data.!Mice!were!anaesthetised!by!inhalational!isofluorane!and!mounted!on!a!custom!NMR!(nuclear!magnetic!resonance)!probe!with!a!coil!overlying!the!skull.!After!calibrating!the!NMR!and!coil,!images!were!obtained!using!preprogramed!T1!and!T2!sequences.!Scans!were!enhanced!by!injecting!mice!with!intraperitoneal!gadolinium!contrast!15!minutes!prior!to!T2Esequences!were!performed.!Representative!images!are!shown!in!Figure!63,!illustrating!both!the!extent!of!tumour!burden!that!develops!following!intracranial!injections,!and!the!resolution!and!detail!obtained!using!the!protocol.!The!technique!was!relayed!to!other!investigators!within!the!lab!and!will!be!used!for!further!assessments!of!tumour!burden!and!response!to!therapy!by!size!criteria!in!future.!!!!!! !
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Figure! 63.! MRI! images! following! intracranial! injection! of! B16EOva.! Mice! were! anaesthetised! prior! to!obtaining! transverse! T1! and! gadoliniumEenhanced! T2! images! by! MRI.! The! images! shown! are! from! one!mouse,!to!allow!direct!comparison!between!of!T1!and!T2!weighting,!15!days!after!administration!of!5x104!tumour! cells! (from! experiment! indicated! in! Figure! 61).! This! mouse! developed! neurological! impairment!necessitating!euthanasia!for!tumour!burden,!later!on!the!day!that!these!images!were!obtained.!! !
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6.2.6 Therapy+studies+The!purpose!of!establishing!this!intracranial!model!was!to!allow!testing!of!immunotherapeutic!strategies!in!the!context!of!intracranial!disease,!and!in!particular!to!assess!and!address!the!impact!of!the!bloodEbrain!and!bloodEtumour!barriers.!Most!immunotherapies!tested!in!mice!use!subcutaneous!disease!models,!though!there!are!reports!of!immunotherapy!in!brain!tumour!models.!Bridle!et!al.!described!an!effective!vaccination!strategy!using!an!adenovirus!expressing!a!TAA,!that!protected!against!tumour!challenge!with!B16EF10!melanoma!(Bridle!et!al.,!2010).!Thomas!et!al.!have!reported!therapy!of!established!melanoma!tumours!implanted!within!the!brain,!using!combinations!of!oncolytic!virus!(myxoma)!and!adoptively!transferred!transgenic!TEcells,!in!mice!lacking!endogenous!lymphocytes!(Thomas!et!al.,!2011).!In!that!study!OV!was!administered!intratumourally,!no!trivial!undertaking!for!brain!tumours.!!In!the!following!studies!fully!systemic!therapy!was!investigated,!specifically!therapy!with!combinations!of!systemically!administered!antigenEexpressing!oncolytic!VSV!(VSVEOva)!and!adoptively!transferred!antigen!specific!transgenic!TEcells!(OT1),!in!the!intracranial!melanoma!model!against!7EdayEold!established!tumours.!!Initially!mice!were!injected!intracranially!with!104!B16EOva!tumour!cells,!and!6!days!later!were!treated!with!naïve!OT1!TEcells!(or!PBS!vehicle!as!a!control)!and!the!following!day!VSVEOva!(or!PBS!vehicle!as!a!control),!all!intravenously.!The!resulting!four!groups!were!followed!and!their!survival!free!from!neurological!symptoms!is!shown!in!Figure!64A.!As!shown!there!was!no!improvement!in!survival!mediated!by!the!addition!of!naïve!OT1!TEcells,!but!virotherapy!enhanced!median!survival!from!14.5!days!(control!mice,!or!OT1!alone)!by!between!8!and!11!days.!To!further!examine!the!effect!of!virotherapy!a!further!experiment!was!established!with!three!independent!groups!treated!with!VSVEOva,!including!one!group!in!which!repeated!VSVEOva!treatment!was!administered!(Figure!64B).!Notably!within!this!experiment!the!use!of!a!VSV!expressing!GFP,!rather!than!tumourEassociated!antigen,!did!not!generate!any!apparent!therapeutic!benefit.!Furthermore!three!consecutive!daily!doses!of!VSVEOva!did!not!appear!to!be!more!or!less!efficacious!than!a!single!dose!of!the!virus.!Combining!the!data!from!these!two!independent!experiments,!and!five!separate!groups!treated!with!VSVEOva!
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the!virus!appears!to!result!in!a!significant!improvement!of!survival!from!15.5!days!amongst!PBSEtreated!animals!to!26!days!in!mice!receiving!one!or!more!doses!of!VSVEOva!(Figure!64C,!LogErank!test!p=0.0002).!Although!these!are!early!data!only,!they!do!serve!to!demonstrate!that!the!model!is!now!well!established;!further!work!to!explore!the!mechanism!of!therapy!seen!is!underway!along!with!other!therapeutic!strategies,!but!these!were!beyond!the!scope!of!this!thesis.!! !
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Figure! 64! Pilot! studies! of! therapeutic! strategies! in! the! intracranial!model! of!metastatic!melanoma.! In! all!experiments!mice!were!treated!with!104!intracranial!B16EOva!cells!and!started!virotherapy!7!days!later.!A.!Mice! were! treated! intravenously! with! VSVEOva,! naive! OTE1! TEcells,! or! both.! B.! Mice! were! treated! with!intravenous!VSV.!At!the!time!of!the!experiment!there!was!a!transition!from!one!batch!of!prepared!virus!to!another,!and!so!Groups!1!and!2!were!compared!within! this!one!experiment! to! test! the!consistency!of! the!therapeutic!agent.!Group!1!were!treated!with!the!batch!of!VSVEOva!used!in!A,!group!2!received!virus!that!was!used! in! subsequent! experiments.!The! effect! of! repeated!dosing!was! explored!by! administering! three!daily!doses!of!virus!(group!2!batch)!to!one!group!of!mice.!VSV!expressing!GFP,!but!no!tumour!antigen,!was!used! to! explore! the! role! of! antigen,!with! the!GFP! insert! serving! to! act! as! control! for! the! effect! of! genetic!modification!on!the!virus.!C.!Data!from!A!and!B!were!combined!to!examine!the!to!compare!the!efficacy!of!VSVEOva!with!untreated!groups.!Dotted!lines!indicate!the!95%!confidence!interval!for!each!group.!!Median!survival!in!control!groups!was!16!days,!and!26!days!amongst!groups!treated!with!VSVEOva.!LogErank!test!of!the!two!curves!identified!a!statistically!significant!difference!in!survival!(p=0.0002).!
0 10 20 30 40
0
50
100
Pe
rc
en
t s
ur
vi
va
l
days since tumour challenge
Controls
VSV-Ova
OT1
VSV + OT1
15 days
26 days
15 days
23 days
M
ed
ia
n 
su
rv
iv
al
days since tumour challenge
Pe
rc
en
t s
ur
vi
va
l
0 10 20 30 40
0
50
100
Control
VSV-Ova (group 1)
VSV-Ova (group 2)
VSV-Ova (multiple doses)
VSV-GFP18 days
27 days
16 days
20 days
M
ed
ia
n 
su
rv
iv
al
27 days
days since tumour challenge
Pe
rc
en
t s
ur
vi
va
l
0 10 20 30 40
0
50
100
Controls
VSV-Ova groups26 days
16 days
M
ed
ia
n 
su
rv
iv
al
B!
C!
B!
A !
C!
!! Brain!metastases!model! !
200!
6.3 Discussion+A!reliable!and!reproducible!model!of!intracranial!melanoma!was!established!in!the!laboratory!in!order!to!test!existing!and!novel!immunotherapeutic!strategies.!In!preliminary!therapy!studies!intravenous!therapy!using!an!antigenEexpressing!oncolytic!virus!prolonged!survival!(Figure!64).!This!is!in!marked!contrast!to!the!subcutaneous!models!of!melanoma!used!in!the!preceding!chapter!in!which!intravenous!virotherapy!alone!confers!little!if!any!benefit.!One!facet!of!the!intracranial!model,!which!will!be!the!subject!of!further!study,!is!the!smaller!number!of!tumour!cells!used!(104!c.f.!5!x!105);!it!is!possible!that!this!model!will!allow!sensitive!examination!of!the!utility!of!virotherapies!and!immunotherapies!in!the!context!of!small!volume!disease,!which!is!a!clinical!scenario!that!many!in!the!field!believe!would!most!benefit!from!such!therapies.!An!important!criticism!of!the!technique!as!described!is!that!the!assessment!of!survival!is!somewhat!subjective.!The!degree!of!neurological!impairment!was!considerable!and!it!is!appropriate!to!try!to!reduce!or!prevent!any!suffering!in!experimental!animals!by!preEemptive!euthanasia.!However!it!will!be!important!in!subsequent!experiments!that!brains!are!harvested!in!order!to!provide!objective!evidence!of!the!disease!burden.!Parallel!experiments!with!predetermined!timepoints!for!euthanasia!should!be!performed!to!provide!further!objective!demonstration!of!the!effect!of!treatment.!!An!appealing!strategy!would!be!to!mimic!many!of!the!standard!practices!of!clinical!trials!–!namely!randomisation!and!blinding,!such!that!the!practitioner!assessing!neurological!burden!is!unaware!of!the!treatment!each!animal!has!received.!!Patients!with!metastatic!melanoma!commonly!have!disease,!whether!identified!or!subEclinical,!within!the!brain!and!therefore!successful!therapies,!immunotherapies!included,!must!have!efficacy!within!the!brain!and!be!able!to!overcome!the!bloodEbrain!barrier.!Although!there!is!some!evidence!of!efficacy!of!ACT!and!CTLAE4!inhibition!in!the!context!of!brain!metastases,!other!therapies!are!impeded!by!the!BBB.!One!of!the!ongoing!aims!associated!with!establishing!this!i.c.!model!is!to!investigate!ancillary!treatments!that!could!augment!existing!strategies.!!One!function!of!the!BBB!is!to!preserve!the!immune!privilege!of!the!brain,!serving!to!impede!the!access!of!leucocytes!to!the!brain!parenchyma!by!the!range!of!
A!
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mechanisms!discussed!earlier,!indeed!disruption!of!the!BBB!is!an!important!step!in!the!development!of!autoimmune!neurological!diseases!such!as!multiple!sclerosis!(Alvarez!et!al.,!2011).!!Radiotherapy!has!been!shown!to!disrupt!the!BBB;!Wilson!et!al.!demonstrated!that!RT!(delivered!as!a!20!Gy!single!fraction)!leads!to!astrogliosis,!increased!permeability!of!the!BBB!and!leukocyte!adhesion!in!a!TNFα!dependent!fashion!(Wilson!et!al.,!2009).!Fractionated!RT!(40!Gy!in!20!fractions)!is!also!capable!of!enhancing!BBB!permeability!but!does!so!more!slowly!than!high!single!fraction!doses!(Yuan!et!al.,!2006).!In!patients!undergoing!radiotherapy!(52E70!Gy!in!1.8E3!Gy!fractions,!mostly!2!Gy!per!fraction)!MRI!based!methods!to!estimate!the!permeability!of!the!BBB!suggested!enhanced!permeability!during!treatment,!particularly!in!the!bloodEtumour!barrier!(Cao!et!al.,!2005).!These!data!suggest!that!immunotherapy!approaches!may!be!enhanced!by!the!addition!of!radiotherapy,!in!order!to!enhance!access!to!the!tumour.!!The!hedgehog!pathway,!aberrant!in!a!range!of!cancers!and!currently!explored!as!a!potential!targeted!therapy,!is!also!involved!in!maintaining!the!integrity!of!the!BBB!(Robarge!et!al.,!2009).!Studies!using!cyclopamine,!an!inhibitor!of!SMO!(Smoothened,!a!cell!membrane!protein!upstream!in!the!hedgehog!pathway)!and!GDCE0449!(a!clinical!grade,!orally!available!SMO!inhibitor)!found!that!the!hedgehog!pathway!not!only!maintains!the!physical!rectitude!of!the!BBB!but!also!mediates!the!levels!of!cytokine!and!chemokine!expression!(Alvarez!et!al.,!2011).!In!a!mouse!model!of!MS,!experimental!autoimmune!encephalomyelitis,!inhibition!of!the!hedgehog!pathway!by!repeated!dosing!with!GDCE0449!led!to!increased!numbers!of!leukocytes,!particularly!of!Th1!and!Th17!phenotypes,!accumulating!within!the!CNS!(Alvarez!et!al.,!2011).!Together!the!data!suggest!that!the!hedgehog!pathway!plays!an!important!role!in!limiting!immune!access!to!the!brain,!and!that!its!inhibition!could!enhance!immunotherapy!for!brain!tumours.!!Protocols!testing!the!ability!of!GDCE0449,!a!hedgehog!inhibitor!being!developed!by!Genentech!(California!USA),!to!augment!adoptive!cell!therapies!are!underway!using!the!intracerebral!model.!Dependent!upon!those!results!further!studies!may!explore!alternative!methods!of!BBB!disruption;!mannitol,!for!example,!is!a!widely!available!osmotic!diuretic!classically!used!to!treat!cerebral!oedema!and!known!to!disrupt!the!function!of!the!BBB!(Brown!et!al.,!2004).!Accordingly!it!has!
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also!been!tested!as!a!method!of!enhancing!the!penetration!of!chemotherapy!into!the!brain!(Doolittle!et!al.,!2000).!!In!parallel!with!the!pilot!studies!of!B16!melanoma!described!above!the!technique!has!been!used!to!establish!an!intracranial!model!of!glioblastoma,!using!the!murine!glioma!cell!line!(GL261).!Glioblastoma!remains!a!recalcitrant!disease!and!further!therapies!are!urgently!required.!Colleagues!have!injected!GL261!transfected!to!express!a!luciferase!reporter!gene!that!allows!monitoring!of!tumour!development!by!live!animal!imaging!(personal!communication!Dr!R.!Diaz!2012).!A!similar!enhancement!of!B16EOva!would!be!a!useful!way!to!supplement!the!data!obtained!by!MRI,!not!least!as!several!mice!can!be!imaged!simultaneously!using!this!technique.!As!discussed!earlier!in!this!chapter!several!methods!of!modelling!intracranial!disease!have!been!reported.!Although!direct!intracranial!injection,!as!used!above,!has!advantages!including!the!ease,!reproducibility!and!scale!of!application,!other!models!may!better!mimic!some!of!the!processes!involved!in!metastasis!in!nature.!Intracranial!metastases!established!following!ICA!injection!presumably!have!selected!tumour!cell!clones!that!are!capable!of!adherence!and!migration!through!vascular!endothelium.!Having!identified!successful!therapeutic!approaches!in!the!intracranial!model!it!may!therefore!be!worthwhile!testing!the!same!therapies!in!smaller!scale!experiments!using!tumours!established!with!an!ICA!approach!for!further!validation.!However,!it!must!be!recognised!that!both!i.c.!and!ICA!administrations!have!fundamental!limitations!in!their!ability!to!mimic!the!‘normal’!metastatic!process.!Recent!data!has!shown!that!one!element!of!metastasis!is!the!preparation!of!a!premetastatic!niche,!mediated!by!bone!marrow!derived!stromal!cells,!a!process!that!presumably!cannot!be!replicated!by!direct!inoculation!of!a!large!number!of!tumour!cells!(Peinado!et!al.,!2012).!!Those!caveats!notwithstanding!this!model!will!allow!refinement!of!existing!and!novel!immunotherapeutic!strategies,!and!where!the!BBB!is!found!to!impede!efficacy!allow!testing!of!supportive!treatments!to!overcome!such!impediments.
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7 Summary+and+conclusions+Metastatic!melanoma!remains!a!considerable!challenge,!despite!recently!identified!therapeutic!successes.!The!enzyme!inhibitor!vemurafenib!is!only!effective!for!the!subset!of!patients!whose!tumours!are!found!to!express!mutant!forms!of!BRAF,!and!though!the!response!rate!is!high,!responses!are!not!durable.!Blockade!of!CTLAE4!with!ipilimumab!is!profoundly!toxic!for!a!significant!number!of!patients,!and!unfortunately!only!generates!meaningful!benefits!for!a!minority!of!patients,!however!of!that!minority!many!seem!to!benefit!from!prolonged!periods!of!disease!control.!Moreover!the!use!of!ipilimumab!provides!clear!evidence!that!the!immune!system!can!be!recruited!to!control!metastatic!disease.!The!aim!of!this!thesis!therefore,!was!to!test!additional!therapies!that!may!contribute!to!immuneEbased!strategies.!!Measles!virus!is!an!effective!oncolytic!agent!against!human!melanoma!in!vitro,!when!tested!against!a!panel!of!immortalised!cell!lines,!against!a!threeEdimensional!model!of!melanoma!and!against!low!passage!human!melanoma!cell!primaries.!MVEinfected!melanoma!cells!produced!a!range!of!cytokines,!chemokines!and!danger!signals!that!would!be!expected!to!generate!an!inflammatory!milieu.!Both!MV!and!MVEinfected!melanoma!cells!matured!antigenEpresenting!dendritic!cells.MV!also!enhanced!the!innate!antiEtumour!functions!of!PBMC,!principally!through!the!activation!of!NK!cells.!MVEinfected!melanoma!cells!are!processed!by!dendritic!cells!which!can!in!turn!stimulate!an!adaptive!melanomaEspecific!cytotoxic!CD8+!TEcell!response.!!Time!constraints!limited!further!exploration!of!MV,!but!future!studies!are!planned.!CD46!is!upregulated!in!several!tumours,!presumably!in!an!effort!to!evade!the!attentions!of!the!complement!system!(Fishelson!et!al.,!2003).!Others!have!shown!that!CD46!is!downregulated!in!response!to!infection!with!MV,!though!it!was!not!explored!in!the!confines!of!this!thesis!(Firsching!et!al.,!1999).!The!in!vitro!work!presented!within!the!thesis!has!used!sera!that!has!been!heat!inactivated!to!neutralise!complement!proteins.!The!potential!of!complement!as!an!anticancer!effector!is!underEexplored!(Macor!and!Tedesco,!2007).!An!avenue!of!further!exploration!would!therefore!be!to!examine!the!ability!of!complement!
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proteins!in!targeting!MVEtreated!melanoma!cells,!which!would!additionally!exploration!of!the!crossEtalk!that!occurs!between!complement!proteins!and!the!innate!or!adaptive!responses!(Heeger!and!Kemper,!2012).!!!!The!most!appealing!way!to!continue!the!study!of!MV!in!melanoma,!as!discussed!in!chapter!3,!would!be!by!clinical!trial.!The!clinical!trial!protocol!outlined!in!that!chapter!predominantly!focuses!on!assessing!viral!delivery!based!on!evidence!of!expression!of!the!sodiumEiodine!symporter!gene,!however!such!a!clinical!trial!would!also!present!opportunities!to!undertake!correlative!immuneEbased!assays,!looking!for!evidence!that!the!antiEtumour!immune!priming!effects!seen!in!vitro!may!also!occur!in!vivo.!One!challenge!for!such!correlative!studies!is!the!absence!of!universal!agreement!of!the!best!assay!to!detect!immune!responses.!Indeed!this!is!a!problem!for!the!entire!field!of!immunotherapy.!Conventional!models!of!treatment!development!require!study!of!pharmacodynamics!and!pharmacokinetics,!along!with!toxicity!assessments!in!order!to!define!suitable!treatment!doses!and!schedules.!Such!parameters!are!difficult!to!measure!for!novel!immune!strategies!such!as!adoptive!cell!therapies!and!oncolytic!viruses.!Though!quite!definitely!outside!the!purview!of!research!laboratories,!efforts!to!standardise!immuneEbased!assays!and!implement!quality!control!and!assessment!programs,!and!in!so!doing!introduce!the!relevant!techniques!to!routine!diagnostic!laboratories,!may!be!of!huge!benefit!for!the!field!(Janetzki!et!al.,!2008;!Hoos!et!al.,!2010).!!Oncolytic!viruses!are!gaining!increasing!attention!as!the!epicentre!of!research!is!moving!from!preclinical!study!to!clinical!trials!(Donnelly!et!al.,!2012a).!A!recent!highEprofile!study!of!reovirus!administered!intravenously!found!that!although!most!virus!is!quickly!neutralised!by!antibodies,!some!virus!does!reach!tumour!and!appears!to!be!delivered!by!various!leukocytes!and!platelets!(Adair!et!al.,!2012;!Donnelly!et!al.,!2012c).!The!identification!of!this!mechanism!has!significant!implications!for!the!field,!and!further!research!to!characterise!and!enhance!this!mechanism!is!underway.!Despite!a!longstanding!assumption!that!radiotherapy!is!distinctly!immunosuppressive,!a!growing!body!of!preEclinical!and!clinical!evidence!suggests!that!RT!can!in!fact!cause!immunologically!relevant!effects!on!tumour!cells,!and!immune!cells.!In!mouse!models!of!melanoma,!a!single!fraction!of!
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external!beam!radiotherapy,!mimicking!commonly!used!palliative!doses,!did!not!enhance!the!effectiveness!of!an!established!preclinical!immunotherapy!strategy.!The!in!vivo!persistence!of!adoptively!transferred!TEcells,!and!their!trafficking!to!tumour,!or!tumourEdraining!lymph!nodes,!did!not!appear!to!be!enhanced!by!palliative!dose!external!beam!radiotherapy.!Preliminary!experiments!using!an!alternative!immunotherapy!pairing!showed!some!promise!and!merit!further!exploration.!If!RT!is!found!to!synergise!with!Pmel!and!VSVEgp100,!having!failed!to!do!so!with!OT1!and!VSVEOva,!then!the!mechanism!behind!that!discrepancy!would!be!particularly!illuminating!for!directing!future!immuneEbased!strategies.!A!model!of!brachytherapy!treatment!was!developed!–!Brachytherapy!did!not!enhance!the!effectiveness!of!an!established!preclinical!immunotherapy!strategy!but!the!model!may!be!useful!for!future!studies!of!the!effects!of!low!versus!high!doseErate!RT.!The!same!challenges!described!above!for!clinical!testing!of!the!immune!effects!of!OV,!pose!a!problem!in!exploiting!the!immune!effects!of!radiotherapy.!Modern!RT!techniques,!external!or!brachytherapy,!are!based!on!a!view!of!radiobiology!in!which!DNA!damage!is!the!sole!mode!of!action.!Accordingly!timings!and!fractionation!revolve!around!subverting!DNA!repair!enzymes,!rather!than!hitting!windows!of!prime!immunotherapeutic!potential,!if!such!windows!exist.!In!order!to!design!therapeutic!combinations!that!take!advantage!of!the!immune!effects!of!RT!it!will!be!necessary!to!have!robust!evidence!of!the!‘radioimmunokinetics’,!and!therefore!such!combinations!will!also!benefit!from!improvements!in!immune!assays.!A!similar!concept!allowed!Markovic!and!colleagues!to!dramatically!enhance!response!rates!to!chemotherapy!for!melanoma!by!ensuring!that!the!treatment!schedule!conformed!to!immune!dynamics,!rather!than!traditional!timings!(Holtan!et!al.,!2011;!Leontovich!et!al.,!2012).!Radiotherapy!techniques!have!progressed!considerably!in!the!last!two!decades,!including!the!ability!to!deliver!hypofractionated!and!imageEguided!ablative!radiotherapy!to!tumours!with!much!smaller!treatment!margins!than!previously!possible.!Such!stereotactic!radiotherapy!techniques!can!be!applied!to!tumours!in!the!brain!and!increasingly!to!areas!throughout!the!body!(SBRT).!Interestingly!the!doses!used!in!SBRT!seem!fortuitously!to!match!many!of!the!doses!used!in!preclinical!studies!that!have!demonstrated!the!immune!potential!of!RT.!
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Furthermore!SBRT!is!generally!given!over!only!a!handful!of!fractions!with!a!short!overall!treatment!time!which!arguably!makes!its!combination!with!immuneEbased!strategies!much!easier!than!conventional!daily!fractionations!that!may!continue!for!up!to!6!weeks.!Although!the!RT!equipment!employed!to!deliver!external!beam!RT!(EBRT)!in!chapter!4!was!able!to!deliver!doses!in!the!palliative!range,!it!was!not!suitable!for!mimicking!the!precision!or!doses!of!SBRT.!Small!animal!radiotherapy!research!platforms!that!can!emulate!frontline!RT!techniques!are!being!developed!and!will!greatly!improve!research!in!this!field!(Verhaegen!et!al.,!2011).!In!future!work!we!plan!to!exploit!such!platforms!to!combine!SBRT!and!immunotherapies!in!mouse!models!of!melanoma!and!glioblastoma.!In!the!interim,!we!have!opened!an!observational!study!of!the!immune!responses!of!patients!having!SBRT!for!oligometastatic!melanoma,!based!at!the!Mayo!Clinic.!!Brachytherapy!is!used!for!a!fairly!limited!number!of!indications!at!present!but!retains!the!key!advantage!over!EBRT!that!dose!rapidly!falls!off!with!distance!from!the!implanted!source,!often!resulting!in!normal!tissues!being!spared!dose!more!so!than!can!be!achieved!with!EBRT.!Although!in!a!limited!number!of!experiments!presented!in!chapter!4!brachytherapy!did!not!enhance!immunotherapy,!others!have!recently!reported!contrasting!results.!Hodge!et!al.!injected!mice!with!the!Lewis!lung!cancer!cell!line,!establishing!both!a!flank!tumour!and!metastases!to!the!lung!(Hodge!et!al.,!2012).!Combining!brachytherapy!to!the!flank!tumour!with!a!virusEbased!vaccine!resulted!in!a!significant!reduction!in!the!number!of!lung!metastases.!Given!that!the!radioimmunokinetics!may!well!vary!considerably!between!cancerEtypes!it!is!possible!that!SBRT!and!similar!techniques!could!be!used!for!some!tumours,!while!lower!dose!rate!therapies!like!brachytherapy!are!more!effectively!combined!with!immunotherapies!in!other!tumours.!!Melanoma!commonly!spreads!to!the!brain!and!causes!a!terrible!symptomatic!burden!when!it!does!so.!A!model!of!intracranial!tumour!was!implemented!in!order!to!allow!testing!of!existing!and!novel!therapeutic!strategies,!to!ensure!that!the!relative!immunological!sanctuary!afforded!by!the!bloodEbrain!barrier!does!not!hinder!otherwise!effective!therapies.!Though!initially!of!interest!purely!for!
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melanomaErelated!research,!this!model!is!now!also!being!used!by!the!lab!to!study!glioblastoma!treatments.!!Finally,!it!is!important!to!note!that!countless!groups!worldwide!are!pursuing!treatments!that!could!generate!and!enhance!antiEtumour!immunity.!Approaches!being!pursued!to!develop!immunotherapy!for!melanoma!and!other!tumours!include!(Donnelly!et!al.,!2012b):!
" ILE2!modified!to!improve!its!receptor!affinity!may!reduce!the!toxicity!associated!with!treatment!(Levin!et!al.,!2012).!!
" Monoclonal!antibodies!against!a!range!of!new!immune!targets,!rather!than!tumourEassociated!targets!are!emerging;!Daclizumab!is!an!antiECD25!agent!that!depletes!regulatory!TEcells!and!is!being!combined!with!other!therapies!(Rech!and!Vonderheide,!2009).!!
" Antibodies!that!target!the!‘other’!immunological!synapse!(TEcellEtoEtumour),!specifically!the!interaction!between!programmed!cell!death!receptor!!(PDE1)!and!its!ligand!PDLE1,!may!have!fewer!toxicities!than!ipilimumab!and!early!trials!have!shown!promise!(Brahmer!et!al.,!2010,!2012).!!
" Vemurafenib!enhances!antigen!expression!on!the!surface!of!melanoma!tumours!and!therefore!its!combination!with!ipilimumab!is!to!be!tested!clinically!(Donnelly!et!al.,!2012b).!!!Metastatic!melanoma!remains!a!cancer!with!one!of!the!worst!prognoses,!despite!recent!therapeutic!developments,!however!there!is!reason!to!be!optimistic!that!further!immunotherapeutic!approaches!may!improve!the!outlook!for!patients!with!this!disease.!!!
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9 Appendices+
9.1 Max+Perutz+submissions+!The!following!are!essays!submitted!to!the!annual!MRC!science!writing!competition!and!selected!by!the!shortlisting!panel.!The!2011!essay!was!highly!commended!by!the!judges.!!
2010+
An+enemy’s+enemy+Viruses!get!a!pretty!bad!press.!From!coughs!and!colds,!right!through!to!serious!viruses!like!manEflu,!most!people!would!say!viruses!are!just!no!good.!!Our!research!is!trying!to!offer!them!a!shot!at!penance,!as!a!treatment!for!cancer.!!When!a!virus!infects!a!cell!it!takes!control!of!the!cell’s!machinery!and!coerces!it!into!producing!more!virus,!instead!of!the!normal!proteins!that!keep!the!cell!happy!and!functioning.!!Eventually!the!cell!dies,!bursting!as!it!does!so!and!releasing!the!newly!copied!viruses!to!go!and!infect!other!cells!nearby.!!Can!this!be!turned!against!cancer?!Viruses!often!have!a!favourite!type!of!cell!to!infect,!one!that!they’re!particularly!comfortable!in!and!find!easy!to!control.!!Herpes!is!most!at!home!in!nerve!cells!and!can!stay!put!for!decades,!coming!back!every!winter!to!give!you!a!cold!sore.!!Norovirus!has!a!penchant!for!the!gut!and!each!year!millions!suffer!diarrhoea!as!a!result.!!Some!viruses!seem!to!be!especially!fond!of!cancer!cells!and!are!far!better!at!infecting!and!killing!cancer!cells!than!they!are!normal!cells.!It’s!these!oncolytic!viruses!(oncoE!tumour,!lysis!–!destruction)!that!we!study!as!potential!treatments!for!cancer!patients.!Given!the!advances!in!virology!and!molecular!biology!over!the!last!20!years!we’re!now!able!to!study!the!way!viruses!infect!and!kill!cells.!!We’re!able!to!choose!viruses!that!prefer!cancer,!or!modify!them!so!that!they’ll!only!infect!the!cells!we’re!targeting.!!We!can!grow!human!cancer!cells!in!Petri!dishes!and!watch!them!be!destroyed!by!adding!tiny!amounts!of!an!oncolytic!virus.!We!can!measure!how!well!a!virus!can!multiply!in!different!types!of!cancer!cells!and!look!for!ways!to!improve!its!effectiveness.!A!further!mechanism!for!these!viruses!lies!in!the!way!they!interact!with!the!
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body’s!natural!defences.!!The!immune!system!is!cold!and!unsympathetic.!!When!a!normal!cell!becomes!infected!with!a!virus!it!releases!distress!signals!to!warn!its!neighbours!and!call!in!help!from!the!immune!system!to!stave!off!the!infection.!!When!the!immune!system!discovers!the!infected!cell!it!will!politely!invite!the!hapless!victim!to!kill!itself,!lest!it!produces!even!more!virus!and!infects!its!as!yet!unharmed!neighbours.!!If!the!virally!laden!cell!doesn’t!obey!(as!cancer!cells!are!wont!to!do)!the!patrolling!immune!cell!will!summon!colleagues!and!ruthlessly!attack!and!destroy!it!in!an!effort!to!contain!the!virus.!This!is!at!the!heart!of!our!research!efforts.!!It!is!hard!to!persuade!the!immune!system!to!recognise!cancer,!mainly!because!cancer!is!very!good!at!hiding!itself.!!Our!theory!is!that!virallyEinfected!cancer!cells!call!for!help!in!much!the!same!way!as!normal!cells!do!when!under!similar!attack.!!In!fact!it’s!quite!possible!that!cancer!cells!produce!even!more!distress!signals!than!normal!cells!because!they’ve!lost!even!the!basic!selfEdefence!systems!that!most!other!cells!possess.!!By!doing!this!the!cancer!becomes!vulnerable,!revealing!itself!and!triggering!an!attack!by!the!immune!system.!!Most!exciting!for!researchers!though!is!that!there!is!evidence!that!the!immune!system,!once!alerted!to!infected!cancer!cells!in!this!way,!becomes!alerted!to!uninfected!cancer!cells!as!well,!attacking!the!cancer!in!other!parts!of!the!body!too;!parts!that!the!virus!may!not!have!reached.!There!are!still!challenges.!!How!do!we!get!the!virus!to!the!tumours?!!Administering!a!virus!directly!into!the!bloodstream!risks!triggering!a!wellEmeant,!but!unhelpful!immune!response!against!it.!This!can!destroy!the!virus!before!it’s!had!a!chance!to!get!to!the!cancer!and!do!any!good.!!An!alternative!is!to!inject!virus!directly!into!tumours,!but!this!can!be!awkward!and!painful,!and!reduces!the!amount!of!virus!getting!to!cancer!that!has!spread!elsewhere!in!the!body.!!By!either!route,+injecting!a!large!dose!of!virus!into!someone!makes!them!feel!pretty!horrible!for!a!few!days!too,!though!no!worse!than!many!of!the!commonly!used!chemotherapy!treatments.!Viruses!do!have!potential!as!another!treatment!for!cancer,!but!it’s!very!early!days.!!Several!viruses!are!being!studied!in!labs.!Some!are!already!being!tested!in!clinical!trials!in!patients!with!promising!results.!!So!far!the!studies!suggest!that!giving!the!right!viruses!in!the!right!way!and!in!the!right!doses!is!safe;!it’s!just!too!early!to!say!whether!the!theory!turns!into!real!benefits!for!patients.!!Will!viruses!
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keep!people!with!cancer!alive!longer?!Answering!that!is!going!to!take!more!trials,!more!lab!work!and!I’m!afraid,!more!time!yet.!By!the!way,!please!don’t!cosy!up!to!that!fluEridden!person!on!the!train,!or!search!out!someone!with!chickenpox!and!have!a!cuddle;!it!won’t!work!like!that,!and!you!might!just!get!yourself!arrested.! !! !
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2011+
Hunting+out+the+enemy+Sarah!died!at!two!in!the!morning,!about!three!hours!after!I!sent!her!parents!home!for!the!nightE!she!was!19.!A!couple!of!weeks!before!Christmas,!completely!out!of!the!blue,!she’d!had!a!seizure.!A!CT!scan!of!her!head!and!a!battery!of!other!tests!revealed!widespread!metastatic!cancer.!Metastatic!melanoma!is!one!of!the!most!aggressive!cancers!and!normally!starts!in!the!skin.!In!Sarah’s!case!it!had!spread!throughout!her!body,!including!her!brain,!before!she’d!ever!known!it!was!there.!The!cancer!in!her!brain!made!her!have!more!and!more!fits.!The!fits!weren’t!well!controlled!with!medications!and!so!Sarah!had!to!come!in!and!out!of!hospital!to!try!and!get!on!top!of!them.!On!one!of!those!admissions!I!was!working!as!a!junior!doctor!in!my!second!year.!We!gave!the!teenager!more!drugs!to!try!and!control!the!most!recent!fit!and!admitted!her!to!the!cancer!ward!for!observation!overnight.!I!thought!I!was!helping!her!parents!by!reassuring!them!that!we’d!look!after!their!daughter!and!that!nothing!more!was!going!to!happen!overnight.!Sarah!died!on!the!ward,!without!her!family,!in!that!hinterland!between!Christmas!and!New!Year’s!Day,!less!than!a!month!after!her!first!seizure.!Sarah!had!always!been!well,!she!had!no!other!medical!problems!and!like!most!other!people!who!develop!cancer,!her!immune!system!was!perfectly!normal.!The!cells!of!the!immune!system!police!the!body,!having!evolved!over!a!thousand!millennia!to!tackle!infection!and!parasites,!but!also!possessing!the!potential!to!act!against!cancers.!Our!research!looks!for!ways!to!trigger!an!immune!response!against!cancer!cells!to!help!patients!fight!the!disease.!If!the!immune!system!is!the!body’s!police!force!then!melanoma!is!a!very!sophisticated!and!aggressive!criminal.!Melanomas,!and!other!cancers,!conceal!their!identity!by!reducing!the!number!of!molecules!on!their!surface!that!normally!provide!information!to!immune!cellsE!essentially!a!system!of!fake!IDs!and!disguises.!When!an!immune!cell!does!recognise!a!cancer!cell!then!it!is!prevented!from!triggering!the!alarm!by!a!range!of!chemicals!released!by!the!cancer;!akin!to!jamming!the!police!radios.!On!the!rare!occasion!that!a!cancer!cell!is!successfully!recognised!and!accosted!it!is!resistant!to!the!actions!of!the!
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immune!cell,!as!if!the!master!criminal!has!already!planned!its!jail!break.!These!barriers!can!be!overcome.!One!approach!we’re!trying!is!to!use!radiotherapy,!a!treatment!to!which!melanoma!in!particular!is!considered!relatively!resistant.!By!giving!radiotherapy!to!an!area!of!metastatic!melanoma!we!hope!to!generate!inflammation!not!just!in!the!tumour!cells!but!also!in!the!nearby!normal!cells.!This!way!even!if!the!tumour!refuses!to!release!inflammatory!signals!then!the!adjacent!healthy!tissue!will,!which!in!turn!will!trigger!an!immune!response.!It’s!essentially!calling!the!fire!brigade!when!you!need!the!police,!but!either!way!help!is!coming,!and!the!cancer’s!ability!to!‘jam!the!radios’!has!been!circumvented.!Another!part!of!our!work!has!been!to!use!viruses!chosen!for!their!ability!to!infect!and!kill!cancer!cells.!We’ve!shown!with!a!number!of!different!viruses!that!the!immune!system!is!better!able!to!recognise!a!virallyEinfected!tumour!cell.!In!fact!having!recognised!a!tumour!cell!riddled!with!virus!the!immune!system!is!primed!to!better!recognise!other!tumour!cells!too,!overcoming!the!cancer’s!system!of!disguises.!With!both!of!these!treatments!the!therapy!is!confined!to!the!area!treated;!you!can’t!give!radiotherapy!to!the!entire!body!if!the!disease!is!widespread!without!doing!more!harm!than!good.!Our!aim!is!to!find!a!treatment,!or!combination!of!treatments,!that!act!on!one!area!of!disease!but!trigger!an!immune!response!to!attack!the!cancer!throughout!the!body.!Many!have!doubted!that!the!immune!system!could!ever!play!an!important!role!in!the!fight!against!cancer!but!recent!studies!have!debunked!that.!For!the!first!time!a!drug!has!been!tested!in!clinical!trials!that!seems!to!have!real!benefits!for!patients!with!metastatic!melanoma,!and!amazingly!it!has!no!direct!action!on!the!cancer!itself.!Ipilimumab!acts!on!cells!of!the!patient’s!immune!system,!not!the!tumour,!and!effectively!takes!the!brakes!off!the!immune!system,!unleashing!it!to!attack!the!cancer.!Like!most!cancer!treatments!there!are!side!effects,!but!it!is!a!huge!leap!forward!for!patients!with!melanoma!and!may!have!impacts!for!other!cancers!too.!It!is!proof!that!the!immune!system!can!be!harnessedE!that!it!can!be!persuaded!to!join!a!fight!it!was!previously!blinkered!to.!It!feels!a!long!time!ago!that!Sarah!died,!but!I!still!remember!telling!her!parents!to!go!and!get!some!sleep,!and!still!I!think!it’s!the!worst!mistake!I’ve!ever!made.!
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Since!then!progress!is!finally!being!made!in!the!search!for!effective!treatments!for!melanoma!and!hopefully!there’s!more!to!come.!
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9.2 SET+for+Britain+poster+2012+!The!following!is!a!poster!presented!at!the!Science!Engineering!and!Technology!meeting,!hosted!by!the!Parliamentary!Science!Committee!at!the!Houses!of!Parliament.!It!was!designed!with!Harry!Donnelly,!and!was!intended!for!a!mixed!audience!of!scientists!and!MPs.!
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